id	sid	tid	token	lemma	pos
dpc-4915	1	1	dermatology	dermatology	NOUN
dpc-4915	1	2	:	:	PUNCT
dpc-4915	1	3	practical	practical	ADJ
dpc-4915	1	4	and	and	CCONJ
dpc-4915	1	5	conceptual	conceptual	ADJ
dpc-4915	1	6	original	original	ADJ
dpc-4915	1	7	article	article	NOUN
dpc-4915	1	8	|	|	ADV
dpc-4915	1	9	dermatol	dermatol	ADJ
dpc-4915	1	10	pract	pract	NOUN
dpc-4915	1	11	concept	concept	NOUN
dpc-4915	1	12	.	.	PUNCT
dpc-4915	2	1	2025;15(1):4915	2025;15(1):4915	NUM
dpc-4915	2	2	1	1	NUM
dpc-4915	2	3	secukinumab	secukinumab	NOUN
dpc-4915	2	4	treatment	treatment	NOUN
dpc-4915	2	5	in	in	ADP
dpc-4915	2	6	patients	patient	NOUN
dpc-4915	2	7	with	with	ADP
dpc-4915	2	8	hidradenitis	hidradenitis	PROPN
dpc-4915	2	9	suppurativa	suppurativa	NOUN
dpc-4915	2	10	in	in	ADP
dpc-4915	2	11	real	real	ADJ
dpc-4915	2	12	-	-	PUNCT
dpc-4915	2	13	world	world	NOUN
dpc-4915	2	14	clinical	clinical	ADJ
dpc-4915	2	15	settings	setting	NOUN
dpc-4915	2	16	:	:	PUNCT
dpc-4915	2	17	a	a	DET
dpc-4915	2	18	multicenter	multicenter	ADJ
dpc-4915	2	19	study	study	NOUN
dpc-4915	2	20	ece	ece	PROPN
dpc-4915	2	21	erbağcı1	erbağcı1	PROPN
dpc-4915	2	22	,	,	PUNCT
dpc-4915	2	23	özge	özge	PROPN
dpc-4915	2	24	sevil	sevil	PROPN
dpc-4915	2	25	karstarlı	karstarlı	PROPN
dpc-4915	2	26	bakay2	bakay2	PROPN
dpc-4915	2	27	,	,	PUNCT
dpc-4915	2	28	fatma	fatma	PROPN
dpc-4915	2	29	aslı	aslı	PROPN
dpc-4915	2	30	hapa3	hapa3	PROPN
dpc-4915	2	31	1	1	NUM
dpc-4915	2	32	uşak	uşak	PROPN
dpc-4915	2	33	university	university	NOUN
dpc-4915	2	34	training	training	NOUN
dpc-4915	2	35	and	and	CCONJ
dpc-4915	2	36	research	research	NOUN
dpc-4915	2	37	hospital	hospital	NOUN
dpc-4915	2	38	,	,	PUNCT
dpc-4915	2	39	department	department	NOUN
dpc-4915	2	40	of	of	ADP
dpc-4915	2	41	dermatology	dermatology	NOUN
dpc-4915	2	42	and	and	CCONJ
dpc-4915	2	43	venereology	venereology	NOUN
dpc-4915	2	44	,	,	PUNCT
dpc-4915	2	45	uşak	uşak	NOUN
dpc-4915	2	46	,	,	PUNCT
dpc-4915	2	47	turkey	turkey	NOUN
dpc-4915	2	48	2	2	NUM
dpc-4915	2	49	pamukkale	pamukkale	PROPN
dpc-4915	2	50	university	university	NOUN
dpc-4915	2	51	faculty	faculty	NOUN
dpc-4915	2	52	of	of	ADP
dpc-4915	2	53	medicine	medicine	NOUN
dpc-4915	2	54	,	,	PUNCT
dpc-4915	2	55	department	department	NOUN
dpc-4915	2	56	of	of	ADP
dpc-4915	2	57	dermatology	dermatology	NOUN
dpc-4915	2	58	and	and	CCONJ
dpc-4915	2	59	venereology	venereology	NOUN
dpc-4915	2	60	,	,	PUNCT
dpc-4915	2	61	denizli	denizli	PROPN
dpc-4915	2	62	,	,	PUNCT
dpc-4915	2	63	turkey	turkey	PROPN
dpc-4915	2	64	3	3	NUM
dpc-4915	2	65	izmir	izmir	X
dpc-4915	2	66	democracy	democracy	PROPN
dpc-4915	2	67	university	university	PROPN
dpc-4915	2	68	buca	buca	PROPN
dpc-4915	2	69	seyfi	seyfi	PROPN
dpc-4915	2	70	demirsoy	demirsoy	ADJ
dpc-4915	2	71	training	training	NOUN
dpc-4915	2	72	and	and	CCONJ
dpc-4915	2	73	research	research	NOUN
dpc-4915	2	74	hospital	hospital	NOUN
dpc-4915	2	75	,	,	PUNCT
dpc-4915	2	76	department	department	NOUN
dpc-4915	2	77	of	of	ADP
dpc-4915	2	78	dermatology	dermatology	NOUN
dpc-4915	2	79	and	and	CCONJ
dpc-4915	2	80	venereology	venereology	NOUN
dpc-4915	2	81	,	,	PUNCT
dpc-4915	2	82	izmir	izmir	PROPN
dpc-4915	2	83	,	,	PUNCT
dpc-4915	2	84	turkey	turkey	PROPN
dpc-4915	2	85	key	key	ADJ
dpc-4915	2	86	words	word	NOUN
dpc-4915	2	87	:	:	PUNCT
dpc-4915	2	88	secukinumab	secukinumab	NOUN
dpc-4915	2	89	,	,	PUNCT
dpc-4915	2	90	hidradenitis	hidradenitis	PROPN
dpc-4915	2	91	suppurativa	suppurativa	PROPN
dpc-4915	2	92	,	,	PUNCT
dpc-4915	2	93	real	real	ADJ
dpc-4915	2	94	-	-	PUNCT
dpc-4915	2	95	world	world	NOUN
dpc-4915	2	96	,	,	PUNCT
dpc-4915	2	97	treatment	treatment	NOUN
dpc-4915	2	98	citation	citation	NOUN
dpc-4915	2	99	:	:	PUNCT
dpc-4915	2	100	erbağcı	erbağcı	NOUN
dpc-4915	2	101	e	e	NOUN
dpc-4915	2	102	,	,	PUNCT
dpc-4915	2	103	karstarlı	karstarlı	VERB
dpc-4915	2	104	bakay	bakay	PROPN
dpc-4915	2	105	os	os	ADV
dpc-4915	2	106	,	,	PUNCT
dpc-4915	2	107	aslı	aslı	VERB
dpc-4915	2	108	hapa	hapa	PROPN
dpc-4915	2	109	f.	f.	PROPN
dpc-4915	2	110	secukinumab	secukinumab	PROPN
dpc-4915	2	111	treatment	treatment	NOUN
dpc-4915	2	112	in	in	ADP
dpc-4915	2	113	patients	patient	NOUN
dpc-4915	2	114	with	with	ADP
dpc-4915	2	115	hidradenitis	hidradenitis	PROPN
dpc-4915	2	116	suppurativa	suppurativa	NOUN
dpc-4915	2	117	in	in	ADP
dpc-4915	2	118	real	real	ADJ
dpc-4915	2	119	-	-	PUNCT
dpc-4915	2	120	world	world	NOUN
dpc-4915	2	121	clinical	clinical	ADJ
dpc-4915	2	122	settings	setting	NOUN
dpc-4915	2	123	:	:	PUNCT
dpc-4915	2	124	a	a	DET
dpc-4915	2	125	multicenter	multicenter	ADJ
dpc-4915	2	126	study	study	NOUN
dpc-4915	2	127	.	.	PUNCT
dpc-4915	3	1	dermatol	dermatol	NOUN
dpc-4915	3	2	pract	pract	PROPN
dpc-4915	3	3	concept	concept	NOUN
dpc-4915	3	4	.	.	PUNCT
dpc-4915	4	1	2025;15(1):4915	2025;15(1):4915	NUM
dpc-4915	4	2	.	.	PUNCT
dpc-4915	4	3	doi	doi	NOUN
dpc-4915	4	4	:	:	PUNCT
dpc-4915	4	5	https://doi.org/10.5826/dpc.1501a4915	https://doi.org/10.5826/dpc.1501a4915	X
dpc-4915	4	6	accepted	accept	VERB
dpc-4915	4	7	:	:	PUNCT
dpc-4915	4	8	october	october	PROPN
dpc-4915	4	9	26	26	NUM
dpc-4915	4	10	,	,	PUNCT
dpc-4915	4	11	2024	2024	NUM
dpc-4915	4	12	;	;	PUNCT
dpc-4915	4	13	published	publish	VERB
dpc-4915	4	14	:	:	PUNCT
dpc-4915	5	1	january	january	PROPN
dpc-4915	5	2	2025	2025	NUM
dpc-4915	5	3	copyright	copyright	NOUN
dpc-4915	5	4	:	:	PUNCT
dpc-4915	6	1	©	©	PROPN
dpc-4915	6	2	2024	2024	NUM
dpc-4915	6	3	erbağcı	erbağcı	NOUN
dpc-4915	6	4	et	et	PROPN
dpc-4915	6	5	al	al	PROPN
dpc-4915	6	6	.	.	PUNCT
dpc-4915	7	1	this	this	PRON
dpc-4915	7	2	is	be	AUX
dpc-4915	7	3	an	an	DET
dpc-4915	7	4	open	open	ADJ
dpc-4915	7	5	-	-	PUNCT
dpc-4915	7	6	access	access	NOUN
dpc-4915	7	7	article	article	NOUN
dpc-4915	7	8	distributed	distribute	VERB
dpc-4915	7	9	under	under	ADP
dpc-4915	7	10	the	the	DET
dpc-4915	7	11	terms	term	NOUN
dpc-4915	7	12	of	of	ADP
dpc-4915	7	13	the	the	DET
dpc-4915	7	14	creative	creative	ADJ
dpc-4915	7	15	commons	common	NOUN
dpc-4915	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4915	7	17	license	license	NOUN
dpc-4915	7	18	(	(	PUNCT
dpc-4915	7	19	by	by	ADP
dpc-4915	7	20	-	-	PUNCT
dpc-4915	7	21	nc-4.0	nc-4.0	NOUN
dpc-4915	7	22	)	)	PUNCT
dpc-4915	7	23	,	,	PUNCT
dpc-4915	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4915	7	25	,	,	PUNCT
dpc-4915	7	26	which	which	PRON
dpc-4915	7	27	permits	permit	VERB
dpc-4915	7	28	unrestricted	unrestricted	ADJ
dpc-4915	7	29	noncommercial	noncommercial	ADJ
dpc-4915	7	30	use	use	NOUN
dpc-4915	7	31	,	,	PUNCT
dpc-4915	7	32	distribution	distribution	NOUN
dpc-4915	7	33	,	,	PUNCT
dpc-4915	7	34	and	and	CCONJ
dpc-4915	7	35	reproduction	reproduction	NOUN
dpc-4915	7	36	in	in	ADP
dpc-4915	7	37	any	any	DET
dpc-4915	7	38	medium	medium	NOUN
dpc-4915	7	39	,	,	PUNCT
dpc-4915	7	40	provided	provide	VERB
dpc-4915	7	41	the	the	DET
dpc-4915	7	42	original	original	ADJ
dpc-4915	7	43	authors	author	NOUN
dpc-4915	7	44	and	and	CCONJ
dpc-4915	7	45	source	source	NOUN
dpc-4915	7	46	are	be	AUX
dpc-4915	7	47	credited	credit	VERB
dpc-4915	7	48	.	.	PUNCT
dpc-4915	8	1	funding	funding	NOUN
dpc-4915	8	2	:	:	PUNCT
dpc-4915	8	3	none	none	NOUN
dpc-4915	8	4	.	.	PUNCT
dpc-4915	9	1	competing	compete	VERB
dpc-4915	9	2	interests	interest	NOUN
dpc-4915	9	3	:	:	PUNCT
dpc-4915	9	4	none	none	NOUN
dpc-4915	9	5	.	.	PUNCT
dpc-4915	10	1	authorship	authorship	NOUN
dpc-4915	10	2	:	:	PUNCT
dpc-4915	10	3	all	all	DET
dpc-4915	10	4	authors	author	NOUN
dpc-4915	10	5	have	have	AUX
dpc-4915	10	6	contributed	contribute	VERB
dpc-4915	10	7	significantly	significantly	ADV
dpc-4915	10	8	to	to	ADP
dpc-4915	10	9	this	this	DET
dpc-4915	10	10	publication	publication	NOUN
dpc-4915	10	11	.	.	PUNCT
dpc-4915	11	1	ethical	ethical	ADJ
dpc-4915	11	2	approval	approval	NOUN
dpc-4915	11	3	:	:	PUNCT
dpc-4915	11	4	izmir	izmir	PROPN
dpc-4915	11	5	democracy	democracy	PROPN
dpc-4915	11	6	university	university	PROPN
dpc-4915	11	7	buca	buca	PROPN
dpc-4915	11	8	seyfi	seyfi	PROPN
dpc-4915	11	9	demirsoy	demirsoy	ADJ
dpc-4915	11	10	training	training	NOUN
dpc-4915	11	11	and	and	CCONJ
dpc-4915	11	12	research	research	NOUN
dpc-4915	11	13	hospital	hospital	NOUN
dpc-4915	11	14	non	non	ADJ
dpc-4915	11	15	-	-	ADJ
dpc-4915	11	16	interventional	interventional	ADJ
dpc-4915	11	17	research	research	NOUN
dpc-4915	11	18	ethics	ethic	NOUN
dpc-4915	11	19	committee2024/252	committee2024/252	PROPN
dpc-4915	11	20	.	.	PUNCT
dpc-4915	12	1	corresponding	correspond	VERB
dpc-4915	12	2	author	author	NOUN
dpc-4915	12	3	:	:	PUNCT
dpc-4915	12	4	ece	ece	PROPN
dpc-4915	12	5	erbağcı	erbağcı	PROPN
dpc-4915	12	6	,	,	PUNCT
dpc-4915	12	7	uşak	uşak	ADJ
dpc-4915	12	8	university	university	NOUN
dpc-4915	12	9	training	training	NOUN
dpc-4915	12	10	and	and	CCONJ
dpc-4915	12	11	research	research	NOUN
dpc-4915	12	12	hospital	hospital	NOUN
dpc-4915	12	13	,	,	PUNCT
dpc-4915	12	14	department	department	NOUN
dpc-4915	12	15	of	of	ADP
dpc-4915	12	16	dermatology	dermatology	NOUN
dpc-4915	12	17	and	and	CCONJ
dpc-4915	12	18	venereology	venereology	NOUN
dpc-4915	12	19	,	,	PUNCT
dpc-4915	12	20	uşak	uşak	NOUN
dpc-4915	12	21	,	,	PUNCT
dpc-4915	12	22	turkey	turkey	NOUN
dpc-4915	12	23	.	.	PUNCT
dpc-4915	13	1	e	e	X
dpc-4915	13	2	-	-	NOUN
dpc-4915	13	3	mail	mail	NOUN
dpc-4915	13	4	:	:	PUNCT
dpc-4915	13	5	ece.erbagci@gmail.com	ece.erbagci@gmail.com	PROPN
dpc-4915	13	6	introduction	introduction	NOUN
dpc-4915	13	7	:	:	PUNCT
dpc-4915	13	8	treatment	treatment	NOUN
dpc-4915	13	9	of	of	ADP
dpc-4915	13	10	hidradenitis	hidradenitis	PROPN
dpc-4915	13	11	suppurativa	suppurativa	PROPN
dpc-4915	13	12	(	(	PUNCT
dpc-4915	13	13	hs	hs	X
dpc-4915	13	14	)	)	PUNCT
dpc-4915	13	15	remains	remain	VERB
dpc-4915	13	16	a	a	DET
dpc-4915	13	17	challenge	challenge	NOUN
dpc-4915	13	18	in	in	ADP
dpc-4915	13	19	clinical	clinical	ADJ
dpc-4915	13	20	practice	practice	NOUN
dpc-4915	13	21	for	for	ADP
dpc-4915	13	22	dermatologists	dermatologist	NOUN
dpc-4915	13	23	.	.	PUNCT
dpc-4915	14	1	although	although	SCONJ
dpc-4915	14	2	the	the	DET
dpc-4915	14	3	effectiveness	effectiveness	NOUN
dpc-4915	14	4	and	and	CCONJ
dpc-4915	14	5	safety	safety	NOUN
dpc-4915	14	6	of	of	ADP
dpc-4915	14	7	secukinumab	secukinumab	NOUN
dpc-4915	14	8	(	(	PUNCT
dpc-4915	14	9	sec	sec	PROPN
dpc-4915	14	10	)	)	PUNCT
dpc-4915	14	11	in	in	ADP
dpc-4915	14	12	the	the	DET
dpc-4915	14	13	treatment	treatment	NOUN
dpc-4915	14	14	of	of	ADP
dpc-4915	14	15	hs	hs	PRON
dpc-4915	14	16	have	have	AUX
dpc-4915	14	17	been	be	AUX
dpc-4915	14	18	demonstrated	demonstrate	VERB
dpc-4915	14	19	in	in	ADP
dpc-4915	14	20	phase	phase	NOUN
dpc-4915	14	21	iii	iii	NUM
dpc-4915	14	22	studies	study	NOUN
dpc-4915	14	23	,	,	PUNCT
dpc-4915	14	24	real	real	ADJ
dpc-4915	14	25	-	-	PUNCT
dpc-4915	14	26	world	world	NOUN
dpc-4915	14	27	data	datum	NOUN
dpc-4915	14	28	is	be	AUX
dpc-4915	14	29	limited	limited	ADJ
dpc-4915	14	30	.	.	PUNCT
dpc-4915	15	1	objectives	objective	NOUN
dpc-4915	15	2	:	:	PUNCT
dpc-4915	15	3	we	we	PRON
dpc-4915	15	4	conducted	conduct	VERB
dpc-4915	15	5	a	a	DET
dpc-4915	15	6	retrospective	retrospective	ADJ
dpc-4915	15	7	multicenter	multicenter	ADJ
dpc-4915	15	8	study	study	NOUN
dpc-4915	15	9	to	to	PART
dpc-4915	15	10	evaluate	evaluate	VERB
dpc-4915	15	11	the	the	DET
dpc-4915	15	12	effectiveness	effectiveness	NOUN
dpc-4915	15	13	and	and	CCONJ
dpc-4915	15	14	safety	safety	NOUN
dpc-4915	15	15	of	of	ADP
dpc-4915	15	16	sec	sec	PROPN
dpc-4915	15	17	treatment	treatment	NOUN
dpc-4915	15	18	in	in	ADP
dpc-4915	15	19	hs	hs	PROPN
dpc-4915	15	20	patients	patient	NOUN
dpc-4915	15	21	in	in	ADP
dpc-4915	15	22	real	real	ADJ
dpc-4915	15	23	-	-	PUNCT
dpc-4915	15	24	world	world	NOUN
dpc-4915	15	25	settings	setting	NOUN
dpc-4915	15	26	.	.	PUNCT
dpc-4915	16	1	methods	method	NOUN
dpc-4915	16	2	:	:	PUNCT
dpc-4915	16	3	adult	adult	NOUN
dpc-4915	16	4	patients	patient	NOUN
dpc-4915	16	5	who	who	PRON
dpc-4915	16	6	were	be	AUX
dpc-4915	16	7	diagnosed	diagnose	VERB
dpc-4915	16	8	with	with	ADP
dpc-4915	16	9	hs	hs	PROPN
dpc-4915	16	10	and	and	CCONJ
dpc-4915	16	11	used	use	VERB
dpc-4915	16	12	sec	sec	PROPN
dpc-4915	16	13	for	for	ADP
dpc-4915	16	14	at	at	ADV
dpc-4915	16	15	least	least	ADV
dpc-4915	16	16	3	3	NUM
dpc-4915	16	17	months	month	NOUN
dpc-4915	16	18	were	be	AUX
dpc-4915	16	19	included	include	VERB
dpc-4915	16	20	in	in	ADP
dpc-4915	16	21	the	the	DET
dpc-4915	16	22	study	study	NOUN
dpc-4915	16	23	.	.	PUNCT
dpc-4915	17	1	results	result	NOUN
dpc-4915	17	2	:	:	PUNCT
dpc-4915	17	3	a	a	DET
dpc-4915	17	4	total	total	NOUN
dpc-4915	17	5	of	of	ADP
dpc-4915	17	6	31	31	NUM
dpc-4915	17	7	patients	patient	NOUN
dpc-4915	17	8	were	be	AUX
dpc-4915	17	9	included	include	VERB
dpc-4915	17	10	in	in	ADP
dpc-4915	17	11	the	the	DET
dpc-4915	17	12	study	study	NOUN
dpc-4915	17	13	;	;	PUNCT
dpc-4915	17	14	14	14	NUM
dpc-4915	17	15	of	of	ADP
dpc-4915	17	16	them	they	PRON
dpc-4915	17	17	(	(	PUNCT
dpc-4915	17	18	45.2	45.2	NUM
dpc-4915	17	19	%	%	NOUN
dpc-4915	17	20	)	)	PUNCT
dpc-4915	17	21	were	be	AUX
dpc-4915	17	22	female	female	ADJ
dpc-4915	17	23	.	.	PUNCT
dpc-4915	18	1	the	the	DET
dpc-4915	18	2	mean	mean	ADJ
dpc-4915	18	3	age	age	NOUN
dpc-4915	18	4	was	be	AUX
dpc-4915	18	5	39.32	39.32	NUM
dpc-4915	18	6	±	±	NUM
dpc-4915	18	7	10.26	10.26	NUM
dpc-4915	18	8	years	year	NOUN
dpc-4915	18	9	,	,	PUNCT
dpc-4915	18	10	and	and	CCONJ
dpc-4915	18	11	the	the	DET
dpc-4915	18	12	mean	mean	ADJ
dpc-4915	18	13	disease	disease	NOUN
dpc-4915	18	14	duration	duration	NOUN
dpc-4915	18	15	was	be	AUX
dpc-4915	18	16	11.77	11.77	NUM
dpc-4915	18	17	±	±	NUM
dpc-4915	18	18	7.99	7.99	NUM
dpc-4915	18	19	years	year	NOUN
dpc-4915	18	20	.	.	PUNCT
dpc-4915	19	1	nine	nine	NUM
dpc-4915	19	2	(	(	PUNCT
dpc-4915	19	3	29	29	NUM
dpc-4915	19	4	%	%	NOUN
dpc-4915	19	5	)	)	PUNCT
dpc-4915	19	6	patients	patient	NOUN
dpc-4915	19	7	were	be	AUX
dpc-4915	19	8	biologic	biologic	ADJ
dpc-4915	19	9	-	-	PUNCT
dpc-4915	19	10	naive	naive	ADJ
dpc-4915	19	11	and	and	CCONJ
dpc-4915	19	12	10	10	NUM
dpc-4915	19	13	(	(	PUNCT
dpc-4915	19	14	32.3	32.3	NUM
dpc-4915	19	15	%	%	NOUN
dpc-4915	19	16	)	)	PUNCT
dpc-4915	19	17	were	be	AUX
dpc-4915	19	18	adalimumab	adalimumab	ADV
dpc-4915	19	19	-	-	PUNCT
dpc-4915	19	20	naive	naive	ADJ
dpc-4915	19	21	.	.	PUNCT
dpc-4915	20	1	disease	disease	NOUN
dpc-4915	20	2	severity	severity	NOUN
dpc-4915	20	3	was	be	AUX
dpc-4915	20	4	hurley	hurley	NOUN
dpc-4915	20	5	i	i	PRON
dpc-4915	20	6	in	in	ADP
dpc-4915	20	7	7	7	NUM
dpc-4915	20	8	patients	patient	NOUN
dpc-4915	20	9	(	(	PUNCT
dpc-4915	20	10	22.6	22.6	NUM
dpc-4915	20	11	%	%	NOUN
dpc-4915	20	12	)	)	PUNCT
dpc-4915	20	13	,	,	PUNCT
dpc-4915	20	14	hurley	hurley	PROPN
dpc-4915	20	15	ii	ii	PROPN
dpc-4915	20	16	in	in	ADP
dpc-4915	20	17	9	9	NUM
dpc-4915	20	18	patients	patient	NOUN
dpc-4915	20	19	(	(	PUNCT
dpc-4915	20	20	29	29	NUM
dpc-4915	20	21	%	%	NOUN
dpc-4915	20	22	)	)	PUNCT
dpc-4915	20	23	,	,	PUNCT
dpc-4915	20	24	and	and	CCONJ
dpc-4915	20	25	hurley	hurley	PROPN
dpc-4915	20	26	iii	iii	PROPN
dpc-4915	20	27	in	in	ADP
dpc-4915	20	28	15	15	NUM
dpc-4915	20	29	patients	patient	NOUN
dpc-4915	20	30	(	(	PUNCT
dpc-4915	20	31	48.4	48.4	NUM
dpc-4915	20	32	%	%	NOUN
dpc-4915	20	33	)	)	PUNCT
dpc-4915	20	34	.	.	PUNCT
dpc-4915	21	1	the	the	DET
dpc-4915	21	2	hidradenitis	hidradenitis	PROPN
dpc-4915	21	3	suppurativa	suppurativa	PROPN
dpc-4915	21	4	clinical	clinical	ADJ
dpc-4915	21	5	response	response	NOUN
dpc-4915	21	6	(	(	PUNCT
dpc-4915	21	7	hiscr	hiscr	PROPN
dpc-4915	21	8	)	)	PUNCT
dpc-4915	21	9	was	be	AUX
dpc-4915	21	10	achieved	achieve	VERB
dpc-4915	21	11	in	in	ADP
dpc-4915	21	12	20	20	NUM
dpc-4915	21	13	patients	patient	NOUN
dpc-4915	21	14	(	(	PUNCT
dpc-4915	21	15	64.5	64.5	NUM
dpc-4915	21	16	%	%	NOUN
dpc-4915	21	17	)	)	PUNCT
dpc-4915	21	18	in	in	ADP
dpc-4915	21	19	the	the	DET
dpc-4915	21	20	third	third	ADJ
dpc-4915	21	21	month	month	NOUN
dpc-4915	21	22	of	of	ADP
dpc-4915	21	23	treatment	treatment	NOUN
dpc-4915	21	24	.	.	PUNCT
dpc-4915	22	1	sec	sec	PROPN
dpc-4915	22	2	treatment	treatment	NOUN
dpc-4915	22	3	was	be	AUX
dpc-4915	22	4	discontinued	discontinue	VERB
dpc-4915	22	5	due	due	ADJ
dpc-4915	22	6	to	to	ADP
dpc-4915	22	7	primary	primary	ADJ
dpc-4915	22	8	ineffectiveness	ineffectiveness	NOUN
dpc-4915	22	9	in	in	ADP
dpc-4915	22	10	9	9	NUM
dpc-4915	22	11	(	(	PUNCT
dpc-4915	22	12	29	29	NUM
dpc-4915	22	13	%	%	NOUN
dpc-4915	22	14	)	)	PUNCT
dpc-4915	22	15	abstract	abstract	ADJ
dpc-4915	22	16	2	2	NUM
dpc-4915	22	17	original	original	ADJ
dpc-4915	22	18	article	article	NOUN
dpc-4915	22	19	|	|	ADV
dpc-4915	22	20	dermatol	dermatol	ADJ
dpc-4915	22	21	pract	pract	NOUN
dpc-4915	22	22	concept	concept	NOUN
dpc-4915	22	23	.	.	PUNCT
dpc-4915	23	1	2025;15(1):4915	2025;15(1):4915	NUM
dpc-4915	23	2	introduction	introduction	NOUN
dpc-4915	23	3	hidradenitis	hidradenitis	PROPN
dpc-4915	23	4	suppurativa	suppurativa	PROPN
dpc-4915	23	5	(	(	PUNCT
dpc-4915	23	6	hs	hs	X
dpc-4915	23	7	)	)	PUNCT
dpc-4915	23	8	is	be	AUX
dpc-4915	23	9	a	a	DET
dpc-4915	23	10	chronic	chronic	NOUN
dpc-4915	23	11	,	,	PUNCT
dpc-4915	23	12	inflammatory	inflammatory	ADJ
dpc-4915	23	13	,	,	PUNCT
dpc-4915	23	14	recurrent	recurrent	NOUN
dpc-4915	23	15	,	,	PUNCT
dpc-4915	23	16	and	and	CCONJ
dpc-4915	23	17	debilitating	debilitate	VERB
dpc-4915	23	18	skin	skin	NOUN
dpc-4915	23	19	follicular	follicular	ADJ
dpc-4915	23	20	disease	disease	NOUN
dpc-4915	23	21	that	that	PRON
dpc-4915	23	22	typically	typically	ADV
dpc-4915	23	23	appears	appear	VERB
dpc-4915	23	24	after	after	ADP
dpc-4915	23	25	puberty	puberty	NOUN
dpc-4915	23	26	with	with	ADP
dpc-4915	23	27	painful	painful	ADJ
dpc-4915	23	28	deep	deep	ADV
dpc-4915	23	29	-	-	PUNCT
dpc-4915	23	30	seated	seat	VERB
dpc-4915	23	31	,	,	PUNCT
dpc-4915	23	32	inflamed	inflame	VERB
dpc-4915	23	33	lesions	lesion	NOUN
dpc-4915	23	34	in	in	ADP
dpc-4915	23	35	the	the	DET
dpc-4915	23	36	apocrine	apocrine	ADJ
dpc-4915	23	37	gland	gland	NOUN
dpc-4915	23	38	-	-	PUNCT
dpc-4915	23	39	bearing	bear	VERB
dpc-4915	23	40	areas	area	NOUN
dpc-4915	23	41	of	of	ADP
dpc-4915	23	42	the	the	DET
dpc-4915	23	43	body	body	NOUN
dpc-4915	23	44	,	,	PUNCT
dpc-4915	23	45	most	most	ADV
dpc-4915	23	46	commonly	commonly	ADV
dpc-4915	23	47	the	the	DET
dpc-4915	23	48	axillary	axillary	ADJ
dpc-4915	23	49	,	,	PUNCT
dpc-4915	23	50	inguinal	inguinal	ADJ
dpc-4915	23	51	,	,	PUNCT
dpc-4915	23	52	and	and	CCONJ
dpc-4915	23	53	anogenital	anogenital	ADJ
dpc-4915	23	54	regions	region	NOUN
dpc-4915	23	55	[	[	X
dpc-4915	23	56	1	1	NUM
dpc-4915	23	57	]	]	PUNCT
dpc-4915	23	58	.	.	PUNCT
dpc-4915	24	1	the	the	DET
dpc-4915	24	2	underlying	underlying	ADJ
dpc-4915	24	3	pathogenic	pathogenic	ADJ
dpc-4915	24	4	mechanism	mechanism	NOUN
dpc-4915	24	5	of	of	ADP
dpc-4915	24	6	hs	hs	PRON
dpc-4915	24	7	mainly	mainly	ADV
dpc-4915	24	8	involves	involve	VERB
dpc-4915	24	9	the	the	DET
dpc-4915	24	10	formation	formation	NOUN
dpc-4915	24	11	of	of	ADP
dpc-4915	24	12	follicular	follicular	ADJ
dpc-4915	24	13	hyperkeratosis	hyperkeratosis	NOUN
dpc-4915	24	14	first	first	ADV
dpc-4915	24	15	,	,	PUNCT
dpc-4915	24	16	causing	cause	VERB
dpc-4915	24	17	plugging	plugging	NOUN
dpc-4915	24	18	and	and	CCONJ
dpc-4915	24	19	dilation	dilation	NOUN
dpc-4915	24	20	that	that	PRON
dpc-4915	24	21	results	result	VERB
dpc-4915	24	22	in	in	ADP
dpc-4915	24	23	follicle	follicle	NOUN
dpc-4915	24	24	rupture	rupture	NOUN
dpc-4915	24	25	with	with	ADP
dpc-4915	24	26	subsequent	subsequent	ADJ
dpc-4915	24	27	inflammation	inflammation	NOUN
dpc-4915	24	28	,	,	PUNCT
dpc-4915	24	29	abscess	abscess	NOUN
dpc-4915	24	30	,	,	PUNCT
dpc-4915	24	31	and	and	CCONJ
dpc-4915	24	32	sinus	sinus	NOUN
dpc-4915	24	33	tract	tract	NOUN
dpc-4915	24	34	formation	formation	NOUN
dpc-4915	24	35	[	[	X
dpc-4915	24	36	1	1	NUM
dpc-4915	24	37	,	,	PUNCT
dpc-4915	24	38	2	2	NUM
dpc-4915	24	39	]	]	PUNCT
dpc-4915	24	40	.	.	PUNCT
dpc-4915	25	1	hs	hs	PROPN
dpc-4915	25	2	immunopathogenesis	immunopathogenesis	PROPN
dpc-4915	25	3	is	be	AUX
dpc-4915	25	4	complex	complex	ADJ
dpc-4915	25	5	and	and	CCONJ
dpc-4915	25	6	still	still	ADV
dpc-4915	25	7	being	be	AUX
dpc-4915	25	8	studied	study	VERB
dpc-4915	25	9	,	,	PUNCT
dpc-4915	25	10	but	but	CCONJ
dpc-4915	25	11	several	several	ADJ
dpc-4915	25	12	cytokines	cytokine	NOUN
dpc-4915	25	13	appear	appear	VERB
dpc-4915	25	14	to	to	PART
dpc-4915	25	15	be	be	AUX
dpc-4915	25	16	especially	especially	ADV
dpc-4915	25	17	important	important	ADJ
dpc-4915	25	18	.	.	PUNCT
dpc-4915	26	1	il-17	il-17	PART
dpc-4915	26	2	levels	level	NOUN
dpc-4915	26	3	are	be	AUX
dpc-4915	26	4	increased	increase	VERB
dpc-4915	26	5	in	in	ADP
dpc-4915	26	6	serum	serum	NOUN
dpc-4915	26	7	and	and	CCONJ
dpc-4915	26	8	in	in	ADP
dpc-4915	26	9	damaged	damage	VERB
dpc-4915	26	10	skin	skin	NOUN
dpc-4915	26	11	of	of	ADP
dpc-4915	26	12	hs	hs	PROPN
dpc-4915	26	13	patients	patient	NOUN
dpc-4915	26	14	compared	compare	VERB
dpc-4915	26	15	with	with	ADP
dpc-4915	26	16	healthy	healthy	ADJ
dpc-4915	26	17	control	control	NOUN
dpc-4915	26	18	subjects	subject	NOUN
dpc-4915	26	19	,	,	PUNCT
dpc-4915	26	20	and	and	CCONJ
dpc-4915	26	21	they	they	PRON
dpc-4915	26	22	correlate	correlate	VERB
dpc-4915	26	23	with	with	ADP
dpc-4915	26	24	disease	disease	NOUN
dpc-4915	26	25	severity	severity	NOUN
dpc-4915	27	1	[	[	X
dpc-4915	27	2	3	3	NUM
dpc-4915	27	3	,	,	PUNCT
dpc-4915	27	4	4	4	NUM
dpc-4915	27	5	]	]	PUNCT
dpc-4915	27	6	.	.	PUNCT
dpc-4915	28	1	therefore	therefore	ADV
dpc-4915	28	2	,	,	PUNCT
dpc-4915	28	3	blockade	blockade	NOUN
dpc-4915	28	4	of	of	ADP
dpc-4915	28	5	the	the	DET
dpc-4915	28	6	il-17	il-17	NUM
dpc-4915	28	7	pathway	pathway	NOUN
dpc-4915	28	8	may	may	AUX
dpc-4915	28	9	be	be	AUX
dpc-4915	28	10	a	a	DET
dpc-4915	28	11	promising	promising	ADJ
dpc-4915	28	12	treatment	treatment	NOUN
dpc-4915	28	13	for	for	ADP
dpc-4915	28	14	hs	hs	PROPN
dpc-4915	28	15	.	.	PROPN
dpc-4915	28	16	secukinumab	secukinumab	PROPN
dpc-4915	28	17	(	(	PUNCT
dpc-4915	28	18	sec	sec	PROPN
dpc-4915	28	19	)	)	PUNCT
dpc-4915	28	20	is	be	AUX
dpc-4915	28	21	a	a	DET
dpc-4915	28	22	monoclonal	monoclonal	NOUN
dpc-4915	28	23	antibody	antibody	NOUN
dpc-4915	28	24	targeting	target	VERB
dpc-4915	28	25	il-17a	il-17a	PROPN
dpc-4915	28	26	,	,	PUNCT
dpc-4915	28	27	and	and	CCONJ
dpc-4915	28	28	its	its	PRON
dpc-4915	28	29	effectiveness	effectiveness	NOUN
dpc-4915	28	30	and	and	CCONJ
dpc-4915	28	31	safety	safety	NOUN
dpc-4915	28	32	in	in	ADP
dpc-4915	28	33	the	the	DET
dpc-4915	28	34	treatment	treatment	NOUN
dpc-4915	28	35	of	of	ADP
dpc-4915	28	36	hs	hs	PRON
dpc-4915	28	37	were	be	AUX
dpc-4915	28	38	demonstrated	demonstrate	VERB
dpc-4915	28	39	in	in	ADP
dpc-4915	28	40	the	the	DET
dpc-4915	28	41	sunshine	sunshine	NOUN
dpc-4915	28	42	and	and	CCONJ
dpc-4915	28	43	sunrise	sunrise	VERB
dpc-4915	28	44	phase	phase	NOUN
dpc-4915	28	45	iii	iii	NOUN
dpc-4915	28	46	randomized	randomize	VERB
dpc-4915	28	47	clinical	clinical	ADJ
dpc-4915	28	48	trials	trial	NOUN
dpc-4915	28	49	[	[	X
dpc-4915	28	50	5	5	NUM
dpc-4915	28	51	]	]	PUNCT
dpc-4915	28	52	.	.	PUNCT
dpc-4915	29	1	adalimumab	adalimumab	PROPN
dpc-4915	29	2	,	,	PUNCT
dpc-4915	29	3	an	an	DET
dpc-4915	29	4	anti	anti	ADJ
dpc-4915	29	5	-	-	ADJ
dpc-4915	29	6	tumor	tumor	ADJ
dpc-4915	29	7	necrosis	necrosis	NOUN
dpc-4915	29	8	factor	factor	NOUN
dpc-4915	29	9	(	(	PUNCT
dpc-4915	29	10	tnf)-α	tnf)-α	NOUN
dpc-4915	29	11	inhibitor	inhibitor	NOUN
dpc-4915	29	12	,	,	PUNCT
dpc-4915	29	13	was	be	AUX
dpc-4915	29	14	the	the	DET
dpc-4915	29	15	first	first	ADJ
dpc-4915	29	16	biologic	biologic	NOUN
dpc-4915	29	17	drug	drug	NOUN
dpc-4915	29	18	approved	approve	VERB
dpc-4915	29	19	for	for	ADP
dpc-4915	29	20	the	the	DET
dpc-4915	29	21	treatment	treatment	NOUN
dpc-4915	29	22	of	of	ADP
dpc-4915	29	23	hs	hs	PROPN
dpc-4915	29	24	.	.	PROPN
dpc-4915	29	25	recently	recently	ADV
dpc-4915	29	26	,	,	PUNCT
dpc-4915	29	27	the	the	DET
dpc-4915	29	28	european	european	PROPN
dpc-4915	29	29	medicines	medicines	PROPN
dpc-4915	29	30	agency	agency	NOUN
dpc-4915	29	31	(	(	PUNCT
dpc-4915	29	32	ema	ema	PROPN
dpc-4915	29	33	)	)	PUNCT
dpc-4915	29	34	and	and	CCONJ
dpc-4915	29	35	the	the	DET
dpc-4915	29	36	us	us	PROPN
dpc-4915	29	37	food	food	NOUN
dpc-4915	29	38	and	and	CCONJ
dpc-4915	29	39	drug	drug	PROPN
dpc-4915	29	40	administration	administration	PROPN
dpc-4915	29	41	(	(	PUNCT
dpc-4915	29	42	fda	fda	PROPN
dpc-4915	29	43	)	)	PUNCT
dpc-4915	29	44	also	also	ADV
dpc-4915	29	45	approved	approve	VERB
dpc-4915	29	46	sec	sec	PROPN
dpc-4915	29	47	for	for	ADP
dpc-4915	29	48	use	use	NOUN
dpc-4915	29	49	in	in	ADP
dpc-4915	29	50	adults	adult	NOUN
dpc-4915	29	51	with	with	ADP
dpc-4915	29	52	active	active	ADJ
dpc-4915	29	53	moderate	moderate	ADJ
dpc-4915	29	54	-	-	PUNCT
dpc-4915	29	55	to	to	ADP
dpc-4915	29	56	-	-	PUNCT
dpc-4915	29	57	severe	severe	ADJ
dpc-4915	29	58	hs	hs	PROPN
dpc-4915	30	1	[	[	X
dpc-4915	30	2	6	6	NUM
dpc-4915	30	3	,	,	PUNCT
dpc-4915	30	4	7	7	NUM
dpc-4915	30	5	]	]	PUNCT
dpc-4915	30	6	.	.	PUNCT
dpc-4915	31	1	however	however	ADV
dpc-4915	31	2	,	,	PUNCT
dpc-4915	31	3	there	there	PRON
dpc-4915	31	4	are	be	VERB
dpc-4915	31	5	few	few	ADJ
dpc-4915	31	6	real	real	ADJ
dpc-4915	31	7	-	-	PUNCT
dpc-4915	31	8	world	world	NOUN
dpc-4915	31	9	studies	study	NOUN
dpc-4915	31	10	on	on	ADP
dpc-4915	31	11	the	the	DET
dpc-4915	31	12	effectiveness	effectiveness	NOUN
dpc-4915	31	13	and	and	CCONJ
dpc-4915	31	14	safety	safety	NOUN
dpc-4915	31	15	of	of	ADP
dpc-4915	31	16	sec	sec	PROPN
dpc-4915	31	17	in	in	ADP
dpc-4915	31	18	hs	hs	PROPN
dpc-4915	31	19	treatment	treatment	PROPN
dpc-4915	31	20	.	.	PUNCT
dpc-4915	32	1	objectives	objective	NOUN
dpc-4915	32	2	in	in	ADP
dpc-4915	32	3	our	our	PRON
dpc-4915	32	4	study	study	NOUN
dpc-4915	32	5	,	,	PUNCT
dpc-4915	32	6	we	we	PRON
dpc-4915	32	7	aimed	aim	VERB
dpc-4915	32	8	to	to	PART
dpc-4915	32	9	share	share	VERB
dpc-4915	32	10	our	our	PRON
dpc-4915	32	11	real	real	ADJ
dpc-4915	32	12	-	-	PUNCT
dpc-4915	32	13	world	world	NOUN
dpc-4915	32	14	data	datum	NOUN
dpc-4915	32	15	on	on	ADP
dpc-4915	32	16	the	the	DET
dpc-4915	32	17	efficacy	efficacy	NOUN
dpc-4915	32	18	and	and	CCONJ
dpc-4915	32	19	safety	safety	NOUN
dpc-4915	32	20	of	of	ADP
dpc-4915	32	21	sec	sec	PROPN
dpc-4915	32	22	treatment	treatment	NOUN
dpc-4915	32	23	in	in	ADP
dpc-4915	32	24	hs	hs	PROPN
dpc-4915	32	25	patients	patient	NOUN
dpc-4915	32	26	.	.	PUNCT
dpc-4915	33	1	methods	method	NOUN
dpc-4915	33	2	we	we	PRON
dpc-4915	33	3	conducted	conduct	VERB
dpc-4915	33	4	a	a	DET
dpc-4915	33	5	retrospective	retrospective	ADJ
dpc-4915	33	6	multicenter	multicenter	ADJ
dpc-4915	33	7	study	study	NOUN
dpc-4915	33	8	to	to	PART
dpc-4915	33	9	evaluate	evaluate	VERB
dpc-4915	33	10	the	the	DET
dpc-4915	33	11	effectiveness	effectiveness	NOUN
dpc-4915	33	12	and	and	CCONJ
dpc-4915	33	13	safety	safety	NOUN
dpc-4915	33	14	of	of	ADP
dpc-4915	33	15	sec	sec	PROPN
dpc-4915	33	16	treatment	treatment	NOUN
dpc-4915	33	17	in	in	ADP
dpc-4915	33	18	hs	hs	PROPN
dpc-4915	33	19	patients	patient	NOUN
dpc-4915	33	20	in	in	ADP
dpc-4915	33	21	a	a	DET
dpc-4915	33	22	real	real	ADJ
dpc-4915	33	23	-	-	PUNCT
dpc-4915	33	24	world	world	NOUN
dpc-4915	33	25	setting	setting	NOUN
dpc-4915	33	26	.	.	PUNCT
dpc-4915	34	1	sec	sec	PROPN
dpc-4915	34	2	has	have	AUX
dpc-4915	34	3	been	be	AUX
dpc-4915	34	4	available	available	ADJ
dpc-4915	34	5	in	in	ADP
dpc-4915	34	6	our	our	PRON
dpc-4915	34	7	country	country	NOUN
dpc-4915	34	8	since	since	SCONJ
dpc-4915	34	9	2018	2018	NUM
dpc-4915	34	10	.	.	PUNCT
dpc-4915	35	1	therefore	therefore	ADV
dpc-4915	35	2	,	,	PUNCT
dpc-4915	35	3	hospital	hospital	NOUN
dpc-4915	35	4	electronic	electronic	ADJ
dpc-4915	35	5	record	record	NOUN
dpc-4915	35	6	systems	system	NOUN
dpc-4915	35	7	were	be	AUX
dpc-4915	35	8	retrospectively	retrospectively	ADV
dpc-4915	35	9	scanned	scan	VERB
dpc-4915	35	10	between	between	ADP
dpc-4915	35	11	1.1.2018	1.1.2018	NUM
dpc-4915	35	12	and	and	CCONJ
dpc-4915	35	13	1.3.2024	1.3.2024	NUM
dpc-4915	35	14	(	(	PUNCT
dpc-4915	35	15	end	end	NOUN
dpc-4915	35	16	date	date	NOUN
dpc-4915	35	17	of	of	ADP
dpc-4915	35	18	inclusion	inclusion	NOUN
dpc-4915	35	19	in	in	ADP
dpc-4915	35	20	the	the	DET
dpc-4915	35	21	study	study	NOUN
dpc-4915	35	22	)	)	PUNCT
dpc-4915	35	23	.	.	PUNCT
dpc-4915	36	1	adult	adult	NOUN
dpc-4915	36	2	patients	patient	NOUN
dpc-4915	36	3	(	(	PUNCT
dpc-4915	36	4	age	age	NOUN
dpc-4915	36	5	≥18	≥18	NUM
dpc-4915	36	6	years	year	NOUN
dpc-4915	36	7	)	)	PUNCT
dpc-4915	36	8	who	who	PRON
dpc-4915	36	9	were	be	AUX
dpc-4915	36	10	diagnosed	diagnose	VERB
dpc-4915	36	11	with	with	ADP
dpc-4915	36	12	hs	hs	PROPN
dpc-4915	36	13	and	and	CCONJ
dpc-4915	36	14	used	use	VERB
dpc-4915	36	15	sec	sec	PROPN
dpc-4915	36	16	for	for	ADP
dpc-4915	36	17	at	at	ADV
dpc-4915	36	18	least	least	ADV
dpc-4915	36	19	3	3	NUM
dpc-4915	36	20	months	month	NOUN
dpc-4915	36	21	during	during	ADP
dpc-4915	36	22	the	the	DET
dpc-4915	36	23	specified	specify	VERB
dpc-4915	36	24	date	date	NOUN
dpc-4915	36	25	range	range	NOUN
dpc-4915	36	26	were	be	AUX
dpc-4915	36	27	included	include	VERB
dpc-4915	36	28	in	in	ADP
dpc-4915	36	29	the	the	DET
dpc-4915	36	30	study	study	NOUN
dpc-4915	36	31	.	.	PUNCT
dpc-4915	37	1	from	from	ADP
dpc-4915	37	2	the	the	DET
dpc-4915	37	3	past	past	ADJ
dpc-4915	37	4	medical	medical	ADJ
dpc-4915	37	5	records	record	NOUN
dpc-4915	37	6	,	,	PUNCT
dpc-4915	37	7	patient	patient	ADJ
dpc-4915	37	8	age	age	NOUN
dpc-4915	37	9	,	,	PUNCT
dpc-4915	37	10	sex	sex	NOUN
dpc-4915	37	11	,	,	PUNCT
dpc-4915	37	12	body	body	NOUN
dpc-4915	37	13	weight	weight	NOUN
dpc-4915	37	14	(	(	PUNCT
dpc-4915	37	15	kg	kg	NOUN
dpc-4915	37	16	)	)	PUNCT
dpc-4915	37	17	,	,	PUNCT
dpc-4915	37	18	height	height	NOUN
dpc-4915	37	19	(	(	PUNCT
dpc-4915	37	20	cm	cm	NOUN
dpc-4915	37	21	)	)	PUNCT
dpc-4915	37	22	,	,	PUNCT
dpc-4915	37	23	body	body	NOUN
dpc-4915	37	24	mass	mass	NOUN
dpc-4915	37	25	index	index	NOUN
dpc-4915	37	26	(	(	PUNCT
dpc-4915	37	27	bmi	bmi	PROPN
dpc-4915	37	28	)	)	PUNCT
dpc-4915	37	29	,	,	PUNCT
dpc-4915	37	30	smoking	smoking	NOUN
dpc-4915	37	31	status	status	NOUN
dpc-4915	37	32	,	,	PUNCT
dpc-4915	37	33	comorbidities	comorbiditie	NOUN
dpc-4915	37	34	,	,	PUNCT
dpc-4915	37	35	age	age	NOUN
dpc-4915	37	36	at	at	ADP
dpc-4915	37	37	disease	disease	NOUN
dpc-4915	37	38	onset	onset	VERB
dpc-4915	37	39	,	,	PUNCT
dpc-4915	37	40	duration	duration	NOUN
dpc-4915	37	41	of	of	ADP
dpc-4915	37	42	disease	disease	NOUN
dpc-4915	37	43	,	,	PUNCT
dpc-4915	37	44	duration	duration	NOUN
dpc-4915	37	45	of	of	ADP
dpc-4915	37	46	medication	medication	NOUN
dpc-4915	37	47	(	(	PUNCT
dpc-4915	37	48	sec	sec	PROPN
dpc-4915	37	49	)	)	PUNCT
dpc-4915	37	50	use	use	NOUN
dpc-4915	37	51	,	,	PUNCT
dpc-4915	37	52	additional	additional	ADJ
dpc-4915	37	53	treatments	treatment	NOUN
dpc-4915	37	54	used	use	VERB
dpc-4915	37	55	for	for	ADP
dpc-4915	37	56	hs	hs	INTJ
dpc-4915	37	57	(	(	PUNCT
dpc-4915	37	58	if	if	SCONJ
dpc-4915	37	59	any	any	PRON
dpc-4915	37	60	)	)	PUNCT
dpc-4915	37	61	,	,	PUNCT
dpc-4915	37	62	previous	previous	ADJ
dpc-4915	37	63	treatments	treatment	NOUN
dpc-4915	37	64	(	(	PUNCT
dpc-4915	37	65	systemic	systemic	ADJ
dpc-4915	37	66	antibiotics	antibiotic	NOUN
dpc-4915	37	67	,	,	PUNCT
dpc-4915	37	68	immunosuppressants	immunosuppressant	NOUN
dpc-4915	37	69	,	,	PUNCT
dpc-4915	37	70	acitretin	acitretin	NOUN
dpc-4915	37	71	,	,	PUNCT
dpc-4915	37	72	surgery	surgery	NOUN
dpc-4915	37	73	,	,	PUNCT
dpc-4915	37	74	etc	etc	X
dpc-4915	37	75	.	.	X
dpc-4915	37	76	)	)	PUNCT
dpc-4915	37	77	,	,	PUNCT
dpc-4915	37	78	areas	area	NOUN
dpc-4915	37	79	of	of	ADP
dpc-4915	37	80	hs	hs	PROPN
dpc-4915	37	81	involvement	involvement	PROPN
dpc-4915	37	82	,	,	PUNCT
dpc-4915	37	83	disease	disease	NOUN
dpc-4915	37	84	severity	severity	NOUN
dpc-4915	37	85	(	(	PUNCT
dpc-4915	37	86	hurley	hurley	NOUN
dpc-4915	37	87	stage	stage	NOUN
dpc-4915	37	88	)	)	PUNCT
dpc-4915	37	89	,	,	PUNCT
dpc-4915	37	90	and	and	CCONJ
dpc-4915	37	91	adverse	adverse	ADJ
dpc-4915	37	92	effects	effect	NOUN
dpc-4915	37	93	(	(	PUNCT
dpc-4915	37	94	if	if	SCONJ
dpc-4915	37	95	any	any	PRON
dpc-4915	37	96	)	)	PUNCT
dpc-4915	37	97	with	with	ADP
dpc-4915	37	98	sec	sec	PROPN
dpc-4915	37	99	treatment	treatment	NOUN
dpc-4915	37	100	were	be	AUX
dpc-4915	37	101	noted	note	VERB
dpc-4915	37	102	.	.	PUNCT
dpc-4915	38	1	the	the	DET
dpc-4915	38	2	hidradenitis	hidradenitis	PROPN
dpc-4915	38	3	suppurativa	suppurativa	PROPN
dpc-4915	38	4	clinical	clinical	ADJ
dpc-4915	38	5	response	response	NOUN
dpc-4915	38	6	(	(	PUNCT
dpc-4915	38	7	hiscr	hiscr	PROPN
dpc-4915	38	8	)	)	PUNCT
dpc-4915	38	9	,	,	PUNCT
dpc-4915	38	10	which	which	PRON
dpc-4915	38	11	is	be	AUX
dpc-4915	38	12	a	a	DET
dpc-4915	38	13	validated	validate	VERB
dpc-4915	38	14	treatment	treatment	NOUN
dpc-4915	38	15	endpoint	endpoint	NOUN
dpc-4915	38	16	for	for	ADP
dpc-4915	38	17	hs	hs	PROPN
dpc-4915	38	18	,	,	PUNCT
dpc-4915	38	19	is	be	AUX
dpc-4915	38	20	defined	define	VERB
dpc-4915	38	21	as	as	ADP
dpc-4915	38	22	a	a	DET
dpc-4915	38	23	≥50	≥50	NUM
dpc-4915	38	24	%	%	NOUN
dpc-4915	38	25	reduction	reduction	NOUN
dpc-4915	38	26	in	in	ADP
dpc-4915	38	27	inflammatory	inflammatory	ADJ
dpc-4915	38	28	lesion	lesion	NOUN
dpc-4915	38	29	count	count	NOUN
dpc-4915	38	30	(	(	PUNCT
dpc-4915	38	31	sum	sum	NOUN
dpc-4915	38	32	of	of	ADP
dpc-4915	38	33	abscesses	abscess	NOUN
dpc-4915	38	34	and	and	CCONJ
dpc-4915	38	35	inflammatory	inflammatory	ADJ
dpc-4915	38	36	nodules	nodule	NOUN
dpc-4915	38	37	)	)	PUNCT
dpc-4915	38	38	and	and	CCONJ
dpc-4915	38	39	no	no	DET
dpc-4915	38	40	increase	increase	NOUN
dpc-4915	38	41	in	in	ADP
dpc-4915	38	42	abscesses	abscess	NOUN
dpc-4915	38	43	or	or	CCONJ
dpc-4915	38	44	draining	drain	VERB
dpc-4915	38	45	fistulas	fistula	NOUN
dpc-4915	38	46	when	when	SCONJ
dpc-4915	38	47	compared	compare	VERB
dpc-4915	38	48	with	with	ADP
dpc-4915	38	49	baseline	baseline	NOUN
dpc-4915	38	50	[	[	X
dpc-4915	38	51	8	8	NUM
dpc-4915	38	52	]	]	PUNCT
dpc-4915	38	53	.	.	PUNCT
dpc-4915	39	1	the	the	DET
dpc-4915	39	2	primary	primary	ADJ
dpc-4915	39	3	endpoint	endpoint	NOUN
dpc-4915	39	4	to	to	PART
dpc-4915	39	5	evaluate	evaluate	VERB
dpc-4915	39	6	the	the	DET
dpc-4915	39	7	effectiveness	effectiveness	NOUN
dpc-4915	39	8	of	of	ADP
dpc-4915	39	9	sec	sec	PROPN
dpc-4915	39	10	in	in	ADP
dpc-4915	39	11	our	our	PRON
dpc-4915	39	12	study	study	NOUN
dpc-4915	39	13	was	be	AUX
dpc-4915	39	14	to	to	PART
dpc-4915	39	15	determine	determine	VERB
dpc-4915	39	16	the	the	DET
dpc-4915	39	17	proportion	proportion	NOUN
dpc-4915	39	18	of	of	ADP
dpc-4915	39	19	patients	patient	NOUN
dpc-4915	39	20	who	who	PRON
dpc-4915	39	21	achieved	achieve	VERB
dpc-4915	39	22	a	a	DET
dpc-4915	39	23	hiscr	hiscr	NOUN
dpc-4915	39	24	response	response	NOUN
dpc-4915	39	25	at	at	ADP
dpc-4915	39	26	3	3	NUM
dpc-4915	39	27	months	month	NOUN
dpc-4915	39	28	of	of	ADP
dpc-4915	39	29	treatment	treatment	NOUN
dpc-4915	39	30	.	.	PUNCT
dpc-4915	40	1	as	as	ADP
dpc-4915	40	2	a	a	DET
dpc-4915	40	3	loading	loading	NOUN
dpc-4915	40	4	dose	dose	NOUN
dpc-4915	40	5	of	of	ADP
dpc-4915	40	6	sec	sec	PROPN
dpc-4915	40	7	,	,	PUNCT
dpc-4915	40	8	300	300	NUM
dpc-4915	40	9	mg	mg	NOUN
dpc-4915	40	10	subcutaneously	subcutaneously	ADV
dpc-4915	40	11	was	be	AUX
dpc-4915	40	12	administered	administer	VERB
dpc-4915	40	13	to	to	ADP
dpc-4915	40	14	all	all	DET
dpc-4915	40	15	patients	patient	NOUN
dpc-4915	40	16	once	once	ADV
dpc-4915	40	17	a	a	DET
dpc-4915	40	18	week	week	NOUN
dpc-4915	40	19	for	for	ADP
dpc-4915	40	20	5	5	NUM
dpc-4915	40	21	weeks	week	NOUN
dpc-4915	40	22	,	,	PUNCT
dpc-4915	40	23	and	and	CCONJ
dpc-4915	40	24	then	then	ADV
dpc-4915	40	25	the	the	DET
dpc-4915	40	26	maintenance	maintenance	NOUN
dpc-4915	40	27	dose	dose	NOUN
dpc-4915	40	28	was	be	AUX
dpc-4915	40	29	started	start	VERB
dpc-4915	40	30	.	.	PUNCT
dpc-4915	41	1	the	the	DET
dpc-4915	41	2	local	local	ADJ
dpc-4915	41	3	ethics	ethic	NOUN
dpc-4915	41	4	committee	committee	NOUN
dpc-4915	41	5	approved	approve	VERB
dpc-4915	41	6	the	the	DET
dpc-4915	41	7	study	study	NOUN
dpc-4915	41	8	protocol	protocol	NOUN
dpc-4915	41	9	.	.	PUNCT
dpc-4915	42	1	statistical	statistical	ADJ
dpc-4915	42	2	analyses	analysis	NOUN
dpc-4915	42	3	were	be	AUX
dpc-4915	42	4	made	make	VERB
dpc-4915	42	5	in	in	ADP
dpc-4915	42	6	the	the	DET
dpc-4915	42	7	spss	spss	NOUN
dpc-4915	42	8	for	for	ADP
dpc-4915	42	9	windows	window	NOUN
dpc-4915	42	10	version	version	PROPN
dpc-4915	42	11	23.0	23.0	NUM
dpc-4915	42	12	package	package	NOUN
dpc-4915	42	13	program	program	NOUN
dpc-4915	42	14	.	.	PUNCT
dpc-4915	43	1	numerical	numerical	PROPN
dpc-4915	43	2	variables	variable	NOUN
dpc-4915	43	3	were	be	AUX
dpc-4915	43	4	summarized	summarize	VERB
dpc-4915	43	5	as	as	ADP
dpc-4915	43	6	mean	mean	NOUN
dpc-4915	43	7	±	±	NUM
dpc-4915	43	8	standard	standard	ADJ
dpc-4915	43	9	deviation	deviation	NOUN
dpc-4915	43	10	(	(	PUNCT
dpc-4915	43	11	sd	sd	NOUN
dpc-4915	43	12	)	)	PUNCT
dpc-4915	43	13	,	,	PUNCT
dpc-4915	43	14	median	median	NOUN
dpc-4915	43	15	,	,	PUNCT
dpc-4915	43	16	min	min	ADJ
dpc-4915	43	17	-	-	ADJ
dpc-4915	43	18	max	max	PROPN
dpc-4915	43	19	values	value	NOUN
dpc-4915	43	20	,	,	PUNCT
dpc-4915	43	21	and	and	CCONJ
dpc-4915	43	22	categorical	categorical	ADJ
dpc-4915	43	23	variables	variable	NOUN
dpc-4915	43	24	were	be	AUX
dpc-4915	43	25	summarized	summarize	VERB
dpc-4915	43	26	as	as	ADP
dpc-4915	43	27	numbers	number	NOUN
dpc-4915	43	28	and	and	CCONJ
dpc-4915	43	29	percentages	percentage	NOUN
dpc-4915	43	30	.	.	PUNCT
dpc-4915	44	1	appropriate	appropriate	ADJ
dpc-4915	44	2	parametric	parametric	ADJ
dpc-4915	44	3	or	or	CCONJ
dpc-4915	44	4	non	non	ADJ
dpc-4915	44	5	-	-	ADJ
dpc-4915	44	6	parametric	parametric	ADJ
dpc-4915	44	7	statistical	statistical	ADJ
dpc-4915	44	8	tests	test	NOUN
dpc-4915	44	9	were	be	AUX
dpc-4915	44	10	used	use	VERB
dpc-4915	44	11	according	accord	VERB
dpc-4915	44	12	to	to	ADP
dpc-4915	44	13	the	the	DET
dpc-4915	44	14	distribution	distribution	NOUN
dpc-4915	44	15	and	and	CCONJ
dpc-4915	44	16	types	type	NOUN
dpc-4915	44	17	of	of	ADP
dpc-4915	44	18	variables	variable	NOUN
dpc-4915	44	19	.	.	PUNCT
dpc-4915	45	1	the	the	DET
dpc-4915	45	2	significance	significance	NOUN
dpc-4915	45	3	level	level	NOUN
dpc-4915	45	4	was	be	AUX
dpc-4915	45	5	taken	take	VERB
dpc-4915	45	6	as	as	ADP
dpc-4915	45	7	p	p	NOUN
dpc-4915	45	8	<	<	X
dpc-4915	45	9	0.05	0.05	NUM
dpc-4915	45	10	.	.	PUNCT
dpc-4915	46	1	results	result	VERB
dpc-4915	46	2	a	a	DET
dpc-4915	46	3	total	total	NOUN
dpc-4915	46	4	of	of	ADP
dpc-4915	46	5	31	31	NUM
dpc-4915	46	6	patients	patient	NOUN
dpc-4915	46	7	diagnosed	diagnose	VERB
dpc-4915	46	8	with	with	ADP
dpc-4915	46	9	hs	hs	PRON
dpc-4915	46	10	who	who	PRON
dpc-4915	46	11	used	use	VERB
dpc-4915	46	12	sec	sec	PROPN
dpc-4915	46	13	for	for	ADP
dpc-4915	46	14	at	at	ADV
dpc-4915	46	15	least	least	ADV
dpc-4915	46	16	3	3	NUM
dpc-4915	46	17	months	month	NOUN
dpc-4915	46	18	were	be	AUX
dpc-4915	46	19	included	include	VERB
dpc-4915	46	20	in	in	ADP
dpc-4915	46	21	the	the	DET
dpc-4915	46	22	study	study	NOUN
dpc-4915	46	23	;	;	PUNCT
dpc-4915	46	24	14	14	NUM
dpc-4915	46	25	(	(	PUNCT
dpc-4915	46	26	45.2	45.2	NUM
dpc-4915	46	27	%	%	NOUN
dpc-4915	46	28	)	)	PUNCT
dpc-4915	46	29	were	be	AUX
dpc-4915	46	30	female	female	ADJ
dpc-4915	46	31	.	.	PUNCT
dpc-4915	47	1	the	the	DET
dpc-4915	47	2	mean	mean	ADJ
dpc-4915	47	3	age	age	NOUN
dpc-4915	47	4	was	be	AUX
dpc-4915	47	5	39.32	39.32	NUM
dpc-4915	47	6	±	±	NUM
dpc-4915	47	7	10.26	10.26	NUM
dpc-4915	47	8	years	year	NOUN
dpc-4915	47	9	,	,	PUNCT
dpc-4915	47	10	the	the	DET
dpc-4915	47	11	mean	mean	ADJ
dpc-4915	47	12	disease	disease	NOUN
dpc-4915	47	13	duration	duration	NOUN
dpc-4915	47	14	was	be	AUX
dpc-4915	47	15	11.77	11.77	NUM
dpc-4915	47	16	±	±	NUM
dpc-4915	47	17	7.99	7.99	NUM
dpc-4915	47	18	years	year	NOUN
dpc-4915	47	19	,	,	PUNCT
dpc-4915	47	20	and	and	CCONJ
dpc-4915	47	21	the	the	DET
dpc-4915	47	22	mean	mean	ADJ
dpc-4915	47	23	body	body	NOUN
dpc-4915	47	24	mass	mass	NOUN
dpc-4915	47	25	index	index	NOUN
dpc-4915	47	26	(	(	PUNCT
dpc-4915	47	27	bmi	bmi	PROPN
dpc-4915	47	28	)	)	PUNCT
dpc-4915	47	29	was	be	AUX
dpc-4915	47	30	28.59	28.59	NUM
dpc-4915	47	31	±	±	NUM
dpc-4915	47	32	5.83	5.83	NUM
dpc-4915	47	33	kg	kg	NOUN
dpc-4915	47	34	/	/	SYM
dpc-4915	47	35	m2	m2	PROPN
dpc-4915	47	36	.	.	PROPN
dpc-4915	48	1	thirteen	thirteen	NUM
dpc-4915	48	2	(	(	PUNCT
dpc-4915	48	3	41.9	41.9	NUM
dpc-4915	48	4	%	%	NOUN
dpc-4915	48	5	)	)	PUNCT
dpc-4915	48	6	patients	patient	NOUN
dpc-4915	48	7	were	be	AUX
dpc-4915	48	8	smokers	smoker	NOUN
dpc-4915	48	9	,	,	PUNCT
dpc-4915	48	10	and	and	CCONJ
dpc-4915	48	11	1	1	NUM
dpc-4915	48	12	(	(	PUNCT
dpc-4915	48	13	3.2	3.2	NUM
dpc-4915	48	14	%	%	NOUN
dpc-4915	48	15	)	)	PUNCT
dpc-4915	48	16	was	be	AUX
dpc-4915	48	17	an	an	DET
dpc-4915	48	18	ex	ex	NOUN
dpc-4915	48	19	-	-	NOUN
dpc-4915	48	20	smoker	smoker	NOUN
dpc-4915	48	21	.	.	PUNCT
dpc-4915	49	1	the	the	DET
dpc-4915	49	2	most	most	ADV
dpc-4915	49	3	common	common	ADJ
dpc-4915	49	4	comorbidity	comorbidity	NOUN
dpc-4915	49	5	was	be	AUX
dpc-4915	49	6	psoriasis	psoriasis	NOUN
dpc-4915	49	7	(	(	PUNCT
dpc-4915	49	8	35.5	35.5	NUM
dpc-4915	49	9	%	%	NOUN
dpc-4915	49	10	)	)	PUNCT
dpc-4915	49	11	,	,	PUNCT
dpc-4915	49	12	followed	follow	VERB
dpc-4915	49	13	patients	patient	NOUN
dpc-4915	49	14	,	,	PUNCT
dpc-4915	49	15	secondary	secondary	ADJ
dpc-4915	49	16	ineffectiveness	ineffectiveness	NOUN
dpc-4915	49	17	in	in	ADP
dpc-4915	49	18	1	1	NUM
dpc-4915	49	19	(	(	PUNCT
dpc-4915	49	20	3.2	3.2	NUM
dpc-4915	49	21	%	%	NOUN
dpc-4915	49	22	)	)	PUNCT
dpc-4915	49	23	patient	patient	NOUN
dpc-4915	49	24	,	,	PUNCT
dpc-4915	49	25	adverse	adverse	ADJ
dpc-4915	49	26	effects	effect	NOUN
dpc-4915	49	27	in	in	ADP
dpc-4915	49	28	1	1	NUM
dpc-4915	49	29	(	(	PUNCT
dpc-4915	49	30	3.2	3.2	NUM
dpc-4915	49	31	%	%	NOUN
dpc-4915	49	32	)	)	PUNCT
dpc-4915	49	33	patient	patient	NOUN
dpc-4915	49	34	,	,	PUNCT
dpc-4915	49	35	and	and	CCONJ
dpc-4915	49	36	loss	loss	NOUN
dpc-4915	49	37	of	of	ADP
dpc-4915	49	38	follow	follow	NOUN
dpc-4915	49	39	-	-	PUNCT
dpc-4915	49	40	up	up	NOUN
dpc-4915	49	41	in	in	ADP
dpc-4915	49	42	1	1	NUM
dpc-4915	49	43	(	(	PUNCT
dpc-4915	49	44	3.2	3.2	NUM
dpc-4915	49	45	%	%	NOUN
dpc-4915	49	46	)	)	PUNCT
dpc-4915	49	47	patient	patient	NOUN
dpc-4915	49	48	.	.	PUNCT
dpc-4915	50	1	paradoxical	paradoxical	ADJ
dpc-4915	50	2	pyoderma	pyoderma	NOUN
dpc-4915	50	3	gangrenosum	gangrenosum	NOUN
dpc-4915	50	4	was	be	AUX
dpc-4915	50	5	observed	observe	VERB
dpc-4915	50	6	as	as	ADP
dpc-4915	50	7	an	an	DET
dpc-4915	50	8	adverse	adverse	ADJ
dpc-4915	50	9	effect	effect	NOUN
dpc-4915	50	10	in	in	ADP
dpc-4915	50	11	1	1	NUM
dpc-4915	50	12	patient	patient	NOUN
dpc-4915	50	13	that	that	PRON
dpc-4915	50	14	resolved	resolve	VERB
dpc-4915	50	15	after	after	ADP
dpc-4915	50	16	discontinuing	discontinue	VERB
dpc-4915	50	17	sec	sec	PROPN
dpc-4915	50	18	and	and	CCONJ
dpc-4915	50	19	starting	start	VERB
dpc-4915	50	20	infliximab	infliximab	PROPN
dpc-4915	50	21	.	.	PUNCT
dpc-4915	51	1	conclusions	conclusion	NOUN
dpc-4915	51	2	:	:	PUNCT
dpc-4915	51	3	sec	sec	PROPN
dpc-4915	51	4	appears	appear	VERB
dpc-4915	51	5	to	to	PART
dpc-4915	51	6	be	be	AUX
dpc-4915	51	7	an	an	DET
dpc-4915	51	8	effective	effective	ADJ
dpc-4915	51	9	and	and	CCONJ
dpc-4915	51	10	safe	safe	ADJ
dpc-4915	51	11	treatment	treatment	NOUN
dpc-4915	51	12	option	option	NOUN
dpc-4915	51	13	for	for	ADP
dpc-4915	51	14	hs	hs	PROPN
dpc-4915	51	15	,	,	PUNCT
dpc-4915	51	16	especially	especially	ADV
dpc-4915	51	17	when	when	SCONJ
dpc-4915	51	18	used	use	VERB
dpc-4915	51	19	in	in	ADP
dpc-4915	51	20	the	the	DET
dpc-4915	51	21	early	early	ADJ
dpc-4915	51	22	and	and	CCONJ
dpc-4915	51	23	mild	mild	ADJ
dpc-4915	51	24	stages	stage	NOUN
dpc-4915	51	25	of	of	ADP
dpc-4915	51	26	the	the	DET
dpc-4915	51	27	disease	disease	NOUN
dpc-4915	51	28	and	and	CCONJ
dpc-4915	51	29	in	in	ADP
dpc-4915	51	30	biologic	biologic	ADJ
dpc-4915	51	31	-	-	PUNCT
dpc-4915	51	32	naive	naive	ADJ
dpc-4915	51	33	patients	patient	NOUN
dpc-4915	51	34	.	.	PUNCT
dpc-4915	52	1	original	original	ADJ
dpc-4915	52	2	article	article	NOUN
dpc-4915	52	3	|	|	ADV
dpc-4915	52	4	dermatol	dermatol	ADJ
dpc-4915	52	5	pract	pract	NOUN
dpc-4915	52	6	concept	concept	NOUN
dpc-4915	52	7	.	.	PUNCT
dpc-4915	53	1	2025;15(1):4915	2025;15(1):4915	NUM
dpc-4915	53	2	3	3	NUM
dpc-4915	53	3	by	by	ADP
dpc-4915	53	4	arthritis	arthritis	NOUN
dpc-4915	53	5	(	(	PUNCT
dpc-4915	53	6	32.3	32.3	NUM
dpc-4915	53	7	%	%	NOUN
dpc-4915	53	8	)	)	PUNCT
dpc-4915	53	9	,	,	PUNCT
dpc-4915	53	10	diabetes	diabetes	NOUN
dpc-4915	53	11	(	(	PUNCT
dpc-4915	53	12	9.7	9.7	NUM
dpc-4915	53	13	%	%	NOUN
dpc-4915	53	14	)	)	PUNCT
dpc-4915	53	15	,	,	PUNCT
dpc-4915	53	16	and	and	CCONJ
dpc-4915	53	17	hypertension	hypertension	NOUN
dpc-4915	53	18	(	(	PUNCT
dpc-4915	53	19	9.7	9.7	NUM
dpc-4915	53	20	%	%	NOUN
dpc-4915	53	21	)	)	PUNCT
dpc-4915	53	22	.	.	PUNCT
dpc-4915	54	1	nine	nine	NUM
dpc-4915	54	2	(	(	PUNCT
dpc-4915	54	3	29	29	NUM
dpc-4915	54	4	%	%	NOUN
dpc-4915	54	5	)	)	PUNCT
dpc-4915	54	6	patients	patient	NOUN
dpc-4915	54	7	were	be	AUX
dpc-4915	54	8	biologic	biologic	ADJ
dpc-4915	54	9	-	-	PUNCT
dpc-4915	54	10	naive	naive	ADJ
dpc-4915	54	11	,	,	PUNCT
dpc-4915	54	12	and	and	CCONJ
dpc-4915	54	13	10	10	NUM
dpc-4915	54	14	(	(	PUNCT
dpc-4915	54	15	32.3	32.3	NUM
dpc-4915	54	16	%	%	NOUN
dpc-4915	54	17	)	)	PUNCT
dpc-4915	54	18	were	be	AUX
dpc-4915	54	19	adalimumab	adalimumab	ADV
dpc-4915	54	20	-	-	PUNCT
dpc-4915	54	21	naive	naive	ADJ
dpc-4915	54	22	.	.	PUNCT
dpc-4915	55	1	disease	disease	NOUN
dpc-4915	55	2	severity	severity	NOUN
dpc-4915	55	3	was	be	AUX
dpc-4915	55	4	hurley	hurley	NOUN
dpc-4915	55	5	i	i	PRON
dpc-4915	55	6	in	in	ADP
dpc-4915	55	7	7	7	NUM
dpc-4915	55	8	patients	patient	NOUN
dpc-4915	55	9	(	(	PUNCT
dpc-4915	55	10	22.6	22.6	NUM
dpc-4915	55	11	%	%	NOUN
dpc-4915	55	12	)	)	PUNCT
dpc-4915	55	13	,	,	PUNCT
dpc-4915	55	14	hurley	hurley	PROPN
dpc-4915	55	15	ii	ii	PROPN
dpc-4915	55	16	in	in	ADP
dpc-4915	55	17	9	9	NUM
dpc-4915	55	18	patients	patient	NOUN
dpc-4915	55	19	(	(	PUNCT
dpc-4915	55	20	29	29	NUM
dpc-4915	55	21	%	%	NOUN
dpc-4915	55	22	)	)	PUNCT
dpc-4915	55	23	,	,	PUNCT
dpc-4915	55	24	and	and	CCONJ
dpc-4915	55	25	hurley	hurley	PROPN
dpc-4915	55	26	iii	iii	PROPN
dpc-4915	55	27	in	in	ADP
dpc-4915	55	28	15	15	NUM
dpc-4915	55	29	patients	patient	NOUN
dpc-4915	55	30	(	(	PUNCT
dpc-4915	55	31	48.4	48.4	NUM
dpc-4915	55	32	%	%	NOUN
dpc-4915	55	33	)	)	PUNCT
dpc-4915	55	34	.	.	PUNCT
dpc-4915	56	1	the	the	DET
dpc-4915	56	2	most	most	ADV
dpc-4915	56	3	common	common	ADJ
dpc-4915	56	4	area	area	NOUN
dpc-4915	56	5	of	of	ADP
dpc-4915	56	6	involvement	involvement	NOUN
dpc-4915	56	7	was	be	AUX
dpc-4915	56	8	the	the	DET
dpc-4915	56	9	pelvic	pelvic	ADJ
dpc-4915	56	10	(	(	PUNCT
dpc-4915	56	11	96.8	96.8	NUM
dpc-4915	56	12	%	%	NOUN
dpc-4915	56	13	)	)	PUNCT
dpc-4915	56	14	,	,	PUNCT
dpc-4915	56	15	followed	follow	VERB
dpc-4915	56	16	by	by	ADP
dpc-4915	56	17	the	the	DET
dpc-4915	56	18	axilla	axilla	NOUN
dpc-4915	56	19	(	(	PUNCT
dpc-4915	56	20	93.5	93.5	NUM
dpc-4915	56	21	%	%	NOUN
dpc-4915	56	22	)	)	PUNCT
dpc-4915	56	23	and	and	CCONJ
dpc-4915	56	24	inframammary	inframammary	ADJ
dpc-4915	56	25	(	(	PUNCT
dpc-4915	56	26	35.5	35.5	NUM
dpc-4915	56	27	%	%	NOUN
dpc-4915	56	28	)	)	PUNCT
dpc-4915	56	29	,	,	PUNCT
dpc-4915	56	30	respectively	respectively	ADV
dpc-4915	56	31	.	.	PUNCT
dpc-4915	57	1	characteristics	characteristic	NOUN
dpc-4915	57	2	of	of	ADP
dpc-4915	57	3	the	the	DET
dpc-4915	57	4	patients	patient	NOUN
dpc-4915	57	5	are	be	AUX
dpc-4915	57	6	shown	show	VERB
dpc-4915	57	7	in	in	ADP
dpc-4915	57	8	table	table	NOUN
dpc-4915	57	9	1	1	NUM
dpc-4915	57	10	.	.	PUNCT
dpc-4915	58	1	the	the	DET
dpc-4915	58	2	dose	dose	NOUN
dpc-4915	58	3	of	of	ADP
dpc-4915	58	4	sec	sec	PROPN
dpc-4915	58	5	was	be	AUX
dpc-4915	58	6	150	150	NUM
dpc-4915	58	7	mg/28	mg/28	PROPN
dpc-4915	58	8	days	day	NOUN
dpc-4915	58	9	in	in	ADP
dpc-4915	58	10	1	1	NUM
dpc-4915	58	11	patient	patient	NOUN
dpc-4915	58	12	(	(	PUNCT
dpc-4915	58	13	due	due	ADP
dpc-4915	58	14	to	to	ADP
dpc-4915	58	15	the	the	DET
dpc-4915	58	16	accompanying	accompanying	ADJ
dpc-4915	58	17	diagnosis	diagnosis	NOUN
dpc-4915	58	18	of	of	ADP
dpc-4915	58	19	ankylosing	ankylose	VERB
dpc-4915	58	20	spondylitis	spondylitis	NOUN
dpc-4915	58	21	)	)	PUNCT
dpc-4915	58	22	,	,	PUNCT
dpc-4915	58	23	300	300	NUM
dpc-4915	58	24	mg/28	mg/28	PROPN
dpc-4915	58	25	days	day	NOUN
dpc-4915	58	26	in	in	ADP
dpc-4915	58	27	19	19	NUM
dpc-4915	58	28	patients	patient	NOUN
dpc-4915	58	29	,	,	PUNCT
dpc-4915	58	30	300	300	NUM
dpc-4915	58	31	mg/14	mg/14	NOUN
dpc-4915	58	32	days	day	NOUN
dpc-4915	58	33	in	in	ADP
dpc-4915	58	34	10	10	NUM
dpc-4915	58	35	patients	patient	NOUN
dpc-4915	58	36	,	,	PUNCT
dpc-4915	58	37	and	and	CCONJ
dpc-4915	58	38	300	300	NUM
dpc-4915	58	39	mg/28	mg/28	NOUN
dpc-4915	58	40	days	day	NOUN
dpc-4915	58	41	initially	initially	ADV
dpc-4915	58	42	and	and	CCONJ
dpc-4915	59	1	then	then	ADV
dpc-4915	59	2	300	300	NUM
dpc-4915	59	3	mg/14	mg/14	NOUN
dpc-4915	59	4	days	day	NOUN
dpc-4915	59	5	(	(	PUNCT
dpc-4915	59	6	due	due	ADP
dpc-4915	59	7	to	to	ADP
dpc-4915	59	8	secondary	secondary	ADJ
dpc-4915	59	9	ineffectiveness	ineffectiveness	NOUN
dpc-4915	59	10	)	)	PUNCT
dpc-4915	59	11	in	in	ADP
dpc-4915	59	12	1	1	NUM
dpc-4915	59	13	patient	patient	NOUN
dpc-4915	59	14	.	.	PUNCT
dpc-4915	60	1	the	the	DET
dpc-4915	60	2	mean	mean	ADJ
dpc-4915	60	3	duration	duration	NOUN
dpc-4915	60	4	of	of	ADP
dpc-4915	60	5	sec	sec	PROPN
dpc-4915	60	6	use	use	NOUN
dpc-4915	60	7	was	be	AUX
dpc-4915	60	8	12.06	12.06	NUM
dpc-4915	60	9	±	±	NUM
dpc-4915	60	10	10.51	10.51	NUM
dpc-4915	60	11	(	(	PUNCT
dpc-4915	60	12	min	min	NOUN
dpc-4915	60	13	:	:	PUNCT
dpc-4915	60	14	3	3	NUM
dpc-4915	60	15	–	–	PUNCT
dpc-4915	60	16	max	max	NOUN
dpc-4915	60	17	:	:	PUNCT
dpc-4915	60	18	48	48	NUM
dpc-4915	60	19	)	)	PUNCT
dpc-4915	60	20	months	month	NOUN
dpc-4915	60	21	.	.	PUNCT
dpc-4915	61	1	as	as	ADP
dpc-4915	61	2	additional	additional	ADJ
dpc-4915	61	3	treatment	treatment	NOUN
dpc-4915	61	4	combined	combine	VERB
dpc-4915	61	5	with	with	ADP
dpc-4915	61	6	sec	sec	PROPN
dpc-4915	61	7	,	,	PUNCT
dpc-4915	61	8	12	12	NUM
dpc-4915	61	9	(	(	PUNCT
dpc-4915	61	10	38.7	38.7	NUM
dpc-4915	61	11	%	%	NOUN
dpc-4915	61	12	)	)	PUNCT
dpc-4915	61	13	patients	patient	NOUN
dpc-4915	61	14	used	use	VERB
dpc-4915	61	15	oral	oral	ADJ
dpc-4915	61	16	antibiotics	antibiotic	NOUN
dpc-4915	61	17	,	,	PUNCT
dpc-4915	61	18	9	9	NUM
dpc-4915	61	19	(	(	PUNCT
dpc-4915	61	20	29	29	NUM
dpc-4915	61	21	%	%	NOUN
dpc-4915	61	22	)	)	PUNCT
dpc-4915	61	23	patients	patient	NOUN
dpc-4915	61	24	used	use	VERB
dpc-4915	61	25	methotrexate	methotrexate	NOUN
dpc-4915	61	26	,	,	PUNCT
dpc-4915	61	27	and	and	CCONJ
dpc-4915	61	28	2	2	NUM
dpc-4915	61	29	(	(	PUNCT
dpc-4915	61	30	6.5	6.5	NUM
dpc-4915	61	31	%	%	NOUN
dpc-4915	61	32	)	)	PUNCT
dpc-4915	61	33	patients	patient	NOUN
dpc-4915	61	34	used	use	VERB
dpc-4915	61	35	zinc	zinc	NOUN
dpc-4915	61	36	gluconate	gluconate	NOUN
dpc-4915	61	37	.	.	PUNCT
dpc-4915	62	1	hiscr	hiscr	PROPN
dpc-4915	62	2	was	be	AUX
dpc-4915	62	3	achieved	achieve	VERB
dpc-4915	62	4	in	in	ADP
dpc-4915	62	5	20	20	NUM
dpc-4915	62	6	patients	patient	NOUN
dpc-4915	62	7	(	(	PUNCT
dpc-4915	62	8	64.5	64.5	NUM
dpc-4915	62	9	%	%	NOUN
dpc-4915	62	10	)	)	PUNCT
dpc-4915	62	11	in	in	ADP
dpc-4915	62	12	the	the	DET
dpc-4915	62	13	third	third	ADJ
dpc-4915	62	14	month	month	NOUN
dpc-4915	62	15	of	of	ADP
dpc-4915	62	16	treatment	treatment	NOUN
dpc-4915	62	17	.	.	PUNCT
dpc-4915	63	1	sec	sec	PROPN
dpc-4915	63	2	treatment	treatment	NOUN
dpc-4915	63	3	was	be	AUX
dpc-4915	63	4	discontinued	discontinue	VERB
dpc-4915	63	5	due	due	ADJ
dpc-4915	63	6	to	to	ADP
dpc-4915	63	7	primary	primary	ADJ
dpc-4915	63	8	ineffectiveness	ineffectiveness	NOUN
dpc-4915	63	9	in	in	ADP
dpc-4915	63	10	9	9	NUM
dpc-4915	63	11	(	(	PUNCT
dpc-4915	63	12	29	29	NUM
dpc-4915	63	13	%	%	NOUN
dpc-4915	63	14	)	)	PUNCT
dpc-4915	63	15	patients	patient	NOUN
dpc-4915	63	16	,	,	PUNCT
dpc-4915	63	17	secondary	secondary	ADJ
dpc-4915	63	18	ineffectiveness	ineffectiveness	NOUN
dpc-4915	63	19	in	in	ADP
dpc-4915	63	20	1	1	NUM
dpc-4915	63	21	(	(	PUNCT
dpc-4915	63	22	3.2	3.2	NUM
dpc-4915	63	23	%	%	NOUN
dpc-4915	63	24	)	)	PUNCT
dpc-4915	63	25	patient	patient	NOUN
dpc-4915	63	26	,	,	PUNCT
dpc-4915	63	27	adverse	adverse	ADJ
dpc-4915	63	28	effects	effect	NOUN
dpc-4915	63	29	in	in	ADP
dpc-4915	63	30	1	1	NUM
dpc-4915	63	31	(	(	PUNCT
dpc-4915	63	32	3.2	3.2	NUM
dpc-4915	63	33	%	%	NOUN
dpc-4915	63	34	)	)	PUNCT
dpc-4915	63	35	patient	patient	NOUN
dpc-4915	63	36	,	,	PUNCT
dpc-4915	63	37	and	and	CCONJ
dpc-4915	63	38	loss	loss	NOUN
dpc-4915	63	39	of	of	ADP
dpc-4915	63	40	follow	follow	NOUN
dpc-4915	63	41	-	-	PUNCT
dpc-4915	63	42	up	up	NOUN
dpc-4915	63	43	in	in	ADP
dpc-4915	63	44	1	1	NUM
dpc-4915	63	45	(	(	PUNCT
dpc-4915	63	46	3.2	3.2	NUM
dpc-4915	63	47	%	%	NOUN
dpc-4915	63	48	)	)	PUNCT
dpc-4915	63	49	patient	patient	NOUN
dpc-4915	63	50	.	.	PUNCT
dpc-4915	64	1	paradoxical	paradoxical	ADJ
dpc-4915	64	2	pyoderma	pyoderma	NOUN
dpc-4915	64	3	gangrenosum	gangrenosum	NOUN
dpc-4915	64	4	was	be	AUX
dpc-4915	64	5	observed	observe	VERB
dpc-4915	64	6	as	as	ADP
dpc-4915	64	7	an	an	DET
dpc-4915	64	8	adverse	adverse	ADJ
dpc-4915	64	9	effect	effect	NOUN
dpc-4915	64	10	that	that	PRON
dpc-4915	64	11	caused	cause	VERB
dpc-4915	64	12	treatment	treatment	NOUN
dpc-4915	64	13	discontinuation	discontinuation	NOUN
dpc-4915	64	14	in	in	ADP
dpc-4915	64	15	one	one	NUM
dpc-4915	64	16	patient	patient	NOUN
dpc-4915	64	17	.	.	PUNCT
dpc-4915	65	1	a	a	DET
dpc-4915	65	2	48	48	NUM
dpc-4915	65	3	-	-	PUNCT
dpc-4915	65	4	year	year	NOUN
dpc-4915	65	5	-	-	PUNCT
dpc-4915	65	6	old	old	ADJ
dpc-4915	65	7	man	man	NOUN
dpc-4915	65	8	with	with	ADP
dpc-4915	65	9	hs	hs	PROPN
dpc-4915	65	10	developed	develop	VERB
dpc-4915	65	11	pyoderma	pyoderma	NOUN
dpc-4915	65	12	gangrenosum	gangrenosum	NOUN
dpc-4915	65	13	after	after	ADP
dpc-4915	65	14	13	13	NUM
dpc-4915	65	15	months	month	NOUN
dpc-4915	65	16	of	of	ADP
dpc-4915	65	17	sec	sec	PROPN
dpc-4915	65	18	treatment	treatment	NOUN
dpc-4915	65	19	.	.	PUNCT
dpc-4915	66	1	the	the	DET
dpc-4915	66	2	patient	patient	NOUN
dpc-4915	66	3	,	,	PUNCT
dpc-4915	66	4	who	who	PRON
dpc-4915	66	5	had	have	VERB
dpc-4915	66	6	no	no	DET
dpc-4915	66	7	other	other	ADJ
dpc-4915	66	8	disease	disease	NOUN
dpc-4915	66	9	that	that	PRON
dpc-4915	66	10	could	could	AUX
dpc-4915	66	11	explain	explain	VERB
dpc-4915	66	12	the	the	DET
dpc-4915	66	13	etiology	etiology	NOUN
dpc-4915	66	14	of	of	ADP
dpc-4915	66	15	pyoderma	pyoderma	NOUN
dpc-4915	66	16	gangrenosum	gangrenosum	NOUN
dpc-4915	66	17	,	,	PUNCT
dpc-4915	66	18	improved	improve	VERB
dpc-4915	66	19	after	after	SCONJ
dpc-4915	66	20	sec	sec	PROPN
dpc-4915	66	21	treatment	treatment	NOUN
dpc-4915	66	22	was	be	AUX
dpc-4915	66	23	discontinued	discontinue	VERB
dpc-4915	66	24	and	and	CCONJ
dpc-4915	66	25	infliximab	infliximab	NOUN
dpc-4915	66	26	was	be	AUX
dpc-4915	66	27	started	start	VERB
dpc-4915	66	28	.	.	PUNCT
dpc-4915	67	1	patients	patient	NOUN
dpc-4915	67	2	who	who	PRON
dpc-4915	67	3	achieved	achieve	VERB
dpc-4915	67	4	hiscr	hiscr	NOUN
dpc-4915	67	5	were	be	AUX
dpc-4915	67	6	compared	compare	VERB
dpc-4915	67	7	with	with	ADP
dpc-4915	67	8	those	those	PRON
dpc-4915	67	9	who	who	PRON
dpc-4915	67	10	did	do	AUX
dpc-4915	67	11	not	not	PART
dpc-4915	67	12	achieve	achieve	VERB
dpc-4915	67	13	it	it	PRON
dpc-4915	67	14	in	in	ADP
dpc-4915	67	15	terms	term	NOUN
dpc-4915	67	16	of	of	ADP
dpc-4915	67	17	their	their	PRON
dpc-4915	67	18	clinical	clinical	ADJ
dpc-4915	67	19	characteristics	characteristic	NOUN
dpc-4915	67	20	.	.	PUNCT
dpc-4915	68	1	in	in	ADP
dpc-4915	68	2	patients	patient	NOUN
dpc-4915	68	3	who	who	PRON
dpc-4915	68	4	achieved	achieve	VERB
dpc-4915	68	5	hiscr	hiscr	NOUN
dpc-4915	68	6	,	,	PUNCT
dpc-4915	68	7	disease	disease	NOUN
dpc-4915	68	8	severity	severity	NOUN
dpc-4915	68	9	was	be	AUX
dpc-4915	68	10	milder	mild	ADJ
dpc-4915	68	11	(	(	PUNCT
dpc-4915	68	12	p	p	X
dpc-4915	68	13	=	=	NOUN
dpc-4915	68	14	0.044	0.044	NUM
dpc-4915	68	15	)	)	PUNCT
dpc-4915	68	16	,	,	PUNCT
dpc-4915	68	17	disease	disease	NOUN
dpc-4915	68	18	duration	duration	NOUN
dpc-4915	68	19	was	be	AUX
dpc-4915	68	20	shorter	short	ADJ
dpc-4915	68	21	(	(	PUNCT
dpc-4915	68	22	p	p	X
dpc-4915	68	23	=	=	NOUN
dpc-4915	68	24	0.04	0.04	NUM
dpc-4915	68	25	)	)	PUNCT
dpc-4915	68	26	,	,	PUNCT
dpc-4915	68	27	duration	duration	NOUN
dpc-4915	68	28	of	of	ADP
dpc-4915	68	29	sec	sec	PROPN
dpc-4915	68	30	use	use	NOUN
dpc-4915	68	31	was	be	AUX
dpc-4915	68	32	longer	long	ADJ
dpc-4915	68	33	(	(	PUNCT
dpc-4915	68	34	due	due	ADP
dpc-4915	68	35	to	to	ADP
dpc-4915	68	36	discontinuation	discontinuation	NOUN
dpc-4915	68	37	of	of	ADP
dpc-4915	68	38	treatment	treatment	NOUN
dpc-4915	68	39	in	in	ADP
dpc-4915	68	40	those	those	PRON
dpc-4915	68	41	who	who	PRON
dpc-4915	68	42	did	do	AUX
dpc-4915	68	43	not	not	PART
dpc-4915	68	44	achieve	achieve	VERB
dpc-4915	68	45	hiscr	hiscr	NOUN
dpc-4915	68	46	)	)	PUNCT
dpc-4915	69	1	(	(	PUNCT
dpc-4915	69	2	p	p	X
dpc-4915	69	3	=	=	NOUN
dpc-4915	69	4	0.032	0.032	NUM
dpc-4915	69	5	)	)	PUNCT
dpc-4915	69	6	,	,	PUNCT
dpc-4915	69	7	use	use	NOUN
dpc-4915	69	8	of	of	ADP
dpc-4915	69	9	additional	additional	ADJ
dpc-4915	69	10	combined	combined	ADJ
dpc-4915	69	11	oral	oral	ADJ
dpc-4915	69	12	antibiotics	antibiotic	NOUN
dpc-4915	69	13	was	be	AUX
dpc-4915	69	14	less	less	ADJ
dpc-4915	69	15	(	(	PUNCT
dpc-4915	69	16	p	p	X
dpc-4915	69	17	=	=	NOUN
dpc-4915	69	18	0.007	0.007	NUM
dpc-4915	69	19	)	)	PUNCT
dpc-4915	69	20	,	,	PUNCT
dpc-4915	69	21	and	and	CCONJ
dpc-4915	69	22	naivety	naivety	NOUN
dpc-4915	69	23	to	to	ADP
dpc-4915	69	24	previous	previous	ADJ
dpc-4915	69	25	biologic	biologic	NOUN
dpc-4915	69	26	drugs	drug	NOUN
dpc-4915	69	27	(	(	PUNCT
dpc-4915	69	28	p	p	X
dpc-4915	69	29	=	=	NOUN
dpc-4915	69	30	0.012	0.012	NUM
dpc-4915	69	31	)	)	PUNCT
dpc-4915	69	32	and	and	CCONJ
dpc-4915	69	33	adalimumab	adalimumab	NOUN
dpc-4915	69	34	(	(	PUNCT
dpc-4915	69	35	p	p	NOUN
dpc-4915	69	36	=	=	NOUN
dpc-4915	69	37	0.005	0.005	NUM
dpc-4915	69	38	)	)	PUNCT
dpc-4915	69	39	was	be	AUX
dpc-4915	69	40	higher	high	ADJ
dpc-4915	69	41	.	.	PUNCT
dpc-4915	70	1	while	while	SCONJ
dpc-4915	70	2	all	all	DET
dpc-4915	70	3	biologic	biologic	ADJ
dpc-4915	70	4	-	-	PUNCT
dpc-4915	70	5	naive	naive	ADJ
dpc-4915	70	6	patients	patient	NOUN
dpc-4915	70	7	achieved	achieve	VERB
dpc-4915	70	8	hiscr	hiscr	NOUN
dpc-4915	70	9	,	,	PUNCT
dpc-4915	70	10	11/22	11/22	NUM
dpc-4915	70	11	(	(	PUNCT
dpc-4915	70	12	50	50	NUM
dpc-4915	70	13	%	%	NOUN
dpc-4915	70	14	)	)	PUNCT
dpc-4915	70	15	of	of	ADP
dpc-4915	70	16	biologic	biologic	NOUN
dpc-4915	70	17	-	-	PUNCT
dpc-4915	70	18	experienced	experience	VERB
dpc-4915	70	19	patients	patient	NOUN
dpc-4915	70	20	achieved	achieve	VERB
dpc-4915	70	21	hiscr	hiscr	NOUN
dpc-4915	70	22	.	.	PUNCT
dpc-4915	71	1	although	although	SCONJ
dpc-4915	71	2	our	our	PRON
dpc-4915	71	3	number	number	NOUN
dpc-4915	71	4	of	of	ADP
dpc-4915	71	5	cases	case	NOUN
dpc-4915	71	6	in	in	ADP
dpc-4915	71	7	the	the	DET
dpc-4915	71	8	study	study	NOUN
dpc-4915	71	9	was	be	AUX
dpc-4915	71	10	very	very	ADV
dpc-4915	71	11	limited	limited	ADJ
dpc-4915	71	12	,	,	PUNCT
dpc-4915	71	13	we	we	PRON
dpc-4915	71	14	did	do	AUX
dpc-4915	71	15	not	not	PART
dpc-4915	71	16	detect	detect	VERB
dpc-4915	71	17	any	any	DET
dpc-4915	71	18	statistically	statistically	ADV
dpc-4915	71	19	significant	significant	ADJ
dpc-4915	71	20	difference	difference	NOUN
dpc-4915	71	21	in	in	ADP
dpc-4915	71	22	terms	term	NOUN
dpc-4915	71	23	of	of	ADP
dpc-4915	71	24	clinical	clinical	ADJ
dpc-4915	71	25	and	and	CCONJ
dpc-4915	71	26	demographic	demographic	ADJ
dpc-4915	71	27	data	datum	NOUN
dpc-4915	71	28	between	between	ADP
dpc-4915	71	29	biologic	biologic	NOUN
dpc-4915	71	30	-	-	PUNCT
dpc-4915	71	31	experienced	experience	VERB
dpc-4915	71	32	patients	patient	NOUN
dpc-4915	71	33	and	and	CCONJ
dpc-4915	71	34	biologic	biologic	ADJ
dpc-4915	71	35	-	-	PUNCT
dpc-4915	71	36	naive	naive	ADJ
dpc-4915	71	37	patients	patient	NOUN
dpc-4915	71	38	(	(	PUNCT
dpc-4915	71	39	statistics	statistic	NOUN
dpc-4915	71	40	are	be	AUX
dpc-4915	71	41	not	not	PART
dpc-4915	71	42	shown	show	VERB
dpc-4915	71	43	)	)	PUNCT
dpc-4915	71	44	.	.	PUNCT
dpc-4915	72	1	no	no	DET
dpc-4915	72	2	statistically	statistically	ADV
dpc-4915	72	3	significant	significant	ADJ
dpc-4915	72	4	relationship	relationship	NOUN
dpc-4915	72	5	was	be	AUX
dpc-4915	72	6	found	find	VERB
dpc-4915	72	7	between	between	ADP
dpc-4915	72	8	hiscr	hiscr	NOUN
dpc-4915	72	9	achievement	achievement	NOUN
dpc-4915	72	10	and	and	CCONJ
dpc-4915	72	11	age	age	NOUN
dpc-4915	72	12	,	,	PUNCT
dpc-4915	72	13	sex	sex	NOUN
dpc-4915	72	14	,	,	PUNCT
dpc-4915	72	15	bmi	bmi	NOUN
dpc-4915	72	16	,	,	PUNCT
dpc-4915	72	17	smoking	smoking	NOUN
dpc-4915	72	18	status	status	NOUN
dpc-4915	72	19	,	,	PUNCT
dpc-4915	72	20	age	age	NOUN
dpc-4915	72	21	at	at	ADP
dpc-4915	72	22	disease	disease	NOUN
dpc-4915	72	23	onset	onset	VERB
dpc-4915	72	24	,	,	PUNCT
dpc-4915	72	25	areas	area	NOUN
dpc-4915	72	26	of	of	ADP
dpc-4915	72	27	involvement	involvement	NOUN
dpc-4915	72	28	,	,	PUNCT
dpc-4915	72	29	and	and	CCONJ
dpc-4915	72	30	sec	sec	PROPN
dpc-4915	72	31	dose	dose	PROPN
dpc-4915	72	32	.	.	PUNCT
dpc-4915	73	1	to	to	PART
dpc-4915	73	2	further	far	ADV
dpc-4915	73	3	analyze	analyze	VERB
dpc-4915	73	4	the	the	DET
dpc-4915	73	5	relationships	relationship	NOUN
dpc-4915	73	6	with	with	ADP
dpc-4915	73	7	hiscr	hiscr	PROPN
dpc-4915	73	8	,	,	PUNCT
dpc-4915	73	9	a	a	DET
dpc-4915	73	10	multivariate	multivariate	NOUN
dpc-4915	73	11	analysis	analysis	NOUN
dpc-4915	73	12	was	be	AUX
dpc-4915	73	13	performed	perform	VERB
dpc-4915	73	14	using	use	VERB
dpc-4915	73	15	logistic	logistic	ADJ
dpc-4915	73	16	regression	regression	NOUN
dpc-4915	73	17	with	with	ADP
dpc-4915	73	18	a	a	DET
dpc-4915	73	19	model	model	NOUN
dpc-4915	73	20	including	include	VERB
dpc-4915	73	21	all	all	DET
dpc-4915	73	22	clinical	clinical	ADJ
dpc-4915	73	23	and	and	CCONJ
dpc-4915	73	24	demographic	demographic	ADJ
dpc-4915	73	25	variables	variable	NOUN
dpc-4915	73	26	.	.	PUNCT
dpc-4915	74	1	the	the	DET
dpc-4915	74	2	multivariate	multivariate	NOUN
dpc-4915	74	3	analysis	analysis	NOUN
dpc-4915	74	4	was	be	AUX
dpc-4915	74	5	then	then	ADV
dpc-4915	74	6	repeated	repeat	VERB
dpc-4915	74	7	with	with	ADP
dpc-4915	74	8	a	a	DET
dpc-4915	74	9	second	second	ADJ
dpc-4915	74	10	model	model	NOUN
dpc-4915	74	11	that	that	PRON
dpc-4915	74	12	included	include	VERB
dpc-4915	74	13	only	only	ADV
dpc-4915	74	14	those	those	DET
dpc-4915	74	15	variables	variable	NOUN
dpc-4915	74	16	that	that	PRON
dpc-4915	74	17	showed	show	VERB
dpc-4915	74	18	a	a	DET
dpc-4915	74	19	significant	significant	ADJ
dpc-4915	74	20	or	or	CCONJ
dpc-4915	74	21	near	near	ADV
dpc-4915	74	22	-	-	PUNCT
dpc-4915	74	23	significant	significant	ADJ
dpc-4915	74	24	association	association	NOUN
dpc-4915	74	25	(	(	PUNCT
dpc-4915	74	26	p	p	NOUN
dpc-4915	74	27	≤	≤	NUM
dpc-4915	74	28	0.25	0.25	NUM
dpc-4915	74	29	)	)	PUNCT
dpc-4915	74	30	with	with	ADP
dpc-4915	74	31	hiscr	hiscr	NOUN
dpc-4915	74	32	response	response	NOUN
dpc-4915	74	33	in	in	ADP
dpc-4915	74	34	univariate	univariate	ADJ
dpc-4915	74	35	analysis	analysis	NOUN
dpc-4915	74	36	(	(	PUNCT
dpc-4915	74	37	smoking	smoking	NOUN
dpc-4915	74	38	status	status	NOUN
dpc-4915	74	39	,	,	PUNCT
dpc-4915	74	40	hurley	hurley	NOUN
dpc-4915	74	41	stage	stage	NOUN
dpc-4915	74	42	,	,	PUNCT
dpc-4915	74	43	disease	disease	NOUN
dpc-4915	74	44	duration	duration	NOUN
dpc-4915	74	45	,	,	PUNCT
dpc-4915	74	46	biologic	biologic	NOUN
dpc-4915	74	47	and	and	CCONJ
dpc-4915	74	48	adalimumab	adalimumab	NOUN
dpc-4915	74	49	naivety	naivety	NOUN
dpc-4915	74	50	)	)	PUNCT
dpc-4915	74	51	.	.	PUNCT
dpc-4915	75	1	however	however	ADV
dpc-4915	75	2	,	,	PUNCT
dpc-4915	75	3	no	no	DET
dpc-4915	75	4	significant	significant	ADJ
dpc-4915	75	5	relationship	relationship	NOUN
dpc-4915	75	6	was	be	AUX
dpc-4915	75	7	found	find	VERB
dpc-4915	75	8	between	between	ADP
dpc-4915	75	9	variables	variable	NOUN
dpc-4915	75	10	and	and	CCONJ
dpc-4915	75	11	hiscr	hiscr	NOUN
dpc-4915	75	12	in	in	ADP
dpc-4915	75	13	both	both	DET
dpc-4915	75	14	models	model	NOUN
dpc-4915	75	15	,	,	PUNCT
dpc-4915	75	16	probably	probably	ADV
dpc-4915	75	17	due	due	ADP
dpc-4915	75	18	to	to	ADP
dpc-4915	75	19	the	the	DET
dpc-4915	75	20	small	small	ADJ
dpc-4915	75	21	number	number	NOUN
dpc-4915	75	22	of	of	ADP
dpc-4915	75	23	patients	patient	NOUN
dpc-4915	75	24	.	.	PUNCT
dpc-4915	76	1	therefore	therefore	ADV
dpc-4915	76	2	,	,	PUNCT
dpc-4915	76	3	the	the	DET
dpc-4915	76	4	linear	linear	ADJ
dpc-4915	76	5	analysis	analysis	NOUN
dpc-4915	76	6	results	result	NOUN
dpc-4915	76	7	are	be	AUX
dpc-4915	76	8	shown	show	VERB
dpc-4915	76	9	in	in	ADP
dpc-4915	76	10	table	table	NOUN
dpc-4915	76	11	1	1	NUM
dpc-4915	76	12	.	.	PUNCT
dpc-4915	77	1	conclusions	conclusion	NOUN
dpc-4915	77	2	the	the	DET
dpc-4915	77	3	results	result	NOUN
dpc-4915	77	4	of	of	ADP
dpc-4915	77	5	our	our	PRON
dpc-4915	77	6	study	study	NOUN
dpc-4915	77	7	support	support	VERB
dpc-4915	77	8	the	the	DET
dpc-4915	77	9	idea	idea	NOUN
dpc-4915	77	10	that	that	SCONJ
dpc-4915	77	11	sec	sec	PROPN
dpc-4915	77	12	is	be	AUX
dpc-4915	77	13	an	an	DET
dpc-4915	77	14	effective	effective	ADJ
dpc-4915	77	15	treatment	treatment	NOUN
dpc-4915	77	16	option	option	NOUN
dpc-4915	77	17	for	for	ADP
dpc-4915	77	18	hs	hs	PROPN
dpc-4915	77	19	in	in	ADP
dpc-4915	77	20	real	real	ADJ
dpc-4915	77	21	-	-	PUNCT
dpc-4915	77	22	world	world	NOUN
dpc-4915	77	23	clinical	clinical	ADJ
dpc-4915	77	24	settings	setting	NOUN
dpc-4915	77	25	.	.	PUNCT
dpc-4915	78	1	hiscr	hiscr	PROPN
dpc-4915	78	2	was	be	AUX
dpc-4915	78	3	achieved	achieve	VERB
dpc-4915	78	4	in	in	ADP
dpc-4915	78	5	20	20	NUM
dpc-4915	78	6	(	(	PUNCT
dpc-4915	78	7	64.5	64.5	NUM
dpc-4915	78	8	%	%	NOUN
dpc-4915	78	9	)	)	PUNCT
dpc-4915	78	10	of	of	ADP
dpc-4915	78	11	our	our	PRON
dpc-4915	78	12	31	31	NUM
dpc-4915	78	13	cases	case	NOUN
dpc-4915	78	14	.	.	PUNCT
dpc-4915	79	1	we	we	PRON
dpc-4915	79	2	observed	observe	VERB
dpc-4915	79	3	that	that	SCONJ
dpc-4915	79	4	the	the	DET
dpc-4915	79	5	response	response	NOUN
dpc-4915	79	6	to	to	ADP
dpc-4915	79	7	treatment	treatment	NOUN
dpc-4915	79	8	was	be	AUX
dpc-4915	79	9	better	well	ADJ
dpc-4915	79	10	in	in	ADP
dpc-4915	79	11	the	the	DET
dpc-4915	79	12	early	early	ADJ
dpc-4915	79	13	stages	stage	NOUN
dpc-4915	79	14	of	of	ADP
dpc-4915	79	15	the	the	DET
dpc-4915	79	16	disease	disease	NOUN
dpc-4915	79	17	,	,	PUNCT
dpc-4915	79	18	in	in	ADP
dpc-4915	79	19	those	those	PRON
dpc-4915	79	20	with	with	ADP
dpc-4915	79	21	less	less	ADV
dpc-4915	79	22	severe	severe	ADJ
dpc-4915	79	23	disease	disease	NOUN
dpc-4915	79	24	,	,	PUNCT
dpc-4915	79	25	and	and	CCONJ
dpc-4915	79	26	in	in	ADP
dpc-4915	79	27	biologic	biologic	ADJ
dpc-4915	79	28	-	-	PUNCT
dpc-4915	79	29	naive	naive	ADJ
dpc-4915	79	30	patients	patient	NOUN
dpc-4915	79	31	.	.	PUNCT
dpc-4915	80	1	in	in	ADP
dpc-4915	80	2	the	the	DET
dpc-4915	80	3	sunshine	sunshine	NOUN
dpc-4915	80	4	and	and	CCONJ
dpc-4915	80	5	sunrise	sunrise	VERB
dpc-4915	80	6	phase	phase	NOUN
dpc-4915	80	7	iii	iii	NUM
dpc-4915	80	8	studies	study	NOUN
dpc-4915	80	9	,	,	PUNCT
dpc-4915	80	10	sec	sec	PROPN
dpc-4915	80	11	treatment	treatment	NOUN
dpc-4915	80	12	in	in	ADP
dpc-4915	80	13	adult	adult	NOUN
dpc-4915	80	14	patients	patient	NOUN
dpc-4915	80	15	with	with	ADP
dpc-4915	80	16	hs	hs	PROPN
dpc-4915	80	17	was	be	AUX
dpc-4915	80	18	compared	compare	VERB
dpc-4915	80	19	with	with	ADP
dpc-4915	80	20	placebo	placebo	NOUN
dpc-4915	80	21	at	at	ADP
dpc-4915	80	22	doses	dose	NOUN
dpc-4915	80	23	of	of	ADP
dpc-4915	80	24	300	300	NUM
dpc-4915	80	25	mg/4	mg/4	NOUN
dpc-4915	80	26	weeks	week	NOUN
dpc-4915	80	27	and	and	CCONJ
dpc-4915	80	28	300	300	NUM
dpc-4915	80	29	mg/2	mg/2	NOUN
dpc-4915	80	30	weeks	week	NOUN
dpc-4915	80	31	.	.	PUNCT
dpc-4915	81	1	the	the	DET
dpc-4915	81	2	proportion	proportion	NOUN
dpc-4915	81	3	of	of	ADP
dpc-4915	81	4	patients	patient	NOUN
dpc-4915	81	5	with	with	ADP
dpc-4915	81	6	hiscr	hiscr	NOUN
dpc-4915	81	7	at	at	ADP
dpc-4915	81	8	the	the	DET
dpc-4915	81	9	16th	16th	ADJ
dpc-4915	81	10	week	week	NOUN
dpc-4915	81	11	of	of	ADP
dpc-4915	81	12	treatment	treatment	NOUN
dpc-4915	81	13	was	be	AUX
dpc-4915	81	14	45	45	NUM
dpc-4915	81	15	%	%	NOUN
dpc-4915	81	16	in	in	ADP
dpc-4915	81	17	the	the	DET
dpc-4915	81	18	sec	sec	PROPN
dpc-4915	81	19	300	300	NUM
dpc-4915	81	20	mg/2	mg/2	NOUN
dpc-4915	81	21	weeks	week	NOUN
dpc-4915	81	22	group	group	NOUN
dpc-4915	81	23	,	,	PUNCT
dpc-4915	81	24	42	42	NUM
dpc-4915	81	25	%	%	NOUN
dpc-4915	81	26	in	in	ADP
dpc-4915	81	27	the	the	DET
dpc-4915	81	28	sec	sec	PROPN
dpc-4915	81	29	300	300	NUM
dpc-4915	81	30	mg/4	mg/4	PROPN
dpc-4915	81	31	weeks	week	NOUN
dpc-4915	81	32	group	group	NOUN
dpc-4915	81	33	,	,	PUNCT
dpc-4915	81	34	and	and	CCONJ
dpc-4915	81	35	34	34	NUM
dpc-4915	81	36	%	%	NOUN
dpc-4915	81	37	in	in	ADP
dpc-4915	81	38	the	the	DET
dpc-4915	81	39	placebo	placebo	NOUN
dpc-4915	81	40	group	group	NOUN
dpc-4915	81	41	in	in	ADP
dpc-4915	81	42	the	the	DET
dpc-4915	81	43	sunshine	sunshine	NOUN
dpc-4915	81	44	study	study	NOUN
dpc-4915	81	45	.	.	PUNCT
dpc-4915	82	1	in	in	ADP
dpc-4915	82	2	the	the	DET
dpc-4915	82	3	sunrise	sunrise	NOUN
dpc-4915	82	4	study	study	NOUN
dpc-4915	82	5	,	,	PUNCT
dpc-4915	82	6	this	this	DET
dpc-4915	82	7	proportion	proportion	NOUN
dpc-4915	82	8	was	be	AUX
dpc-4915	82	9	42	42	NUM
dpc-4915	82	10	%	%	NOUN
dpc-4915	82	11	in	in	ADP
dpc-4915	82	12	the	the	DET
dpc-4915	82	13	sec	sec	PROPN
dpc-4915	82	14	300	300	NUM
dpc-4915	82	15	mg/2	mg/2	NOUN
dpc-4915	82	16	weeks	week	NOUN
dpc-4915	82	17	group	group	NOUN
dpc-4915	82	18	,	,	PUNCT
dpc-4915	82	19	46	46	NUM
dpc-4915	82	20	%	%	NOUN
dpc-4915	82	21	in	in	ADP
dpc-4915	82	22	the	the	DET
dpc-4915	82	23	sec	sec	PROPN
dpc-4915	82	24	300	300	NUM
dpc-4915	82	25	mg/4	mg/4	PROPN
dpc-4915	82	26	weeks	week	NOUN
dpc-4915	82	27	group	group	NOUN
dpc-4915	82	28	,	,	PUNCT
dpc-4915	82	29	and	and	CCONJ
dpc-4915	82	30	31	31	NUM
dpc-4915	82	31	%	%	NOUN
dpc-4915	82	32	in	in	ADP
dpc-4915	82	33	the	the	DET
dpc-4915	82	34	placebo	placebo	NOUN
dpc-4915	82	35	group	group	NOUN
dpc-4915	82	36	.	.	PUNCT
dpc-4915	83	1	the	the	DET
dpc-4915	83	2	proportion	proportion	NOUN
dpc-4915	83	3	of	of	ADP
dpc-4915	83	4	patients	patient	NOUN
dpc-4915	83	5	achieving	achieve	VERB
dpc-4915	83	6	hiscr	hiscr	NOUN
dpc-4915	83	7	in	in	ADP
dpc-4915	83	8	the	the	DET
dpc-4915	83	9	sec	sec	PROPN
dpc-4915	83	10	treatment	treatment	NOUN
dpc-4915	83	11	groups	group	NOUN
dpc-4915	83	12	was	be	AUX
dpc-4915	83	13	sustained	sustain	VERB
dpc-4915	83	14	,	,	PUNCT
dpc-4915	83	15	with	with	ADP
dpc-4915	83	16	a	a	DET
dpc-4915	83	17	trend	trend	NOUN
dpc-4915	83	18	toward	toward	ADP
dpc-4915	83	19	improvement	improvement	NOUN
dpc-4915	83	20	up	up	ADP
dpc-4915	83	21	to	to	ADP
dpc-4915	83	22	week	week	NOUN
dpc-4915	83	23	52	52	NUM
dpc-4915	83	24	in	in	ADP
dpc-4915	83	25	both	both	DET
dpc-4915	83	26	studies	study	NOUN
dpc-4915	83	27	.	.	PUNCT
dpc-4915	84	1	in	in	ADP
dpc-4915	84	2	both	both	DET
dpc-4915	84	3	trials	trial	NOUN
dpc-4915	84	4	,	,	PUNCT
dpc-4915	84	5	treatment	treatment	NOUN
dpc-4915	84	6	with	with	ADP
dpc-4915	84	7	both	both	DET
dpc-4915	84	8	sec	sec	PROPN
dpc-4915	84	9	regimens	regimen	NOUN
dpc-4915	84	10	was	be	AUX
dpc-4915	84	11	well	well	ADV
dpc-4915	84	12	tolerated	tolerate	VERB
dpc-4915	84	13	.	.	PUNCT
dpc-4915	85	1	the	the	DET
dpc-4915	85	2	most	most	ADV
dpc-4915	85	3	frequently	frequently	ADV
dpc-4915	85	4	reported	report	VERB
dpc-4915	85	5	adverse	adverse	ADJ
dpc-4915	85	6	events	event	NOUN
dpc-4915	85	7	were	be	AUX
dpc-4915	85	8	headache	headache	NOUN
dpc-4915	85	9	,	,	PUNCT
dpc-4915	85	10	nasopharyngitis	nasopharyngitis	NOUN
dpc-4915	85	11	,	,	PUNCT
dpc-4915	85	12	and	and	CCONJ
dpc-4915	85	13	worsening	worsen	VERB
dpc-4915	85	14	of	of	ADP
dpc-4915	85	15	hs	hs	PROPN
dpc-4915	85	16	.	.	PUNCT
dpc-4915	86	1	no	no	DET
dpc-4915	86	2	new	new	ADJ
dpc-4915	86	3	treatment	treatment	NOUN
dpc-4915	86	4	-	-	PUNCT
dpc-4915	86	5	emergent	emergent	ADJ
dpc-4915	86	6	adverse	adverse	ADJ
dpc-4915	86	7	events	event	NOUN
dpc-4915	86	8	were	be	AUX
dpc-4915	86	9	identified	identify	VERB
dpc-4915	86	10	up	up	ADP
dpc-4915	86	11	to	to	ADP
dpc-4915	86	12	week	week	NOUN
dpc-4915	86	13	52	52	NUM
dpc-4915	87	1	[	[	X
dpc-4915	87	2	5	5	NUM
dpc-4915	87	3	]	]	PUNCT
dpc-4915	87	4	.	.	PUNCT
dpc-4915	88	1	in	in	ADP
dpc-4915	88	2	the	the	DET
dpc-4915	88	3	sunshine	sunshine	NOUN
dpc-4915	88	4	and	and	CCONJ
dpc-4915	88	5	sunrise	sunrise	VERB
dpc-4915	88	6	studies	study	NOUN
dpc-4915	88	7	,	,	PUNCT
dpc-4915	88	8	when	when	SCONJ
dpc-4915	88	9	subgroup	subgroup	ADJ
dpc-4915	88	10	analysis	analysis	NOUN
dpc-4915	88	11	was	be	AUX
dpc-4915	88	12	performed	perform	VERB
dpc-4915	88	13	according	accord	VERB
dpc-4915	88	14	to	to	ADP
dpc-4915	88	15	the	the	DET
dpc-4915	88	16	patients	patient	NOUN
dpc-4915	88	17	biological	biological	ADJ
dpc-4915	88	18	experience	experience	NOUN
dpc-4915	88	19	,	,	PUNCT
dpc-4915	88	20	it	it	PRON
dpc-4915	88	21	was	be	AUX
dpc-4915	88	22	found	find	VERB
dpc-4915	88	23	that	that	SCONJ
dpc-4915	88	24	biologic	biologic	NOUN
dpc-4915	88	25	-	-	PUNCT
dpc-4915	88	26	naive	naive	ADJ
dpc-4915	88	27	patients	patient	NOUN
dpc-4915	88	28	tended	tend	VERB
dpc-4915	88	29	to	to	PART
dpc-4915	88	30	show	show	VERB
dpc-4915	88	31	greater	great	ADJ
dpc-4915	88	32	treatment	treatment	NOUN
dpc-4915	88	33	effectiveness	effectiveness	NOUN
dpc-4915	88	34	,	,	PUNCT
dpc-4915	88	35	similar	similar	ADJ
dpc-4915	88	36	to	to	ADP
dpc-4915	88	37	our	our	PRON
dpc-4915	88	38	study	study	NOUN
dpc-4915	88	39	[	[	X
dpc-4915	88	40	9	9	NUM
dpc-4915	88	41	]	]	PUNCT
dpc-4915	88	42	.	.	PUNCT
dpc-4915	89	1	however	however	ADV
dpc-4915	89	2	,	,	PUNCT
dpc-4915	89	3	this	this	DET
dpc-4915	89	4	analysis	analysis	NOUN
dpc-4915	89	5	also	also	ADV
dpc-4915	89	6	noted	note	VERB
dpc-4915	89	7	that	that	SCONJ
dpc-4915	89	8	biologic	biologic	NOUN
dpc-4915	89	9	-	-	PUNCT
dpc-4915	89	10	experienced	experience	VERB
dpc-4915	89	11	patients	patient	NOUN
dpc-4915	89	12	had	have	VERB
dpc-4915	89	13	more	more	ADV
dpc-4915	89	14	severe	severe	ADJ
dpc-4915	89	15	hurley	hurley	NOUN
dpc-4915	89	16	stage	stage	NOUN
dpc-4915	89	17	,	,	PUNCT
dpc-4915	89	18	longer	long	ADJ
dpc-4915	89	19	disease	disease	NOUN
dpc-4915	89	20	duration	duration	NOUN
dpc-4915	89	21	,	,	PUNCT
dpc-4915	89	22	and	and	CCONJ
dpc-4915	89	23	a	a	DET
dpc-4915	89	24	higher	high	ADJ
dpc-4915	89	25	rate	rate	NOUN
dpc-4915	89	26	of	of	ADP
dpc-4915	89	27	previous	previous	ADJ
dpc-4915	89	28	hs	hs	PROPN
dpc-4915	89	29	surgery	surgery	NOUN
dpc-4915	89	30	than	than	ADP
dpc-4915	89	31	biologic	biologic	ADJ
dpc-4915	89	32	-	-	PUNCT
dpc-4915	89	33	naive	naive	ADJ
dpc-4915	89	34	patients	patient	NOUN
dpc-4915	89	35	[	[	X
dpc-4915	89	36	9	9	NUM
dpc-4915	89	37	]	]	PUNCT
dpc-4915	89	38	.	.	PUNCT
dpc-4915	90	1	additionally	additionally	ADV
dpc-4915	90	2	,	,	PUNCT
dpc-4915	90	3	in	in	ADP
dpc-4915	90	4	real	real	ADJ
dpc-4915	90	5	-	-	PUNCT
dpc-4915	90	6	world	world	NOUN
dpc-4915	90	7	experience	experience	NOUN
dpc-4915	90	8	,	,	PUNCT
dpc-4915	90	9	biological	biological	ADJ
dpc-4915	90	10	agents	agent	NOUN
dpc-4915	90	11	tend	tend	VERB
dpc-4915	90	12	to	to	PART
dpc-4915	90	13	be	be	AUX
dpc-4915	90	14	preferred	prefer	VERB
dpc-4915	90	15	for	for	ADP
dpc-4915	90	16	more	more	ADV
dpc-4915	90	17	severe	severe	ADJ
dpc-4915	90	18	disease	disease	NOUN
dpc-4915	90	19	that	that	PRON
dpc-4915	90	20	is	be	AUX
dpc-4915	90	21	unresponsive	unresponsive	ADJ
dpc-4915	90	22	to	to	ADP
dpc-4915	90	23	conventional	conventional	ADJ
dpc-4915	90	24	treatment	treatment	NOUN
dpc-4915	90	25	.	.	PUNCT
dpc-4915	91	1	therefore	therefore	ADV
dpc-4915	91	2	,	,	PUNCT
dpc-4915	91	3	when	when	SCONJ
dpc-4915	91	4	interpreting	interpret	VERB
dpc-4915	91	5	the	the	DET
dpc-4915	91	6	difference	difference	NOUN
dpc-4915	91	7	in	in	ADP
dpc-4915	91	8	clinical	clinical	ADJ
dpc-4915	91	9	response	response	NOUN
dpc-4915	91	10	,	,	PUNCT
dpc-4915	91	11	it	it	PRON
dpc-4915	91	12	is	be	AUX
dpc-4915	91	13	necessary	necessary	ADJ
dpc-4915	91	14	to	to	PART
dpc-4915	91	15	consider	consider	VERB
dpc-4915	91	16	that	that	SCONJ
dpc-4915	91	17	this	this	PRON
dpc-4915	91	18	may	may	AUX
dpc-4915	91	19	be	be	AUX
dpc-4915	91	20	related	relate	VERB
dpc-4915	91	21	to	to	ADP
dpc-4915	91	22	the	the	DET
dpc-4915	91	23	biological	biological	ADJ
dpc-4915	91	24	experience	experience	NOUN
dpc-4915	91	25	as	as	ADV
dpc-4915	91	26	well	well	ADV
dpc-4915	91	27	as	as	ADP
dpc-4915	91	28	hs	hs	PROPN
dpc-4915	91	29	severity	severity	NOUN
dpc-4915	91	30	,	,	PUNCT
dpc-4915	91	31	disease	disease	NOUN
dpc-4915	91	32	duration	duration	NOUN
dpc-4915	91	33	,	,	PUNCT
dpc-4915	91	34	previous	previous	ADJ
dpc-4915	91	35	treatment	treatment	NOUN
dpc-4915	91	36	history	history	NOUN
dpc-4915	91	37	,	,	PUNCT
dpc-4915	91	38	or	or	CCONJ
dpc-4915	91	39	a	a	DET
dpc-4915	91	40	mixture	mixture	NOUN
dpc-4915	91	41	of	of	ADP
dpc-4915	91	42	all	all	DET
dpc-4915	91	43	these	these	PRON
dpc-4915	91	44	.	.	PUNCT
dpc-4915	92	1	case	case	NOUN
dpc-4915	92	2	series	series	NOUN
dpc-4915	92	3	,	,	PUNCT
dpc-4915	92	4	case	case	NOUN
dpc-4915	92	5	reports	report	VERB
dpc-4915	92	6	,	,	PUNCT
dpc-4915	92	7	and	and	CCONJ
dpc-4915	92	8	retrospective	retrospective	ADJ
dpc-4915	92	9	studies	study	NOUN
dpc-4915	92	10	on	on	ADP
dpc-4915	92	11	the	the	DET
dpc-4915	92	12	real	real	ADJ
dpc-4915	92	13	-	-	PUNCT
dpc-4915	92	14	world	world	NOUN
dpc-4915	92	15	effectiveness	effectiveness	NOUN
dpc-4915	92	16	and	and	CCONJ
dpc-4915	92	17	safety	safety	NOUN
dpc-4915	92	18	of	of	ADP
dpc-4915	92	19	sec	sec	PROPN
dpc-4915	92	20	in	in	ADP
dpc-4915	92	21	hs	hs	PROPN
dpc-4915	92	22	are	be	AUX
dpc-4915	92	23	available	available	ADJ
dpc-4915	92	24	in	in	ADP
dpc-4915	92	25	the	the	DET
dpc-4915	92	26	literature	literature	NOUN
dpc-4915	92	27	.	.	PUNCT
dpc-4915	93	1	in	in	ADP
dpc-4915	93	2	the	the	DET
dpc-4915	93	3	open	open	ADJ
dpc-4915	93	4	-	-	PUNCT
dpc-4915	93	5	label	label	NOUN
dpc-4915	93	6	pilot	pilot	NOUN
dpc-4915	93	7	study	study	NOUN
dpc-4915	93	8	of	of	ADP
dpc-4915	93	9	prussick	prussick	NOUN
dpc-4915	93	10	et	et	PROPN
dpc-4915	93	11	al	al	PROPN
dpc-4915	93	12	,	,	PUNCT
dpc-4915	93	13	9	9	NUM
dpc-4915	93	14	patients	patient	NOUN
dpc-4915	93	15	with	with	ADP
dpc-4915	93	16	moderate	moderate	ADJ
dpc-4915	93	17	to	to	ADP
dpc-4915	93	18	severe	severe	ADJ
dpc-4915	93	19	hs	hs	PROPN
dpc-4915	93	20	were	be	AUX
dpc-4915	93	21	administered	administer	VERB
dpc-4915	93	22	4	4	NUM
dpc-4915	93	23	original	original	ADJ
dpc-4915	93	24	article	article	NOUN
dpc-4915	93	25	|	|	ADV
dpc-4915	93	26	dermatol	dermatol	ADJ
dpc-4915	93	27	pract	pract	NOUN
dpc-4915	93	28	concept	concept	NOUN
dpc-4915	93	29	.	.	PUNCT
dpc-4915	94	1	2025;15(1):4915	2025;15(1):4915	NUM
dpc-4915	94	2	table	table	NOUN
dpc-4915	94	3	1	1	NUM
dpc-4915	94	4	.	.	PUNCT
dpc-4915	94	5	demographic	demographic	ADJ
dpc-4915	94	6	and	and	CCONJ
dpc-4915	94	7	clinical	clinical	ADJ
dpc-4915	94	8	characteristics	characteristic	NOUN
dpc-4915	94	9	of	of	ADP
dpc-4915	94	10	patients	patient	NOUN
dpc-4915	94	11	according	accord	VERB
dpc-4915	94	12	to	to	ADP
dpc-4915	94	13	hiscr	hiscr	PROPN
dpc-4915	94	14	.	.	PUNCT
dpc-4915	95	1	hiscr	hiscr	NOUN
dpc-4915	95	2	(	(	PUNCT
dpc-4915	95	3	+	+	NOUN
dpc-4915	95	4	)	)	PUNCT
dpc-4915	95	5	(	(	PUNCT
dpc-4915	95	6	n	n	NOUN
dpc-4915	95	7	=	=	SYM
dpc-4915	95	8	20	20	NUM
dpc-4915	95	9	,	,	PUNCT
dpc-4915	95	10	64.5	64.5	NUM
dpc-4915	95	11	%	%	NOUN
dpc-4915	95	12	)	)	PUNCT
dpc-4915	95	13	hiscr	hiscr	NOUN
dpc-4915	95	14	(	(	PUNCT
dpc-4915	95	15	-	-	PUNCT
dpc-4915	95	16	)	)	PUNCT
dpc-4915	95	17	(	(	PUNCT
dpc-4915	95	18	n	n	NOUN
dpc-4915	95	19	=	=	SYM
dpc-4915	95	20	11	11	NUM
dpc-4915	95	21	,	,	PUNCT
dpc-4915	95	22	35.5	35.5	NUM
dpc-4915	95	23	%	%	NOUN
dpc-4915	95	24	)	)	PUNCT
dpc-4915	96	1	p	p	NOUN
dpc-4915	96	2	total	total	NOUN
dpc-4915	96	3	(	(	PUNCT
dpc-4915	96	4	n	n	NOUN
dpc-4915	96	5	=	=	SYM
dpc-4915	96	6	31	31	NUM
dpc-4915	96	7	,	,	PUNCT
dpc-4915	96	8	100	100	NUM
dpc-4915	96	9	%	%	NOUN
dpc-4915	96	10	)	)	PUNCT
dpc-4915	96	11	age	age	NOUN
dpc-4915	96	12	,	,	PUNCT
dpc-4915	96	13	years	year	NOUN
dpc-4915	96	14	mean	mean	VERB
dpc-4915	96	15	±	±	NUM
dpc-4915	96	16	sd	sd	ADP
dpc-4915	96	17	min	min	PROPN
dpc-4915	96	18	max	max	PROPN
dpc-4915	97	1	37.05	37.05	NUM
dpc-4915	97	2	±	±	NUM
dpc-4915	97	3	9.11	9.11	NUM
dpc-4915	97	4	20	20	NUM
dpc-4915	97	5	-	-	SYM
dpc-4915	97	6	54	54	NUM
dpc-4915	97	7	43.45	43.45	NUM
dpc-4915	97	8	±	±	NUM
dpc-4915	97	9	11.36	11.36	NUM
dpc-4915	97	10	25	25	NUM
dpc-4915	97	11	-	-	SYM
dpc-4915	97	12	68	68	NUM
dpc-4915	97	13	0.97	0.97	NUM
dpc-4915	97	14	39.32	39.32	NUM
dpc-4915	97	15	±	±	NUM
dpc-4915	97	16	10.26	10.26	NUM
dpc-4915	97	17	20	20	NUM
dpc-4915	97	18	-	-	SYM
dpc-4915	97	19	68	68	NUM
dpc-4915	97	20	sex	sex	NOUN
dpc-4915	97	21	female	female	NOUN
dpc-4915	97	22	,	,	PUNCT
dpc-4915	97	23	n	n	CCONJ
dpc-4915	97	24	(	(	PUNCT
dpc-4915	97	25	%	%	INTJ
dpc-4915	97	26	)	)	PUNCT
dpc-4915	97	27	male	male	NOUN
dpc-4915	97	28	,	,	PUNCT
dpc-4915	97	29	n	n	CCONJ
dpc-4915	97	30	(	(	PUNCT
dpc-4915	97	31	%	%	INTJ
dpc-4915	97	32	)	)	PUNCT
dpc-4915	97	33	11	11	NUM
dpc-4915	97	34	(	(	PUNCT
dpc-4915	97	35	55	55	NUM
dpc-4915	97	36	)	)	PUNCT
dpc-4915	97	37	9	9	NUM
dpc-4915	97	38	(	(	PUNCT
dpc-4915	97	39	45	45	NUM
dpc-4915	97	40	)	)	PUNCT
dpc-4915	97	41	3	3	NUM
dpc-4915	97	42	(	(	PUNCT
dpc-4915	97	43	27.3	27.3	NUM
dpc-4915	97	44	)	)	PUNCT
dpc-4915	97	45	8	8	NUM
dpc-4915	97	46	(	(	PUNCT
dpc-4915	97	47	72.7	72.7	NUM
dpc-4915	97	48	)	)	PUNCT
dpc-4915	97	49	0.258	0.258	NUM
dpc-4915	97	50	14	14	NUM
dpc-4915	97	51	(	(	PUNCT
dpc-4915	97	52	45.2	45.2	NUM
dpc-4915	97	53	)	)	PUNCT
dpc-4915	97	54	17	17	NUM
dpc-4915	97	55	(	(	PUNCT
dpc-4915	97	56	54.8	54.8	NUM
dpc-4915	97	57	)	)	PUNCT
dpc-4915	97	58	body	body	NOUN
dpc-4915	97	59	weight	weight	NOUN
dpc-4915	97	60	,	,	PUNCT
dpc-4915	97	61	kg	kg	INTJ
dpc-4915	97	62	mean	mean	VERB
dpc-4915	97	63	±	±	PROPN
dpc-4915	97	64	sd	sd	ADP
dpc-4915	97	65	min	min	PROPN
dpc-4915	97	66	max	max	PROPN
dpc-4915	97	67	87.1	87.1	NUM
dpc-4915	97	68	±	±	NUM
dpc-4915	97	69	21.67	21.67	NUM
dpc-4915	97	70	55	55	NUM
dpc-4915	97	71	-	-	SYM
dpc-4915	97	72	130	130	NUM
dpc-4915	97	73	85	85	NUM
dpc-4915	97	74	±	±	NUM
dpc-4915	97	75	16.34	16.34	NUM
dpc-4915	97	76	65	65	NUM
dpc-4915	97	77	-	-	SYM
dpc-4915	97	78	120	120	NUM
dpc-4915	97	79	0.782	0.782	NUM
dpc-4915	97	80	86.35	86.35	NUM
dpc-4915	97	81	±	±	NUM
dpc-4915	97	82	19.68	19.68	NUM
dpc-4915	97	83	55	55	NUM
dpc-4915	97	84	-	-	SYM
dpc-4915	97	85	130	130	NUM
dpc-4915	97	86	height	height	NOUN
dpc-4915	97	87	,	,	PUNCT
dpc-4915	97	88	cm	cm	NOUN
dpc-4915	97	89	mean	mean	VERB
dpc-4915	97	90	±	±	PROPN
dpc-4915	97	91	sd	sd	ADP
dpc-4915	97	92	min	min	PROPN
dpc-4915	97	93	max	max	PROPN
dpc-4915	97	94	173.65	173.65	NUM
dpc-4915	97	95	±	±	NUM
dpc-4915	97	96	11.05	11.05	NUM
dpc-4915	97	97	155	155	NUM
dpc-4915	97	98	-	-	SYM
dpc-4915	97	99	191	191	NUM
dpc-4915	97	100	173.55	173.55	NUM
dpc-4915	97	101	±	±	NOUN
dpc-4915	97	102	6.56	6.56	NUM
dpc-4915	97	103	161	161	NUM
dpc-4915	97	104	-	-	SYM
dpc-4915	97	105	186	186	NUM
dpc-4915	97	106	0.977	0.977	NUM
dpc-4915	97	107	173.61	173.61	NUM
dpc-4915	97	108	±	±	NUM
dpc-4915	97	109	9.58	9.58	NUM
dpc-4915	97	110	155	155	NUM
dpc-4915	97	111	-	-	SYM
dpc-4915	97	112	191	191	NUM
dpc-4915	97	113	body	body	NOUN
dpc-4915	97	114	mass	mass	NOUN
dpc-4915	97	115	index	index	NOUN
dpc-4915	97	116	(	(	PUNCT
dpc-4915	97	117	bmi	bmi	PROPN
dpc-4915	97	118	)	)	PUNCT
dpc-4915	97	119	,	,	PUNCT
dpc-4915	97	120	kg	kg	PROPN
dpc-4915	97	121	/	/	SYM
dpc-4915	97	122	m2	m2	PROPN
dpc-4915	97	123	mean	mean	VERB
dpc-4915	97	124	±	±	PROPN
dpc-4915	97	125	sd	sd	ADP
dpc-4915	97	126	min	min	PROPN
dpc-4915	97	127	max	max	PROPN
dpc-4915	97	128	28.8	28.8	NUM
dpc-4915	97	129	±	±	NUM
dpc-4915	97	130	6.3	6.3	NUM
dpc-4915	97	131	19	19	NUM
dpc-4915	97	132	-	-	SYM
dpc-4915	97	133	40.8	40.8	NUM
dpc-4915	97	134	28.2	28.2	NUM
dpc-4915	97	135	±	±	NUM
dpc-4915	97	136	5.12	5.12	NUM
dpc-4915	97	137	22.6	22.6	NUM
dpc-4915	97	138	-	-	SYM
dpc-4915	97	139	37.9	37.9	NUM
dpc-4915	97	140	0.887	0.887	NUM
dpc-4915	97	141	28.59	28.59	NUM
dpc-4915	97	142	±	±	NUM
dpc-4915	97	143	5.83	5.83	NUM
dpc-4915	97	144	19	19	NUM
dpc-4915	97	145	-	-	SYM
dpc-4915	97	146	40.8	40.8	NUM
dpc-4915	97	147	smoking	smoking	NOUN
dpc-4915	97	148	status	status	NOUN
dpc-4915	97	149	no	no	PROPN
dpc-4915	97	150	,	,	PUNCT
dpc-4915	97	151	n	n	PROPN
dpc-4915	97	152	(	(	PUNCT
dpc-4915	97	153	%	%	INTJ
dpc-4915	97	154	)	)	PUNCT
dpc-4915	98	1	yes	yes	INTJ
dpc-4915	98	2	,	,	PUNCT
dpc-4915	98	3	n	n	PROPN
dpc-4915	98	4	(	(	PUNCT
dpc-4915	98	5	%	%	INTJ
dpc-4915	98	6	)	)	PUNCT
dpc-4915	98	7	ex	ex	NOUN
dpc-4915	98	8	-	-	NOUN
dpc-4915	98	9	smoker	smoker	ADJ
dpc-4915	98	10	,	,	PUNCT
dpc-4915	98	11	n	n	CCONJ
dpc-4915	98	12	(	(	PUNCT
dpc-4915	98	13	%	%	INTJ
dpc-4915	98	14	)	)	PUNCT
dpc-4915	98	15	13	13	NUM
dpc-4915	98	16	(	(	PUNCT
dpc-4915	98	17	65	65	NUM
dpc-4915	98	18	)	)	PUNCT
dpc-4915	98	19	7	7	NUM
dpc-4915	98	20	(	(	PUNCT
dpc-4915	98	21	35	35	NUM
dpc-4915	98	22	)	)	PUNCT
dpc-4915	98	23	4	4	NUM
dpc-4915	98	24	(	(	PUNCT
dpc-4915	98	25	36.4	36.4	NUM
dpc-4915	98	26	)	)	PUNCT
dpc-4915	98	27	6	6	NUM
dpc-4915	98	28	(	(	PUNCT
dpc-4915	98	29	54.5	54.5	NUM
dpc-4915	98	30	)	)	PUNCT
dpc-4915	98	31	1	1	NUM
dpc-4915	98	32	(	(	PUNCT
dpc-4915	98	33	9.1	9.1	NUM
dpc-4915	98	34	)	)	PUNCT
dpc-4915	98	35	0.153	0.153	NUM
dpc-4915	98	36	17	17	NUM
dpc-4915	98	37	(	(	PUNCT
dpc-4915	98	38	54.8	54.8	NUM
dpc-4915	98	39	)	)	PUNCT
dpc-4915	98	40	13	13	NUM
dpc-4915	98	41	(	(	PUNCT
dpc-4915	98	42	41.9	41.9	NUM
dpc-4915	98	43	)	)	SYM
dpc-4915	98	44	1	1	NUM
dpc-4915	98	45	(	(	PUNCT
dpc-4915	98	46	3.2	3.2	NUM
dpc-4915	98	47	)	)	PUNCT
dpc-4915	98	48	hurley	hurley	NOUN
dpc-4915	98	49	stage	stage	NOUN
dpc-4915	98	50	i	i	PRON
dpc-4915	98	51	,	,	PUNCT
dpc-4915	98	52	n	n	PROPN
dpc-4915	98	53	(	(	PUNCT
dpc-4915	98	54	%	%	INTJ
dpc-4915	98	55	)	)	PUNCT
dpc-4915	98	56	ii	ii	PROPN
dpc-4915	98	57	,	,	PUNCT
dpc-4915	98	58	n	n	PROPN
dpc-4915	98	59	(	(	PUNCT
dpc-4915	98	60	%	%	INTJ
dpc-4915	98	61	)	)	PUNCT
dpc-4915	98	62	iii	iii	PROPN
dpc-4915	98	63	,	,	PUNCT
dpc-4915	98	64	n	n	CCONJ
dpc-4915	98	65	(	(	PUNCT
dpc-4915	98	66	%	%	INTJ
dpc-4915	98	67	)	)	PUNCT
dpc-4915	98	68	7	7	NUM
dpc-4915	98	69	(	(	PUNCT
dpc-4915	98	70	35	35	NUM
dpc-4915	98	71	)	)	PUNCT
dpc-4915	98	72	6	6	NUM
dpc-4915	98	73	(	(	PUNCT
dpc-4915	98	74	30	30	NUM
dpc-4915	98	75	)	)	PUNCT
dpc-4915	98	76	7	7	NUM
dpc-4915	98	77	(	(	PUNCT
dpc-4915	98	78	35	35	NUM
dpc-4915	98	79	)	)	PUNCT
dpc-4915	98	80	3	3	NUM
dpc-4915	98	81	(	(	PUNCT
dpc-4915	98	82	27.3	27.3	NUM
dpc-4915	98	83	)	)	PUNCT
dpc-4915	98	84	8	8	NUM
dpc-4915	98	85	(	(	PUNCT
dpc-4915	98	86	72.7	72.7	NUM
dpc-4915	98	87	)	)	PUNCT
dpc-4915	98	88	0.044	0.044	NUM
dpc-4915	98	89	7	7	NUM
dpc-4915	98	90	(	(	PUNCT
dpc-4915	98	91	22.6	22.6	NUM
dpc-4915	98	92	)	)	PUNCT
dpc-4915	98	93	9	9	NUM
dpc-4915	98	94	(	(	PUNCT
dpc-4915	98	95	29	29	NUM
dpc-4915	98	96	)	)	SYM
dpc-4915	98	97	15	15	NUM
dpc-4915	98	98	(	(	PUNCT
dpc-4915	98	99	48.4	48.4	NUM
dpc-4915	98	100	)	)	PUNCT
dpc-4915	98	101	age	age	NOUN
dpc-4915	98	102	of	of	ADP
dpc-4915	98	103	the	the	DET
dpc-4915	98	104	disease	disease	NOUN
dpc-4915	98	105	onset	onset	VERB
dpc-4915	98	106	,	,	PUNCT
dpc-4915	98	107	years	year	NOUN
dpc-4915	98	108	mean	mean	VERB
dpc-4915	98	109	±	±	NUM
dpc-4915	98	110	sd	sd	ADP
dpc-4915	98	111	min	min	PROPN
dpc-4915	98	112	max	max	PROPN
dpc-4915	98	113	27.55	27.55	NUM
dpc-4915	98	114	±	±	NUM
dpc-4915	98	115	9.19	9.19	NUM
dpc-4915	98	116	13	13	NUM
dpc-4915	98	117	-	-	SYM
dpc-4915	98	118	51	51	NUM
dpc-4915	98	119	27.82	27.82	NUM
dpc-4915	98	120	±	±	NUM
dpc-4915	98	121	9.29	9.29	NUM
dpc-4915	98	122	15	15	NUM
dpc-4915	98	123	-	-	SYM
dpc-4915	98	124	46	46	NUM
dpc-4915	98	125	0.939	0.939	NUM
dpc-4915	98	126	27.65	27.65	NUM
dpc-4915	98	127	±	±	NUM
dpc-4915	98	128	9.07	9.07	NUM
dpc-4915	98	129	13	13	NUM
dpc-4915	98	130	-	-	SYM
dpc-4915	98	131	51	51	NUM
dpc-4915	98	132	duration	duration	NOUN
dpc-4915	98	133	of	of	ADP
dpc-4915	98	134	the	the	DET
dpc-4915	98	135	disease	disease	NOUN
dpc-4915	98	136	,	,	PUNCT
dpc-4915	98	137	years	year	NOUN
dpc-4915	98	138	mean	mean	VERB
dpc-4915	98	139	±	±	NUM
dpc-4915	98	140	sd	sd	ADP
dpc-4915	98	141	min	min	PROPN
dpc-4915	98	142	max	max	PROPN
dpc-4915	98	143	9.6	9.6	NUM
dpc-4915	98	144	±	±	NUM
dpc-4915	98	145	6.4	6.4	NUM
dpc-4915	98	146	2	2	NUM
dpc-4915	98	147	-	-	SYM
dpc-4915	98	148	30	30	NUM
dpc-4915	98	149	15.73	15.73	NUM
dpc-4915	98	150	±	±	NUM
dpc-4915	98	151	9.34	9.34	NUM
dpc-4915	98	152	3	3	NUM
dpc-4915	98	153	-	-	SYM
dpc-4915	98	154	37	37	NUM
dpc-4915	98	155	0.04	0.04	NUM
dpc-4915	98	156	11.77	11.77	NUM
dpc-4915	98	157	±	±	NUM
dpc-4915	98	158	7.99	7.99	NUM
dpc-4915	98	159	2	2	NUM
dpc-4915	98	160	-	-	SYM
dpc-4915	98	161	37	37	NUM
dpc-4915	98	162	duration	duration	NOUN
dpc-4915	98	163	of	of	ADP
dpc-4915	98	164	secukinumab	secukinumab	NOUN
dpc-4915	98	165	use	use	NOUN
dpc-4915	98	166	,	,	PUNCT
dpc-4915	98	167	months	month	NOUN
dpc-4915	98	168	mean	mean	VERB
dpc-4915	99	1	±	±	NUM
dpc-4915	99	2	sd	sd	ADP
dpc-4915	99	3	min	min	PROPN
dpc-4915	99	4	max	max	PROPN
dpc-4915	99	5	15.15	15.15	NUM
dpc-4915	99	6	±	±	NUM
dpc-4915	99	7	11.75	11.75	NUM
dpc-4915	99	8	3	3	NUM
dpc-4915	99	9	-	-	SYM
dpc-4915	99	10	48	48	NUM
dpc-4915	99	11	6.45	6.45	NUM
dpc-4915	99	12	±	±	NUM
dpc-4915	99	13	3.96	3.96	NUM
dpc-4915	99	14	3	3	NUM
dpc-4915	99	15	-	-	SYM
dpc-4915	99	16	14	14	NUM
dpc-4915	99	17	0.032	0.032	NUM
dpc-4915	99	18	12.06	12.06	NUM
dpc-4915	99	19	±	±	NUM
dpc-4915	99	20	10.51	10.51	NUM
dpc-4915	99	21	3	3	NUM
dpc-4915	99	22	-	-	SYM
dpc-4915	99	23	48	48	NUM
dpc-4915	99	24	secukinumab	secukinumab	NOUN
dpc-4915	99	25	(	(	PUNCT
dpc-4915	99	26	sec	sec	PROPN
dpc-4915	99	27	)	)	PUNCT
dpc-4915	99	28	dosage	dosage	NOUN
dpc-4915	99	29	150	150	NUM
dpc-4915	99	30	mg/28days	mg/28day	NOUN
dpc-4915	99	31	,	,	PUNCT
dpc-4915	99	32	n	n	CCONJ
dpc-4915	99	33	(	(	PUNCT
dpc-4915	99	34	%	%	INTJ
dpc-4915	99	35	)	)	PUNCT
dpc-4915	99	36	300	300	NUM
dpc-4915	99	37	mg/28days	mg/28day	NOUN
dpc-4915	99	38	,	,	PUNCT
dpc-4915	99	39	n	n	CCONJ
dpc-4915	99	40	(	(	PUNCT
dpc-4915	99	41	%	%	INTJ
dpc-4915	99	42	)	)	PUNCT
dpc-4915	99	43	300	300	NUM
dpc-4915	99	44	mg/14days	mg/14day	NOUN
dpc-4915	99	45	,	,	PUNCT
dpc-4915	99	46	n	n	PROPN
dpc-4915	99	47	(	(	PUNCT
dpc-4915	99	48	%	%	INTJ
dpc-4915	99	49	)	)	PUNCT
dpc-4915	99	50	300mg/28	300mg/28	NUM
dpc-4915	99	51	days	day	NOUN
dpc-4915	99	52	and	and	CCONJ
dpc-4915	100	1	then	then	ADV
dpc-4915	100	2	300	300	NUM
dpc-4915	100	3	mg/14	mg/14	NOUN
dpc-4915	100	4	days	day	NOUN
dpc-4915	100	5	,	,	PUNCT
dpc-4915	100	6	n	n	CCONJ
dpc-4915	100	7	(	(	PUNCT
dpc-4915	100	8	%	%	INTJ
dpc-4915	100	9	)	)	PUNCT
dpc-4915	100	10	1	1	NUM
dpc-4915	100	11	(	(	PUNCT
dpc-4915	100	12	5	5	NUM
dpc-4915	100	13	)	)	PUNCT
dpc-4915	100	14	13	13	NUM
dpc-4915	100	15	(	(	PUNCT
dpc-4915	100	16	65	65	NUM
dpc-4915	100	17	)	)	SYM
dpc-4915	100	18	5	5	NUM
dpc-4915	100	19	(	(	PUNCT
dpc-4915	100	20	25	25	NUM
dpc-4915	100	21	)	)	SYM
dpc-4915	100	22	1	1	NUM
dpc-4915	100	23	(	(	PUNCT
dpc-4915	100	24	5	5	NUM
dpc-4915	100	25	)	)	PUNCT
dpc-4915	100	26	6	6	NUM
dpc-4915	100	27	(	(	PUNCT
dpc-4915	100	28	54.5	54.5	NUM
dpc-4915	100	29	)	)	PUNCT
dpc-4915	100	30	5	5	NUM
dpc-4915	100	31	(	(	PUNCT
dpc-4915	100	32	45.5	45.5	NUM
dpc-4915	100	33	)	)	PUNCT
dpc-4915	100	34	0.452	0.452	NUM
dpc-4915	100	35	1	1	NUM
dpc-4915	100	36	(	(	PUNCT
dpc-4915	100	37	3.2	3.2	NUM
dpc-4915	100	38	)	)	PUNCT
dpc-4915	100	39	19	19	NUM
dpc-4915	100	40	(	(	PUNCT
dpc-4915	100	41	61.3	61.3	NUM
dpc-4915	100	42	)	)	PUNCT
dpc-4915	100	43	10	10	NUM
dpc-4915	100	44	(	(	PUNCT
dpc-4915	100	45	32.3	32.3	NUM
dpc-4915	100	46	)	)	PUNCT
dpc-4915	100	47	1	1	NUM
dpc-4915	100	48	(	(	PUNCT
dpc-4915	100	49	3.2	3.2	NUM
dpc-4915	100	50	)	)	PUNCT
dpc-4915	100	51	areas	area	NOUN
dpc-4915	100	52	of	of	ADP
dpc-4915	100	53	involvement	involvement	NOUN
dpc-4915	100	54	scalp	scalp	NOUN
dpc-4915	100	55	,	,	PUNCT
dpc-4915	100	56	n	n	PROPN
dpc-4915	100	57	(	(	PUNCT
dpc-4915	100	58	%	%	INTJ
dpc-4915	100	59	)	)	PUNCT
dpc-4915	100	60	axillary	axillary	ADJ
dpc-4915	100	61	,	,	PUNCT
dpc-4915	100	62	n	n	CCONJ
dpc-4915	100	63	(	(	PUNCT
dpc-4915	100	64	%	%	INTJ
dpc-4915	100	65	)	)	PUNCT
dpc-4915	100	66	inframammary	inframammary	ADJ
dpc-4915	100	67	,	,	PUNCT
dpc-4915	100	68	n	n	CCONJ
dpc-4915	100	69	(	(	PUNCT
dpc-4915	100	70	%	%	INTJ
dpc-4915	100	71	)	)	PUNCT
dpc-4915	100	72	trunk	trunk	NOUN
dpc-4915	100	73	,	,	PUNCT
dpc-4915	100	74	n	n	CCONJ
dpc-4915	100	75	(	(	PUNCT
dpc-4915	100	76	%	%	INTJ
dpc-4915	100	77	)	)	PUNCT
dpc-4915	100	78	pelvic	pelvic	ADJ
dpc-4915	100	79	,	,	PUNCT
dpc-4915	100	80	n	n	PROPN
dpc-4915	100	81	(	(	PUNCT
dpc-4915	100	82	%	%	INTJ
dpc-4915	100	83	)	)	PUNCT
dpc-4915	100	84	1	1	NUM
dpc-4915	100	85	(	(	PUNCT
dpc-4915	100	86	5	5	NUM
dpc-4915	100	87	)	)	PUNCT
dpc-4915	100	88	19	19	NUM
dpc-4915	100	89	(	(	PUNCT
dpc-4915	100	90	95	95	NUM
dpc-4915	100	91	)	)	PUNCT
dpc-4915	100	92	7	7	NUM
dpc-4915	100	93	(	(	PUNCT
dpc-4915	100	94	35	35	NUM
dpc-4915	100	95	)	)	SYM
dpc-4915	100	96	1	1	NUM
dpc-4915	100	97	(	(	PUNCT
dpc-4915	100	98	5	5	NUM
dpc-4915	100	99	)	)	PUNCT
dpc-4915	100	100	20	20	NUM
dpc-4915	100	101	(	(	PUNCT
dpc-4915	100	102	100	100	NUM
dpc-4915	100	103	)	)	PUNCT
dpc-4915	100	104	2	2	NUM
dpc-4915	100	105	(	(	PUNCT
dpc-4915	100	106	18.2	18.2	NUM
dpc-4915	100	107	)	)	PUNCT
dpc-4915	100	108	10	10	NUM
dpc-4915	100	109	(	(	PUNCT
dpc-4915	100	110	90.9	90.9	NUM
dpc-4915	100	111	)	)	PUNCT
dpc-4915	100	112	4	4	NUM
dpc-4915	100	113	(	(	PUNCT
dpc-4915	100	114	36.4	36.4	NUM
dpc-4915	100	115	)	)	PUNCT
dpc-4915	100	116	3	3	NUM
dpc-4915	100	117	(	(	PUNCT
dpc-4915	100	118	27.3	27.3	NUM
dpc-4915	100	119	)	)	PUNCT
dpc-4915	100	120	10	10	NUM
dpc-4915	100	121	(	(	PUNCT
dpc-4915	100	122	90.9	90.9	NUM
dpc-4915	100	123	)	)	PUNCT
dpc-4915	100	124	0.281	0.281	NUM
dpc-4915	100	125	1	1	NUM
dpc-4915	100	126	1	1	NUM
dpc-4915	100	127	0.115	0.115	NUM
dpc-4915	100	128	0.355	0.355	NUM
dpc-4915	100	129	3	3	NUM
dpc-4915	100	130	(	(	PUNCT
dpc-4915	100	131	9.7	9.7	NUM
dpc-4915	100	132	)	)	SYM
dpc-4915	100	133	29	29	NUM
dpc-4915	100	134	(	(	PUNCT
dpc-4915	100	135	93.5	93.5	NUM
dpc-4915	100	136	)	)	PUNCT
dpc-4915	100	137	11	11	NUM
dpc-4915	100	138	(	(	PUNCT
dpc-4915	100	139	35.5	35.5	NUM
dpc-4915	100	140	)	)	SYM
dpc-4915	100	141	4	4	NUM
dpc-4915	100	142	(	(	PUNCT
dpc-4915	100	143	12.9	12.9	NUM
dpc-4915	100	144	)	)	PUNCT
dpc-4915	100	145	30	30	NUM
dpc-4915	100	146	(	(	PUNCT
dpc-4915	100	147	96.8	96.8	NUM
dpc-4915	100	148	)	)	PUNCT
dpc-4915	100	149	comorbidities	comorbiditie	NOUN
dpc-4915	100	150	arthritis	arthritis	NOUN
dpc-4915	100	151	,	,	PUNCT
dpc-4915	100	152	n	n	PROPN
dpc-4915	100	153	(	(	PUNCT
dpc-4915	100	154	%	%	INTJ
dpc-4915	100	155	)	)	PUNCT
dpc-4915	100	156	ankylosing	ankylose	VERB
dpc-4915	100	157	spondylitis	spondylitis	NOUN
dpc-4915	100	158	,	,	PUNCT
dpc-4915	100	159	n	n	PROPN
dpc-4915	100	160	(	(	PUNCT
dpc-4915	100	161	%	%	INTJ
dpc-4915	100	162	)	)	PUNCT
dpc-4915	100	163	psoriatic	psoriatic	ADJ
dpc-4915	100	164	arthritis	arthritis	NOUN
dpc-4915	100	165	,	,	PUNCT
dpc-4915	100	166	n	n	CCONJ
dpc-4915	100	167	(	(	PUNCT
dpc-4915	100	168	%	%	INTJ
dpc-4915	100	169	)	)	PUNCT
dpc-4915	100	170	rheumatoid	rheumatoid	NOUN
dpc-4915	100	171	arthritis	arthritis	NOUN
dpc-4915	100	172	,	,	PUNCT
dpc-4915	100	173	n	n	PROPN
dpc-4915	100	174	(	(	PUNCT
dpc-4915	100	175	%	%	INTJ
dpc-4915	100	176	)	)	PUNCT
dpc-4915	100	177	psoriasis	psoriasis	NOUN
dpc-4915	100	178	,	,	PUNCT
dpc-4915	100	179	n	n	CCONJ
dpc-4915	100	180	(	(	PUNCT
dpc-4915	100	181	%	%	INTJ
dpc-4915	100	182	)	)	PUNCT
dpc-4915	100	183	diabetes	diabetes	NOUN
dpc-4915	100	184	mellitus	mellitus	NOUN
dpc-4915	100	185	,	,	PUNCT
dpc-4915	100	186	n	n	PROPN
dpc-4915	100	187	(	(	PUNCT
dpc-4915	100	188	%	%	INTJ
dpc-4915	100	189	)	)	PUNCT
dpc-4915	100	190	hypertension	hypertension	NOUN
dpc-4915	100	191	,	,	PUNCT
dpc-4915	100	192	n	n	CCONJ
dpc-4915	100	193	(	(	PUNCT
dpc-4915	100	194	%	%	INTJ
dpc-4915	100	195	)	)	PUNCT
dpc-4915	100	196	7	7	NUM
dpc-4915	100	197	(	(	PUNCT
dpc-4915	100	198	35	35	NUM
dpc-4915	100	199	)	)	PUNCT
dpc-4915	100	200	3	3	NUM
dpc-4915	100	201	(	(	PUNCT
dpc-4915	100	202	15	15	NUM
dpc-4915	100	203	)	)	SYM
dpc-4915	100	204	2	2	NUM
dpc-4915	100	205	(	(	PUNCT
dpc-4915	100	206	10	10	NUM
dpc-4915	100	207	)	)	SYM
dpc-4915	100	208	2	2	NUM
dpc-4915	100	209	(	(	PUNCT
dpc-4915	100	210	10	10	NUM
dpc-4915	100	211	)	)	PUNCT
dpc-4915	100	212	10	10	NUM
dpc-4915	100	213	(	(	PUNCT
dpc-4915	100	214	50	50	NUM
dpc-4915	100	215	)	)	SYM
dpc-4915	100	216	1	1	NUM
dpc-4915	100	217	(	(	PUNCT
dpc-4915	100	218	5	5	NUM
dpc-4915	100	219	)	)	SYM
dpc-4915	100	220	2	2	NUM
dpc-4915	100	221	(	(	PUNCT
dpc-4915	100	222	10	10	NUM
dpc-4915	100	223	)	)	PUNCT
dpc-4915	100	224	3	3	NUM
dpc-4915	100	225	(	(	PUNCT
dpc-4915	100	226	27.3	27.3	NUM
dpc-4915	100	227	)	)	SYM
dpc-4915	100	228	2	2	NUM
dpc-4915	100	229	(	(	PUNCT
dpc-4915	100	230	18.2	18.2	NUM
dpc-4915	100	231	)	)	PUNCT
dpc-4915	100	232	1	1	NUM
dpc-4915	100	233	(	(	PUNCT
dpc-4915	100	234	9.1	9.1	NUM
dpc-4915	100	235	)	)	SYM
dpc-4915	100	236	1	1	NUM
dpc-4915	100	237	(	(	PUNCT
dpc-4915	100	238	9.1	9.1	NUM
dpc-4915	100	239	)	)	SYM
dpc-4915	100	240	2	2	NUM
dpc-4915	100	241	(	(	PUNCT
dpc-4915	100	242	18.2	18.2	NUM
dpc-4915	100	243	)	)	PUNCT
dpc-4915	100	244	1	1	NUM
dpc-4915	100	245	(	(	PUNCT
dpc-4915	100	246	9.1	9.1	NUM
dpc-4915	100	247	)	)	PUNCT
dpc-4915	100	248	1	1	NUM
dpc-4915	100	249	0.121	0.121	NUM
dpc-4915	100	250	0.281	0.281	NUM
dpc-4915	100	251	1	1	NUM
dpc-4915	100	252	10	10	NUM
dpc-4915	100	253	(	(	PUNCT
dpc-4915	100	254	32.3	32.3	NUM
dpc-4915	100	255	)	)	PUNCT
dpc-4915	100	256	5	5	NUM
dpc-4915	100	257	(	(	PUNCT
dpc-4915	100	258	16.1	16.1	NUM
dpc-4915	100	259	)	)	PUNCT
dpc-4915	100	260	3	3	NUM
dpc-4915	100	261	(	(	PUNCT
dpc-4915	100	262	9.7	9.7	NUM
dpc-4915	100	263	)	)	SYM
dpc-4915	100	264	2	2	NUM
dpc-4915	100	265	(	(	PUNCT
dpc-4915	100	266	6.5	6.5	NUM
dpc-4915	100	267	)	)	PUNCT
dpc-4915	100	268	11	11	NUM
dpc-4915	100	269	(	(	PUNCT
dpc-4915	100	270	35.5	35.5	NUM
dpc-4915	100	271	)	)	SYM
dpc-4915	100	272	3	3	NUM
dpc-4915	100	273	(	(	PUNCT
dpc-4915	100	274	9.7	9.7	NUM
dpc-4915	100	275	)	)	SYM
dpc-4915	100	276	3	3	NUM
dpc-4915	100	277	(	(	PUNCT
dpc-4915	100	278	9.7	9.7	NUM
dpc-4915	100	279	)	)	PUNCT
dpc-4915	100	280	original	original	ADJ
dpc-4915	100	281	article	article	NOUN
dpc-4915	100	282	|	|	ADV
dpc-4915	100	283	dermatol	dermatol	ADJ
dpc-4915	100	284	pract	pract	NOUN
dpc-4915	100	285	concept	concept	NOUN
dpc-4915	100	286	.	.	PUNCT
dpc-4915	101	1	2025;15(1):4915	2025;15(1):4915	NUM
dpc-4915	101	2	5	5	NUM
dpc-4915	101	3	hiscr	hiscr	NOUN
dpc-4915	101	4	(	(	PUNCT
dpc-4915	101	5	+	+	NOUN
dpc-4915	101	6	)	)	PUNCT
dpc-4915	101	7	(	(	PUNCT
dpc-4915	101	8	n	n	NOUN
dpc-4915	101	9	=	=	SYM
dpc-4915	101	10	20	20	NUM
dpc-4915	101	11	,	,	PUNCT
dpc-4915	101	12	64.5	64.5	NUM
dpc-4915	101	13	%	%	NOUN
dpc-4915	101	14	)	)	PUNCT
dpc-4915	101	15	hiscr	hiscr	NOUN
dpc-4915	101	16	(	(	PUNCT
dpc-4915	101	17	-	-	PUNCT
dpc-4915	101	18	)	)	PUNCT
dpc-4915	101	19	(	(	PUNCT
dpc-4915	101	20	n	n	NOUN
dpc-4915	101	21	=	=	SYM
dpc-4915	101	22	11	11	NUM
dpc-4915	101	23	,	,	PUNCT
dpc-4915	101	24	35.5	35.5	NUM
dpc-4915	101	25	%	%	NOUN
dpc-4915	101	26	)	)	PUNCT
dpc-4915	101	27	p	p	NOUN
dpc-4915	101	28	total	total	NOUN
dpc-4915	101	29	(	(	PUNCT
dpc-4915	101	30	n	n	NOUN
dpc-4915	101	31	=	=	SYM
dpc-4915	101	32	31	31	NUM
dpc-4915	101	33	,	,	PUNCT
dpc-4915	101	34	100	100	NUM
dpc-4915	101	35	%	%	NOUN
dpc-4915	101	36	)	)	PUNCT
dpc-4915	101	37	chronic	chronic	ADJ
dpc-4915	101	38	obstructive	obstructive	ADJ
dpc-4915	101	39	pulmonary	pulmonary	ADJ
dpc-4915	101	40	disease	disease	NOUN
dpc-4915	101	41	,	,	PUNCT
dpc-4915	101	42	n	n	CCONJ
dpc-4915	101	43	(	(	PUNCT
dpc-4915	101	44	%	%	INTJ
dpc-4915	101	45	)	)	PUNCT
dpc-4915	101	46	chronic	chronic	ADJ
dpc-4915	101	47	spontaneous	spontaneous	ADJ
dpc-4915	101	48	urticaria	urticaria	NOUN
dpc-4915	101	49	,	,	PUNCT
dpc-4915	101	50	n	n	PROPN
dpc-4915	101	51	(	(	PUNCT
dpc-4915	101	52	%	%	INTJ
dpc-4915	101	53	)	)	PUNCT
dpc-4915	101	54	familial	familial	ADJ
dpc-4915	101	55	mediterranean	mediterranean	ADJ
dpc-4915	101	56	fever	fever	NOUN
dpc-4915	101	57	,	,	PUNCT
dpc-4915	101	58	n	n	PROPN
dpc-4915	101	59	(	(	PUNCT
dpc-4915	101	60	%	%	INTJ
dpc-4915	101	61	)	)	PUNCT
dpc-4915	101	62	multiple	multiple	ADJ
dpc-4915	101	63	sclerosis	sclerosis	NOUN
dpc-4915	101	64	,	,	PUNCT
dpc-4915	101	65	n	n	PROPN
dpc-4915	101	66	(	(	PUNCT
dpc-4915	101	67	%	%	INTJ
dpc-4915	101	68	)	)	PUNCT
dpc-4915	101	69	alopecia	alopecia	NOUN
dpc-4915	101	70	universalis	universali	VERB
dpc-4915	101	71	,	,	PUNCT
dpc-4915	101	72	n	n	PROPN
dpc-4915	101	73	(	(	PUNCT
dpc-4915	101	74	%	%	INTJ
dpc-4915	101	75	)	)	PUNCT
dpc-4915	101	76	1	1	NUM
dpc-4915	101	77	(	(	PUNCT
dpc-4915	101	78	5	5	NUM
dpc-4915	101	79	)	)	SYM
dpc-4915	101	80	2	2	NUM
dpc-4915	101	81	(	(	PUNCT
dpc-4915	101	82	10	10	NUM
dpc-4915	101	83	)	)	SYM
dpc-4915	101	84	2	2	NUM
dpc-4915	101	85	(	(	PUNCT
dpc-4915	101	86	10	10	NUM
dpc-4915	101	87	)	)	SYM
dpc-4915	101	88	1	1	NUM
dpc-4915	101	89	(	(	PUNCT
dpc-4915	101	90	5	5	NUM
dpc-4915	101	91	)	)	SYM
dpc-4915	101	92	1	1	NUM
dpc-4915	101	93	(	(	PUNCT
dpc-4915	101	94	9.1	9.1	NUM
dpc-4915	101	95	)	)	SYM
dpc-4915	101	96	1	1	NUM
dpc-4915	101	97	(	(	PUNCT
dpc-4915	101	98	3.2	3.2	NUM
dpc-4915	101	99	)	)	SYM
dpc-4915	101	100	2	2	NUM
dpc-4915	101	101	(	(	PUNCT
dpc-4915	101	102	6.5	6.5	NUM
dpc-4915	101	103	)	)	SYM
dpc-4915	101	104	2	2	NUM
dpc-4915	101	105	(	(	PUNCT
dpc-4915	101	106	6.5	6.5	NUM
dpc-4915	101	107	)	)	PUNCT
dpc-4915	101	108	1	1	NUM
dpc-4915	101	109	(	(	PUNCT
dpc-4915	101	110	3.2	3.2	NUM
dpc-4915	101	111	)	)	PUNCT
dpc-4915	101	112	1	1	NUM
dpc-4915	101	113	(	(	PUNCT
dpc-4915	101	114	3.2	3.2	NUM
dpc-4915	101	115	)	)	PUNCT
dpc-4915	101	116	additional	additional	ADJ
dpc-4915	101	117	treatments	treatment	NOUN
dpc-4915	101	118	combined	combine	VERB
dpc-4915	101	119	with	with	ADP
dpc-4915	101	120	sec	sec	PROPN
dpc-4915	101	121	oral	oral	ADJ
dpc-4915	101	122	antibiotics	antibiotic	NOUN
dpc-4915	101	123	,	,	PUNCT
dpc-4915	101	124	n	n	CCONJ
dpc-4915	101	125	(	(	PUNCT
dpc-4915	101	126	%	%	INTJ
dpc-4915	101	127	)	)	PUNCT
dpc-4915	101	128	zinc	zinc	NOUN
dpc-4915	101	129	gluconate	gluconate	NOUN
dpc-4915	101	130	,	,	PUNCT
dpc-4915	101	131	n	n	PROPN
dpc-4915	101	132	(	(	PUNCT
dpc-4915	101	133	%	%	INTJ
dpc-4915	101	134	)	)	PUNCT
dpc-4915	101	135	methotrexate	methotrexate	NOUN
dpc-4915	101	136	,	,	PUNCT
dpc-4915	101	137	n	n	CCONJ
dpc-4915	101	138	(	(	PUNCT
dpc-4915	101	139	%	%	INTJ
dpc-4915	101	140	)	)	PUNCT
dpc-4915	101	141	4	4	NUM
dpc-4915	101	142	(	(	PUNCT
dpc-4915	101	143	20	20	NUM
dpc-4915	101	144	)	)	SYM
dpc-4915	101	145	2	2	NUM
dpc-4915	101	146	(	(	PUNCT
dpc-4915	101	147	10	10	NUM
dpc-4915	101	148	)	)	PUNCT
dpc-4915	101	149	8	8	NUM
dpc-4915	101	150	(	(	PUNCT
dpc-4915	101	151	40	40	NUM
dpc-4915	101	152	)	)	PUNCT
dpc-4915	101	153	8	8	NUM
dpc-4915	101	154	(	(	PUNCT
dpc-4915	101	155	72.7	72.7	NUM
dpc-4915	101	156	)	)	SYM
dpc-4915	101	157	1	1	NUM
dpc-4915	101	158	(	(	PUNCT
dpc-4915	101	159	9.1	9.1	NUM
dpc-4915	101	160	)	)	PUNCT
dpc-4915	101	161	0.007	0.007	NUM
dpc-4915	101	162	0.106	0.106	NUM
dpc-4915	101	163	12	12	NUM
dpc-4915	101	164	(	(	PUNCT
dpc-4915	101	165	38.7	38.7	NUM
dpc-4915	101	166	)	)	SYM
dpc-4915	101	167	2	2	NUM
dpc-4915	101	168	(	(	PUNCT
dpc-4915	101	169	6.5	6.5	NUM
dpc-4915	101	170	)	)	PUNCT
dpc-4915	101	171	9	9	NUM
dpc-4915	101	172	(	(	PUNCT
dpc-4915	101	173	29	29	NUM
dpc-4915	101	174	)	)	PUNCT
dpc-4915	101	175	previous	previous	ADJ
dpc-4915	101	176	treatments	treatment	NOUN
dpc-4915	101	177	adalimumab	adalimumab	PROPN
dpc-4915	101	178	,	,	PUNCT
dpc-4915	101	179	n	n	PROPN
dpc-4915	101	180	(	(	PUNCT
dpc-4915	101	181	%	%	INTJ
dpc-4915	101	182	)	)	PUNCT
dpc-4915	101	183	oral	oral	ADJ
dpc-4915	101	184	antibiotics	antibiotic	NOUN
dpc-4915	101	185	,	,	PUNCT
dpc-4915	101	186	n	n	CCONJ
dpc-4915	101	187	(	(	PUNCT
dpc-4915	101	188	%	%	INTJ
dpc-4915	101	189	)	)	PUNCT
dpc-4915	101	190	intralesional	intralesional	ADJ
dpc-4915	101	191	steroid	steroid	NOUN
dpc-4915	101	192	,	,	PUNCT
dpc-4915	101	193	n	n	PROPN
dpc-4915	101	194	(	(	PUNCT
dpc-4915	101	195	%	%	INTJ
dpc-4915	101	196	)	)	PUNCT
dpc-4915	101	197	surgery	surgery	NOUN
dpc-4915	101	198	,	,	PUNCT
dpc-4915	101	199	n	n	CCONJ
dpc-4915	101	200	(	(	PUNCT
dpc-4915	101	201	%	%	INTJ
dpc-4915	101	202	)	)	PUNCT
dpc-4915	101	203	acitretin	acitretin	NOUN
dpc-4915	101	204	,	,	PUNCT
dpc-4915	101	205	n	n	CCONJ
dpc-4915	101	206	(	(	PUNCT
dpc-4915	101	207	%	%	INTJ
dpc-4915	101	208	)	)	PUNCT
dpc-4915	101	209	isotretinoin	isotretinoin	PROPN
dpc-4915	101	210	,	,	PUNCT
dpc-4915	101	211	n	n	PROPN
dpc-4915	101	212	(	(	PUNCT
dpc-4915	101	213	%	%	INTJ
dpc-4915	101	214	)	)	PUNCT
dpc-4915	101	215	methotrexate	methotrexate	NOUN
dpc-4915	101	216	,	,	PUNCT
dpc-4915	101	217	n	n	CCONJ
dpc-4915	101	218	(	(	PUNCT
dpc-4915	101	219	%	%	INTJ
dpc-4915	101	220	)	)	PUNCT
dpc-4915	101	221	dapsone	dapsone	PROPN
dpc-4915	101	222	,	,	PUNCT
dpc-4915	101	223	n	n	CCONJ
dpc-4915	101	224	(	(	PUNCT
dpc-4915	101	225	%	%	INTJ
dpc-4915	101	226	)	)	PUNCT
dpc-4915	101	227	cyclosporine	cyclosporine	NOUN
dpc-4915	101	228	,	,	PUNCT
dpc-4915	101	229	n	n	PROPN
dpc-4915	101	230	(	(	PUNCT
dpc-4915	101	231	%	%	INTJ
dpc-4915	101	232	)	)	PUNCT
dpc-4915	101	233	etanercept	etanercept	NOUN
dpc-4915	101	234	,	,	PUNCT
dpc-4915	101	235	n	n	CCONJ
dpc-4915	101	236	(	(	PUNCT
dpc-4915	101	237	%	%	INTJ
dpc-4915	101	238	)	)	PUNCT
dpc-4915	101	239	infliximab	infliximab	NOUN
dpc-4915	101	240	,	,	PUNCT
dpc-4915	101	241	n	n	CCONJ
dpc-4915	101	242	(	(	PUNCT
dpc-4915	101	243	%	%	INTJ
dpc-4915	101	244	)	)	PUNCT
dpc-4915	101	245	golimumab	golimumab	NOUN
dpc-4915	101	246	,	,	PUNCT
dpc-4915	101	247	n	n	CCONJ
dpc-4915	101	248	(	(	PUNCT
dpc-4915	101	249	%	%	INTJ
dpc-4915	101	250	)	)	PUNCT
dpc-4915	101	251	10	10	NUM
dpc-4915	101	252	(	(	PUNCT
dpc-4915	101	253	50	50	NUM
dpc-4915	101	254	)	)	PUNCT
dpc-4915	101	255	8	8	NUM
dpc-4915	101	256	(	(	PUNCT
dpc-4915	101	257	40	40	NUM
dpc-4915	101	258	)	)	SYM
dpc-4915	101	259	1	1	NUM
dpc-4915	101	260	(	(	PUNCT
dpc-4915	101	261	5	5	NUM
dpc-4915	101	262	)	)	SYM
dpc-4915	101	263	1	1	NUM
dpc-4915	101	264	(	(	PUNCT
dpc-4915	101	265	5	5	NUM
dpc-4915	101	266	)	)	PUNCT
dpc-4915	101	267	8	8	NUM
dpc-4915	101	268	(	(	PUNCT
dpc-4915	101	269	40	40	NUM
dpc-4915	101	270	)	)	SYM
dpc-4915	101	271	1	1	NUM
dpc-4915	101	272	(	(	PUNCT
dpc-4915	101	273	5	5	NUM
dpc-4915	101	274	)	)	PUNCT
dpc-4915	101	275	4	4	NUM
dpc-4915	101	276	(	(	PUNCT
dpc-4915	101	277	20	20	NUM
dpc-4915	101	278	)	)	SYM
dpc-4915	101	279	2	2	NUM
dpc-4915	101	280	(	(	PUNCT
dpc-4915	101	281	10	10	NUM
dpc-4915	101	282	)	)	SYM
dpc-4915	101	283	1	1	NUM
dpc-4915	101	284	(	(	PUNCT
dpc-4915	101	285	5	5	NUM
dpc-4915	101	286	)	)	PUNCT
dpc-4915	101	287	11	11	NUM
dpc-4915	101	288	(	(	PUNCT
dpc-4915	101	289	100	100	NUM
dpc-4915	101	290	)	)	PUNCT
dpc-4915	101	291	7	7	NUM
dpc-4915	101	292	(	(	PUNCT
dpc-4915	101	293	63.6	63.6	NUM
dpc-4915	101	294	)	)	SYM
dpc-4915	101	295	2	2	NUM
dpc-4915	101	296	(	(	PUNCT
dpc-4915	101	297	18.2	18.2	NUM
dpc-4915	101	298	)	)	SYM
dpc-4915	101	299	2	2	NUM
dpc-4915	101	300	(	(	PUNCT
dpc-4915	101	301	18.2	18.2	NUM
dpc-4915	101	302	)	)	PUNCT
dpc-4915	101	303	1	1	NUM
dpc-4915	101	304	(	(	PUNCT
dpc-4915	101	305	9.1	9.1	NUM
dpc-4915	101	306	)	)	SYM
dpc-4915	101	307	2	2	NUM
dpc-4915	101	308	(	(	PUNCT
dpc-4915	101	309	18.2	18.2	NUM
dpc-4915	101	310	)	)	PUNCT
dpc-4915	101	311	1	1	NUM
dpc-4915	101	312	(	(	PUNCT
dpc-4915	101	313	9.1	9.1	NUM
dpc-4915	101	314	)	)	SYM
dpc-4915	101	315	1	1	NUM
dpc-4915	101	316	(	(	PUNCT
dpc-4915	101	317	9.1	9.1	NUM
dpc-4915	101	318	)	)	PUNCT
dpc-4915	101	319	3	3	NUM
dpc-4915	101	320	(	(	PUNCT
dpc-4915	101	321	27.3	27.3	NUM
dpc-4915	101	322	)	)	PUNCT
dpc-4915	101	323	0.005	0.005	NUM
dpc-4915	101	324	0.208	0.208	NUM
dpc-4915	101	325	0.281	0.281	NUM
dpc-4915	101	326	0.281	0.281	NUM
dpc-4915	101	327	0.106	0.106	NUM
dpc-4915	101	328	0.317	0.317	NUM
dpc-4915	101	329	21	21	NUM
dpc-4915	101	330	(	(	PUNCT
dpc-4915	101	331	67.7	67.7	NUM
dpc-4915	101	332	)	)	PUNCT
dpc-4915	101	333	15	15	NUM
dpc-4915	101	334	(	(	PUNCT
dpc-4915	101	335	48.4	48.4	NUM
dpc-4915	101	336	)	)	PUNCT
dpc-4915	101	337	3	3	NUM
dpc-4915	101	338	(	(	PUNCT
dpc-4915	101	339	9.7	9.7	NUM
dpc-4915	101	340	)	)	SYM
dpc-4915	101	341	2	2	NUM
dpc-4915	101	342	(	(	PUNCT
dpc-4915	101	343	6.5	6.5	NUM
dpc-4915	101	344	)	)	PUNCT
dpc-4915	101	345	1	1	NUM
dpc-4915	101	346	(	(	PUNCT
dpc-4915	101	347	3.2	3.2	NUM
dpc-4915	101	348	)	)	PUNCT
dpc-4915	101	349	3	3	NUM
dpc-4915	101	350	(	(	PUNCT
dpc-4915	101	351	9.7	9.7	NUM
dpc-4915	101	352	)	)	PUNCT
dpc-4915	101	353	9	9	NUM
dpc-4915	101	354	(	(	PUNCT
dpc-4915	101	355	29	29	NUM
dpc-4915	101	356	)	)	SYM
dpc-4915	101	357	1	1	NUM
dpc-4915	101	358	(	(	PUNCT
dpc-4915	101	359	3.2	3.2	NUM
dpc-4915	101	360	)	)	PUNCT
dpc-4915	101	361	1	1	NUM
dpc-4915	101	362	(	(	PUNCT
dpc-4915	101	363	3.2	3.2	NUM
dpc-4915	101	364	)	)	PUNCT
dpc-4915	101	365	4	4	NUM
dpc-4915	101	366	(	(	PUNCT
dpc-4915	101	367	12.9	12.9	NUM
dpc-4915	101	368	)	)	SYM
dpc-4915	101	369	5	5	NUM
dpc-4915	101	370	(	(	PUNCT
dpc-4915	101	371	16.1	16.1	NUM
dpc-4915	101	372	)	)	PUNCT
dpc-4915	101	373	1	1	NUM
dpc-4915	101	374	(	(	PUNCT
dpc-4915	101	375	3.2	3.2	NUM
dpc-4915	101	376	)	)	PUNCT
dpc-4915	101	377	previous	previous	ADJ
dpc-4915	101	378	exposure	exposure	NOUN
dpc-4915	101	379	to	to	ADP
dpc-4915	101	380	biologics	biologic	NOUN
dpc-4915	101	381	naive	naive	ADJ
dpc-4915	101	382	,	,	PUNCT
dpc-4915	101	383	n	n	CCONJ
dpc-4915	101	384	(	(	PUNCT
dpc-4915	101	385	%	%	INTJ
dpc-4915	101	386	)	)	PUNCT
dpc-4915	101	387	non	non	ADJ
dpc-4915	101	388	-	-	ADJ
dpc-4915	101	389	naive	naive	ADJ
dpc-4915	101	390	,	,	PUNCT
dpc-4915	101	391	n	n	CCONJ
dpc-4915	101	392	(	(	PUNCT
dpc-4915	101	393	%	%	INTJ
dpc-4915	101	394	)	)	PUNCT
dpc-4915	101	395	9	9	NUM
dpc-4915	101	396	(	(	PUNCT
dpc-4915	101	397	45	45	NUM
dpc-4915	101	398	)	)	PUNCT
dpc-4915	101	399	11	11	NUM
dpc-4915	101	400	(	(	PUNCT
dpc-4915	101	401	55	55	NUM
dpc-4915	101	402	)	)	PUNCT
dpc-4915	101	403	11	11	NUM
dpc-4915	101	404	(	(	PUNCT
dpc-4915	101	405	100	100	NUM
dpc-4915	101	406	)	)	PUNCT
dpc-4915	101	407	0.012	0.012	NUM
dpc-4915	101	408	9	9	NUM
dpc-4915	101	409	(	(	PUNCT
dpc-4915	101	410	29	29	NUM
dpc-4915	101	411	)	)	SYM
dpc-4915	101	412	22	22	NUM
dpc-4915	101	413	(	(	PUNCT
dpc-4915	101	414	71	71	NUM
dpc-4915	101	415	)	)	PUNCT
dpc-4915	101	416	sec	sec	PROPN
dpc-4915	101	417	discontinued	discontinue	VERB
dpc-4915	101	418	no	no	ADP
dpc-4915	101	419	,	,	PUNCT
dpc-4915	101	420	n	n	PROPN
dpc-4915	101	421	(	(	PUNCT
dpc-4915	101	422	%	%	INTJ
dpc-4915	101	423	)	)	PUNCT
dpc-4915	101	424	primary	primary	ADJ
dpc-4915	101	425	ineffectiveness	ineffectiveness	NOUN
dpc-4915	101	426	,	,	PUNCT
dpc-4915	101	427	n	n	PROPN
dpc-4915	101	428	(	(	PUNCT
dpc-4915	101	429	%	%	INTJ
dpc-4915	101	430	)	)	PUNCT
dpc-4915	101	431	secondary	secondary	ADJ
dpc-4915	101	432	ineffectiveness	ineffectiveness	NOUN
dpc-4915	101	433	,	,	PUNCT
dpc-4915	101	434	n	n	PROPN
dpc-4915	101	435	(	(	PUNCT
dpc-4915	101	436	%	%	INTJ
dpc-4915	101	437	)	)	PUNCT
dpc-4915	101	438	adverse	adverse	ADJ
dpc-4915	101	439	effects	effect	NOUN
dpc-4915	101	440	,	,	PUNCT
dpc-4915	101	441	n	n	CCONJ
dpc-4915	101	442	(	(	PUNCT
dpc-4915	101	443	%	%	INTJ
dpc-4915	101	444	)	)	PUNCT
dpc-4915	101	445	loss	loss	NOUN
dpc-4915	101	446	of	of	ADP
dpc-4915	101	447	follow	follow	NOUN
dpc-4915	101	448	-	-	PUNCT
dpc-4915	101	449	up	up	NOUN
dpc-4915	101	450	,	,	PUNCT
dpc-4915	101	451	n	n	CCONJ
dpc-4915	101	452	(	(	PUNCT
dpc-4915	101	453	%	%	INTJ
dpc-4915	101	454	)	)	PUNCT
dpc-4915	101	455	19	19	NUM
dpc-4915	101	456	(	(	PUNCT
dpc-4915	101	457	95	95	NUM
dpc-4915	101	458	)	)	PUNCT
dpc-4915	101	459	1	1	NUM
dpc-4915	101	460	(	(	PUNCT
dpc-4915	101	461	5	5	NUM
dpc-4915	101	462	)	)	PUNCT
dpc-4915	101	463	9	9	NUM
dpc-4915	101	464	(	(	PUNCT
dpc-4915	101	465	81.8	81.8	NUM
dpc-4915	101	466	)	)	PUNCT
dpc-4915	101	467	1	1	NUM
dpc-4915	101	468	(	(	PUNCT
dpc-4915	101	469	9.1	9.1	NUM
dpc-4915	101	470	)	)	SYM
dpc-4915	101	471	1	1	NUM
dpc-4915	101	472	(	(	PUNCT
dpc-4915	101	473	9.1	9.1	NUM
dpc-4915	101	474	)	)	PUNCT
dpc-4915	101	475	19	19	NUM
dpc-4915	101	476	(	(	PUNCT
dpc-4915	101	477	61.3	61.3	NUM
dpc-4915	101	478	)	)	PUNCT
dpc-4915	101	479	9	9	NUM
dpc-4915	101	480	(	(	PUNCT
dpc-4915	101	481	29	29	NUM
dpc-4915	101	482	)	)	SYM
dpc-4915	101	483	1	1	NUM
dpc-4915	101	484	(	(	PUNCT
dpc-4915	101	485	3.2	3.2	NUM
dpc-4915	101	486	)	)	PUNCT
dpc-4915	101	487	1	1	NUM
dpc-4915	101	488	(	(	PUNCT
dpc-4915	101	489	3.2	3.2	NUM
dpc-4915	101	490	)	)	PUNCT
dpc-4915	101	491	1	1	NUM
dpc-4915	101	492	(	(	PUNCT
dpc-4915	101	493	3.2	3.2	NUM
dpc-4915	101	494	)	)	PUNCT
dpc-4915	101	495	hiscr	hiscr	NOUN
dpc-4915	101	496	=	=	PUNCT
dpc-4915	101	497	hidradenitis	hidradenitis	PROPN
dpc-4915	101	498	suppurativa	suppurativa	PROPN
dpc-4915	101	499	clinical	clinical	ADJ
dpc-4915	101	500	response	response	NOUN
dpc-4915	101	501	;	;	PUNCT
dpc-4915	101	502	sd	sd	NOUN
dpc-4915	101	503	=	=	SYM
dpc-4915	101	504	standard	standard	ADJ
dpc-4915	101	505	deviation	deviation	NOUN
dpc-4915	101	506	;	;	PUNCT
dpc-4915	101	507	sec	sec	PROPN
dpc-4915	101	508	=	=	SYM
dpc-4915	101	509	secukinumab	secukinumab	NOUN
dpc-4915	101	510	.	.	PUNCT
dpc-4915	102	1	300	300	NUM
dpc-4915	102	2	mg/4	mg/4	PROPN
dpc-4915	102	3	weeks	week	NOUN
dpc-4915	102	4	of	of	ADP
dpc-4915	102	5	sec	sec	PROPN
dpc-4915	102	6	following	follow	VERB
dpc-4915	102	7	a	a	DET
dpc-4915	102	8	loading	loading	NOUN
dpc-4915	102	9	dose	dose	NOUN
dpc-4915	102	10	.	.	PUNCT
dpc-4915	103	1	six	six	NUM
dpc-4915	103	2	of	of	ADP
dpc-4915	103	3	nine	nine	NUM
dpc-4915	103	4	patients	patient	NOUN
dpc-4915	103	5	(	(	PUNCT
dpc-4915	103	6	67	67	NUM
dpc-4915	103	7	%	%	NOUN
dpc-4915	103	8	)	)	PUNCT
dpc-4915	103	9	achieved	achieve	VERB
dpc-4915	103	10	hiscr	hiscr	NOUN
dpc-4915	103	11	at	at	ADP
dpc-4915	103	12	24	24	NUM
dpc-4915	103	13	weeks	week	NOUN
dpc-4915	103	14	.	.	PUNCT
dpc-4915	104	1	no	no	DET
dpc-4915	104	2	serious	serious	ADJ
dpc-4915	104	3	adverse	adverse	ADJ
dpc-4915	104	4	effects	effect	NOUN
dpc-4915	104	5	were	be	AUX
dpc-4915	104	6	observed	observe	VERB
dpc-4915	104	7	[	[	PUNCT
dpc-4915	104	8	10	10	NUM
dpc-4915	104	9	]	]	PUNCT
dpc-4915	104	10	.	.	PUNCT
dpc-4915	105	1	in	in	ADP
dpc-4915	105	2	the	the	DET
dpc-4915	105	3	open	open	ADJ
dpc-4915	105	4	-	-	PUNCT
dpc-4915	105	5	label	label	NOUN
dpc-4915	105	6	study	study	NOUN
dpc-4915	105	7	of	of	ADP
dpc-4915	105	8	casseres	cassere	NOUN
dpc-4915	105	9	et	et	PROPN
dpc-4915	105	10	al	al	PROPN
dpc-4915	105	11	,	,	PUNCT
dpc-4915	105	12	following	follow	VERB
dpc-4915	105	13	the	the	DET
dpc-4915	105	14	loading	loading	NOUN
dpc-4915	105	15	dose	dose	NOUN
dpc-4915	105	16	,	,	PUNCT
dpc-4915	105	17	sec	sec	PROPN
dpc-4915	105	18	was	be	AUX
dpc-4915	105	19	administered	administer	VERB
dpc-4915	105	20	to	to	ADP
dpc-4915	105	21	9	9	NUM
dpc-4915	105	22	patients	patient	NOUN
dpc-4915	105	23	at	at	ADP
dpc-4915	105	24	a	a	DET
dpc-4915	105	25	dose	dose	NOUN
dpc-4915	105	26	of	of	ADP
dpc-4915	105	27	300	300	NUM
dpc-4915	105	28	mg/4	mg/4	NOUN
dpc-4915	105	29	weeks	week	NOUN
dpc-4915	105	30	and	and	CCONJ
dpc-4915	105	31	to	to	ADP
dpc-4915	105	32	11	11	NUM
dpc-4915	105	33	patients	patient	NOUN
dpc-4915	105	34	at	at	ADP
dpc-4915	105	35	a	a	DET
dpc-4915	105	36	dose	dose	NOUN
dpc-4915	105	37	of	of	ADP
dpc-4915	105	38	300	300	NUM
dpc-4915	105	39	mg/2	mg/2	NOUN
dpc-4915	105	40	weeks	week	NOUN
dpc-4915	105	41	.	.	PUNCT
dpc-4915	106	1	seventy	seventy	NUM
dpc-4915	106	2	percent	percent	NOUN
dpc-4915	106	3	(	(	PUNCT
dpc-4915	106	4	14/20	14/20	NUM
dpc-4915	106	5	)	)	PUNCT
dpc-4915	106	6	of	of	ADP
dpc-4915	106	7	all	all	DET
dpc-4915	106	8	patients	patient	NOUN
dpc-4915	106	9	achieved	achieve	VERB
dpc-4915	106	10	hiscr	hiscr	NOUN
dpc-4915	106	11	by	by	ADP
dpc-4915	106	12	week	week	NOUN
dpc-4915	106	13	24	24	NUM
dpc-4915	106	14	.	.	PUNCT
dpc-4915	107	1	no	no	DET
dpc-4915	107	2	serious	serious	ADJ
dpc-4915	107	3	adverse	adverse	ADJ
dpc-4915	107	4	effects	effect	NOUN
dpc-4915	107	5	were	be	AUX
dpc-4915	107	6	observed	observe	VERB
dpc-4915	107	7	[	[	PUNCT
dpc-4915	107	8	11	11	NUM
dpc-4915	107	9	]	]	PUNCT
dpc-4915	107	10	.	.	PUNCT
dpc-4915	108	1	these	these	DET
dpc-4915	108	2	results	result	NOUN
dpc-4915	108	3	were	be	AUX
dpc-4915	108	4	similar	similar	ADJ
dpc-4915	108	5	to	to	ADP
dpc-4915	108	6	our	our	PRON
dpc-4915	108	7	study	study	NOUN
dpc-4915	108	8	.	.	PUNCT
dpc-4915	109	1	in	in	ADP
dpc-4915	109	2	the	the	DET
dpc-4915	109	3	single	single	ADJ
dpc-4915	109	4	-	-	PUNCT
dpc-4915	109	5	center	center	NOUN
dpc-4915	109	6	study	study	NOUN
dpc-4915	109	7	of	of	ADP
dpc-4915	109	8	reguiai	reguiai	NOUN
dpc-4915	109	9	et	et	PROPN
dpc-4915	109	10	al	al	PROPN
dpc-4915	109	11	,	,	PUNCT
dpc-4915	109	12	sec	sec	PROPN
dpc-4915	109	13	was	be	AUX
dpc-4915	109	14	used	use	VERB
dpc-4915	109	15	in	in	ADP
dpc-4915	109	16	20	20	NUM
dpc-4915	109	17	patients	patient	NOUN
dpc-4915	109	18	with	with	ADP
dpc-4915	109	19	hs	hs	PRON
dpc-4915	109	20	at	at	ADP
dpc-4915	109	21	a	a	DET
dpc-4915	109	22	dose	dose	NOUN
dpc-4915	109	23	of	of	ADP
dpc-4915	109	24	300	300	NUM
dpc-4915	109	25	mg/4	mg/4	NOUN
dpc-4915	109	26	weeks	week	NOUN
dpc-4915	109	27	following	follow	VERB
dpc-4915	109	28	the	the	DET
dpc-4915	109	29	loading	loading	NOUN
dpc-4915	109	30	dose	dose	NOUN
dpc-4915	109	31	.	.	PUNCT
dpc-4915	110	1	hiscr	hiscr	PROPN
dpc-4915	110	2	was	be	AUX
dpc-4915	110	3	achieved	achieve	VERB
dpc-4915	110	4	in	in	ADP
dpc-4915	110	5	75	75	NUM
dpc-4915	110	6	%	%	NOUN
dpc-4915	110	7	(	(	PUNCT
dpc-4915	110	8	15/20	15/20	NUM
dpc-4915	110	9	)	)	PUNCT
dpc-4915	110	10	of	of	ADP
dpc-4915	110	11	patients	patient	NOUN
dpc-4915	110	12	at	at	ADP
dpc-4915	110	13	the	the	DET
dpc-4915	110	14	16th	16th	ADJ
dpc-4915	110	15	week	week	NOUN
dpc-4915	110	16	of	of	ADP
dpc-4915	110	17	treatment	treatment	NOUN
dpc-4915	110	18	.	.	PUNCT
dpc-4915	111	1	after	after	ADP
dpc-4915	111	2	sec	sec	PROPN
dpc-4915	111	3	treatment	treatment	NOUN
dpc-4915	111	4	,	,	PUNCT
dpc-4915	111	5	no	no	DET
dpc-4915	111	6	recurrence	recurrence	NOUN
dpc-4915	111	7	was	be	AUX
dpc-4915	111	8	observed	observe	VERB
dpc-4915	111	9	after	after	ADP
dpc-4915	111	10	a	a	DET
dpc-4915	111	11	mean	mean	ADJ
dpc-4915	111	12	follow	follow	NOUN
dpc-4915	111	13	-	-	PUNCT
dpc-4915	111	14	up	up	NOUN
dpc-4915	111	15	of	of	ADP
dpc-4915	111	16	14	14	NUM
dpc-4915	111	17	months	month	NOUN
dpc-4915	111	18	(	(	PUNCT
dpc-4915	111	19	range	range	NOUN
dpc-4915	111	20	3	3	NUM
dpc-4915	111	21	to	to	PART
dpc-4915	111	22	36	36	NUM
dpc-4915	111	23	months	month	NOUN
dpc-4915	111	24	)	)	PUNCT
dpc-4915	111	25	.	.	PUNCT
dpc-4915	112	1	no	no	DET
dpc-4915	112	2	patient	patient	NOUN
dpc-4915	112	3	required	require	VERB
dpc-4915	112	4	rescue	rescue	NOUN
dpc-4915	112	5	table	table	NOUN
dpc-4915	112	6	1	1	NUM
dpc-4915	112	7	.	.	PUNCT
dpc-4915	113	1	demographic	demographic	ADJ
dpc-4915	113	2	and	and	CCONJ
dpc-4915	113	3	clinical	clinical	ADJ
dpc-4915	113	4	characteristics	characteristic	NOUN
dpc-4915	113	5	of	of	ADP
dpc-4915	113	6	patients	patient	NOUN
dpc-4915	113	7	according	accord	VERB
dpc-4915	113	8	to	to	ADP
dpc-4915	113	9	hiscr	hiscr	PROPN
dpc-4915	113	10	.	.	PUNCT
dpc-4915	114	1	(	(	PUNCT
dpc-4915	114	2	continued	continue	VERB
dpc-4915	114	3	)	)	PUNCT
dpc-4915	114	4	therapy	therapy	NOUN
dpc-4915	114	5	.	.	PUNCT
dpc-4915	115	1	in	in	ADP
dpc-4915	115	2	this	this	DET
dpc-4915	115	3	study	study	NOUN
dpc-4915	115	4	,	,	PUNCT
dpc-4915	115	5	it	it	PRON
dpc-4915	115	6	was	be	AUX
dpc-4915	115	7	observed	observe	VERB
dpc-4915	115	8	that	that	SCONJ
dpc-4915	115	9	smoking	smoking	NOUN
dpc-4915	115	10	status	status	NOUN
dpc-4915	115	11	,	,	PUNCT
dpc-4915	115	12	weight	weight	NOUN
dpc-4915	115	13	,	,	PUNCT
dpc-4915	115	14	and	and	CCONJ
dpc-4915	115	15	hs	hs	PROPN
dpc-4915	115	16	severity	severity	NOUN
dpc-4915	115	17	did	do	AUX
dpc-4915	115	18	not	not	PART
dpc-4915	115	19	affect	affect	VERB
dpc-4915	115	20	the	the	DET
dpc-4915	115	21	treatment	treatment	NOUN
dpc-4915	115	22	results	result	NOUN
dpc-4915	115	23	.	.	PUNCT
dpc-4915	116	1	two	two	NUM
dpc-4915	116	2	patients	patient	NOUN
dpc-4915	116	3	with	with	ADP
dpc-4915	116	4	no	no	DET
dpc-4915	116	5	personal	personal	ADJ
dpc-4915	116	6	or	or	CCONJ
dpc-4915	116	7	family	family	NOUN
dpc-4915	116	8	history	history	NOUN
dpc-4915	116	9	of	of	ADP
dpc-4915	116	10	inflammatory	inflammatory	ADJ
dpc-4915	116	11	bowel	bowel	NOUN
dpc-4915	116	12	disease	disease	NOUN
dpc-4915	116	13	developed	develop	VERB
dpc-4915	116	14	crohn	crohn	PROPN
dpc-4915	116	15	disease	disease	NOUN
dpc-4915	116	16	after	after	ADP
dpc-4915	116	17	3	3	NUM
dpc-4915	116	18	and	and	CCONJ
dpc-4915	116	19	5	5	NUM
dpc-4915	116	20	months	month	NOUN
dpc-4915	116	21	of	of	ADP
dpc-4915	116	22	treatment	treatment	NOUN
dpc-4915	116	23	,	,	PUNCT
dpc-4915	116	24	respectively	respectively	ADV
dpc-4915	116	25	[	[	X
dpc-4915	116	26	12	12	NUM
dpc-4915	116	27	]	]	PUNCT
dpc-4915	116	28	.	.	PUNCT
dpc-4915	117	1	in	in	ADP
dpc-4915	117	2	the	the	DET
dpc-4915	117	3	single	single	ADJ
dpc-4915	117	4	-	-	PUNCT
dpc-4915	117	5	center	center	NOUN
dpc-4915	117	6	studies	study	NOUN
dpc-4915	117	7	reported	report	VERB
dpc-4915	117	8	by	by	ADP
dpc-4915	117	9	melgosa	melgosa	PROPN
dpc-4915	117	10	ramos	ramos	PROPN
dpc-4915	117	11	et	et	PROPN
dpc-4915	117	12	al	al	PROPN
dpc-4915	117	13	from	from	ADP
dpc-4915	117	14	spain	spain	PROPN
dpc-4915	117	15	,	,	PUNCT
dpc-4915	117	16	sec	sec	PROPN
dpc-4915	117	17	was	be	AUX
dpc-4915	117	18	used	use	VERB
dpc-4915	117	19	at	at	ADP
dpc-4915	117	20	a	a	DET
dpc-4915	117	21	dose	dose	NOUN
dpc-4915	117	22	of	of	ADP
dpc-4915	117	23	300	300	NUM
dpc-4915	117	24	mg	mg	NOUN
dpc-4915	117	25	every	every	DET
dpc-4915	117	26	14	14	NUM
dpc-4915	117	27	or	or	CCONJ
dpc-4915	117	28	28	28	NUM
dpc-4915	117	29	days	day	NOUN
dpc-4915	117	30	in	in	ADP
dpc-4915	117	31	23	23	NUM
dpc-4915	117	32	patients	patient	NOUN
dpc-4915	117	33	with	with	ADP
dpc-4915	117	34	hs	hs	PROPN
dpc-4915	117	35	.	.	PUNCT
dpc-4915	117	36	considering	consider	VERB
dpc-4915	117	37	only	only	ADJ
dpc-4915	117	38	patients	patient	NOUN
dpc-4915	117	39	who	who	PRON
dpc-4915	117	40	reached	reach	VERB
dpc-4915	117	41	the	the	DET
dpc-4915	117	42	different	different	ADJ
dpc-4915	117	43	follow	follow	NOUN
dpc-4915	117	44	-	-	PUNCT
dpc-4915	117	45	up	up	ADP
dpc-4915	117	46	evaluation	evaluation	NOUN
dpc-4915	117	47	periods	period	NOUN
dpc-4915	117	48	,	,	PUNCT
dpc-4915	117	49	17/21	17/21	NUM
dpc-4915	117	50	(	(	PUNCT
dpc-4915	117	51	73.9	73.9	NUM
dpc-4915	117	52	%	%	NOUN
dpc-4915	117	53	)	)	PUNCT
dpc-4915	117	54	reached	reach	VERB
dpc-4915	117	55	hiscr	hiscr	NOUN
dpc-4915	117	56	at	at	ADP
dpc-4915	117	57	week	week	NOUN
dpc-4915	117	58	16	16	NUM
dpc-4915	117	59	,	,	PUNCT
dpc-4915	117	60	15/21	15/21	NUM
dpc-4915	117	61	(	(	PUNCT
dpc-4915	117	62	71.4	71.4	NUM
dpc-4915	117	63	%	%	NOUN
dpc-4915	117	64	)	)	PUNCT
dpc-4915	117	65	at	at	ADP
dpc-4915	117	66	week	week	NOUN
dpc-4915	117	67	24	24	NUM
dpc-4915	117	68	,	,	PUNCT
dpc-4915	117	69	10/14	10/14	NUM
dpc-4915	117	70	(	(	PUNCT
dpc-4915	117	71	71.4	71.4	NUM
dpc-4915	117	72	%	%	NOUN
dpc-4915	117	73	)	)	PUNCT
dpc-4915	117	74	at	at	ADP
dpc-4915	117	75	week	week	NOUN
dpc-4915	117	76	36	36	NUM
dpc-4915	117	77	,	,	PUNCT
dpc-4915	117	78	and	and	CCONJ
dpc-4915	117	79	10/12	10/12	NUM
dpc-4915	117	80	(	(	PUNCT
dpc-4915	117	81	83.3	83.3	NUM
dpc-4915	117	82	%	%	NOUN
dpc-4915	117	83	)	)	PUNCT
dpc-4915	117	84	at	at	ADP
dpc-4915	117	85	week	week	NOUN
dpc-4915	117	86	52	52	NUM
dpc-4915	117	87	.	.	PUNCT
dpc-4915	118	1	no	no	DET
dpc-4915	118	2	severe	severe	ADJ
dpc-4915	118	3	adverse	adverse	ADJ
dpc-4915	118	4	effects	effect	NOUN
dpc-4915	118	5	were	be	AUX
dpc-4915	118	6	reported	report	VERB
dpc-4915	118	7	[	[	X
dpc-4915	118	8	13	13	NUM
dpc-4915	118	9	]	]	PUNCT
dpc-4915	118	10	.	.	PUNCT
dpc-4915	119	1	in	in	ADP
dpc-4915	119	2	their	their	PRON
dpc-4915	119	3	single	single	ADJ
dpc-4915	119	4	-	-	PUNCT
dpc-4915	119	5	center	center	NOUN
dpc-4915	119	6	study	study	NOUN
dpc-4915	119	7	,	,	PUNCT
dpc-4915	119	8	martora	martora	PROPN
dpc-4915	119	9	et	et	PROPN
dpc-4915	119	10	al	al	PROPN
dpc-4915	119	11	used	use	VERB
dpc-4915	119	12	sec	sec	PROPN
dpc-4915	119	13	at	at	ADP
dpc-4915	119	14	a	a	DET
dpc-4915	119	15	dose	dose	NOUN
dpc-4915	119	16	of	of	ADP
dpc-4915	119	17	300	300	NUM
dpc-4915	119	18	mg/4	mg/4	NOUN
dpc-4915	119	19	weeks	week	NOUN
dpc-4915	119	20	following	follow	VERB
dpc-4915	119	21	the	the	DET
dpc-4915	119	22	loading	loading	NOUN
dpc-4915	119	23	dose	dose	VERB
dpc-4915	119	24	in	in	ADP
dpc-4915	119	25	the	the	DET
dpc-4915	119	26	treatment	treatment	NOUN
dpc-4915	119	27	of	of	ADP
dpc-4915	119	28	moderate	moderate	ADJ
dpc-4915	119	29	to	to	ADP
dpc-4915	119	30	severe	severe	ADJ
dpc-4915	119	31	hs	hs	PROPN
dpc-4915	119	32	in	in	ADP
dpc-4915	119	33	4	4	NUM
dpc-4915	119	34	biologic	biologic	NOUN
dpc-4915	119	35	-	-	PUNCT
dpc-4915	119	36	naive	naive	ADJ
dpc-4915	119	37	6	6	NUM
dpc-4915	119	38	original	original	ADJ
dpc-4915	119	39	article	article	NOUN
dpc-4915	119	40	|	|	ADV
dpc-4915	119	41	dermatol	dermatol	ADJ
dpc-4915	119	42	pract	pract	NOUN
dpc-4915	119	43	concept	concept	NOUN
dpc-4915	119	44	.	.	PUNCT
dpc-4915	120	1	2025;15(1):4915	2025;15(1):4915	NUM
dpc-4915	120	2	of	of	ADP
dpc-4915	120	3	obesity	obesity	NOUN
dpc-4915	120	4	and	and	CCONJ
dpc-4915	120	5	smoking	smoking	NOUN
dpc-4915	120	6	is	be	AUX
dpc-4915	120	7	higher	high	ADJ
dpc-4915	120	8	in	in	ADP
dpc-4915	120	9	patients	patient	NOUN
dpc-4915	120	10	with	with	ADP
dpc-4915	120	11	the	the	DET
dpc-4915	120	12	coexistence	coexistence	NOUN
dpc-4915	120	13	of	of	ADP
dpc-4915	120	14	psoriasis	psoriasis	NOUN
dpc-4915	120	15	and	and	CCONJ
dpc-4915	120	16	hs	hs	PRON
dpc-4915	120	17	than	than	ADP
dpc-4915	120	18	in	in	ADP
dpc-4915	120	19	patients	patient	NOUN
dpc-4915	120	20	with	with	ADP
dpc-4915	120	21	psoriasis	psoriasis	NOUN
dpc-4915	120	22	alone	alone	ADV
dpc-4915	120	23	[	[	X
dpc-4915	120	24	24	24	NUM
dpc-4915	120	25	]	]	PUNCT
dpc-4915	120	26	.	.	PUNCT
dpc-4915	121	1	therefore	therefore	ADV
dpc-4915	121	2	,	,	PUNCT
dpc-4915	121	3	this	this	DET
dpc-4915	121	4	association	association	NOUN
dpc-4915	121	5	may	may	AUX
dpc-4915	121	6	be	be	AUX
dpc-4915	121	7	an	an	DET
dpc-4915	121	8	indicator	indicator	NOUN
dpc-4915	121	9	of	of	ADP
dpc-4915	121	10	increased	increase	VERB
dpc-4915	121	11	inflammatory	inflammatory	ADJ
dpc-4915	121	12	burden	burden	NOUN
dpc-4915	121	13	.	.	PUNCT
dpc-4915	122	1	the	the	DET
dpc-4915	122	2	other	other	ADJ
dpc-4915	122	3	most	most	ADV
dpc-4915	122	4	common	common	ADJ
dpc-4915	122	5	comorbidities	comorbiditie	NOUN
dpc-4915	122	6	in	in	ADP
dpc-4915	122	7	our	our	PRON
dpc-4915	122	8	study	study	NOUN
dpc-4915	122	9	population	population	NOUN
dpc-4915	122	10	were	be	AUX
dpc-4915	122	11	arthritis	arthritis	NOUN
dpc-4915	122	12	(	(	PUNCT
dpc-4915	122	13	32.3	32.3	NUM
dpc-4915	122	14	%	%	NOUN
dpc-4915	122	15	)	)	PUNCT
dpc-4915	122	16	,	,	PUNCT
dpc-4915	122	17	diabetes	diabetes	NOUN
dpc-4915	122	18	(	(	PUNCT
dpc-4915	122	19	9.7	9.7	NUM
dpc-4915	122	20	%	%	NOUN
dpc-4915	122	21	)	)	PUNCT
dpc-4915	122	22	,	,	PUNCT
dpc-4915	122	23	and	and	CCONJ
dpc-4915	122	24	hypertension	hypertension	NOUN
dpc-4915	122	25	(	(	PUNCT
dpc-4915	122	26	9.7	9.7	NUM
dpc-4915	122	27	%	%	NOUN
dpc-4915	122	28	)	)	PUNCT
dpc-4915	122	29	.	.	PUNCT
dpc-4915	123	1	hs	hs	PROPN
dpc-4915	123	2	has	have	AUX
dpc-4915	123	3	been	be	AUX
dpc-4915	123	4	associated	associate	VERB
dpc-4915	123	5	with	with	ADP
dpc-4915	123	6	many	many	ADJ
dpc-4915	123	7	comorbid	comorbid	NOUN
dpc-4915	123	8	diseases	disease	NOUN
dpc-4915	123	9	,	,	PUNCT
dpc-4915	123	10	such	such	ADJ
dpc-4915	123	11	as	as	ADP
dpc-4915	123	12	diabetes	diabetes	NOUN
dpc-4915	123	13	,	,	PUNCT
dpc-4915	123	14	metabolic	metabolic	NOUN
dpc-4915	123	15	syndrome	syndrome	NOUN
dpc-4915	123	16	,	,	PUNCT
dpc-4915	123	17	cardiovascular	cardiovascular	ADJ
dpc-4915	123	18	diseases	disease	NOUN
dpc-4915	123	19	,	,	PUNCT
dpc-4915	123	20	mental	mental	ADJ
dpc-4915	123	21	illnesses	illness	NOUN
dpc-4915	123	22	,	,	PUNCT
dpc-4915	123	23	inflammatory	inflammatory	ADJ
dpc-4915	123	24	bowel	bowel	NOUN
dpc-4915	123	25	disease	disease	NOUN
dpc-4915	123	26	,	,	PUNCT
dpc-4915	123	27	spondylo	spondylo	NOUN
dpc-4915	123	28	-	-	PUNCT
dpc-4915	123	29	arthropathies	arthropathy	NOUN
dpc-4915	123	30	and	and	CCONJ
dpc-4915	123	31	other	other	ADJ
dpc-4915	123	32	immune	immune	NOUN
dpc-4915	123	33	-	-	PUNCT
dpc-4915	123	34	mediated	mediate	VERB
dpc-4915	123	35	diseases	disease	NOUN
dpc-4915	123	36	[	[	X
dpc-4915	123	37	25	25	NUM
dpc-4915	123	38	]	]	PUNCT
dpc-4915	123	39	.	.	PUNCT
dpc-4915	124	1	therefore	therefore	ADV
dpc-4915	124	2	,	,	PUNCT
dpc-4915	124	3	it	it	PRON
dpc-4915	124	4	is	be	AUX
dpc-4915	124	5	important	important	ADJ
dpc-4915	124	6	to	to	PART
dpc-4915	124	7	question	question	VERB
dpc-4915	124	8	patients	patient	NOUN
dpc-4915	124	9	about	about	ADP
dpc-4915	124	10	these	these	DET
dpc-4915	124	11	common	common	ADJ
dpc-4915	124	12	comorbidities	comorbiditie	NOUN
dpc-4915	124	13	and	and	CCONJ
dpc-4915	124	14	take	take	VERB
dpc-4915	124	15	them	they	PRON
dpc-4915	124	16	into	into	ADP
dpc-4915	124	17	consideration	consideration	NOUN
dpc-4915	124	18	in	in	ADP
dpc-4915	124	19	treatment	treatment	NOUN
dpc-4915	124	20	selection	selection	NOUN
dpc-4915	124	21	.	.	PUNCT
dpc-4915	125	1	in	in	ADP
dpc-4915	125	2	our	our	PRON
dpc-4915	125	3	study	study	NOUN
dpc-4915	125	4	,	,	PUNCT
dpc-4915	125	5	paradoxical	paradoxical	ADJ
dpc-4915	125	6	pyoderma	pyoderma	NOUN
dpc-4915	125	7	gangrenosum	gangrenosum	NOUN
dpc-4915	125	8	as	as	ADP
dpc-4915	125	9	an	an	DET
dpc-4915	125	10	adverse	adverse	ADJ
dpc-4915	125	11	effect	effect	NOUN
dpc-4915	125	12	that	that	PRON
dpc-4915	125	13	caused	cause	VERB
dpc-4915	125	14	discontinuation	discontinuation	NOUN
dpc-4915	125	15	of	of	ADP
dpc-4915	125	16	treatment	treatment	NOUN
dpc-4915	125	17	with	with	ADP
dpc-4915	125	18	sec	sec	PROPN
dpc-4915	125	19	was	be	AUX
dpc-4915	125	20	observed	observe	VERB
dpc-4915	125	21	in	in	ADP
dpc-4915	125	22	one	one	NUM
dpc-4915	125	23	case	case	NOUN
dpc-4915	125	24	.	.	PUNCT
dpc-4915	126	1	apart	apart	ADV
dpc-4915	126	2	from	from	ADP
dpc-4915	126	3	this	this	PRON
dpc-4915	126	4	,	,	PUNCT
dpc-4915	126	5	no	no	DET
dpc-4915	126	6	serious	serious	ADJ
dpc-4915	126	7	adverse	adverse	ADJ
dpc-4915	126	8	effects	effect	NOUN
dpc-4915	126	9	were	be	AUX
dpc-4915	126	10	observed	observe	VERB
dpc-4915	126	11	.	.	PUNCT
dpc-4915	127	1	drug	drug	NOUN
dpc-4915	127	2	-	-	PUNCT
dpc-4915	127	3	induced	induce	VERB
dpc-4915	127	4	paradoxical	paradoxical	ADJ
dpc-4915	127	5	pyoderma	pyoderma	NOUN
dpc-4915	127	6	gangrenosum	gangrenosum	NOUN
dpc-4915	127	7	is	be	AUX
dpc-4915	127	8	a	a	DET
dpc-4915	127	9	very	very	ADV
dpc-4915	127	10	rare	rare	ADJ
dpc-4915	127	11	adverse	adverse	ADJ
dpc-4915	127	12	effect	effect	NOUN
dpc-4915	127	13	.	.	PUNCT
dpc-4915	128	1	in	in	ADP
dpc-4915	128	2	the	the	DET
dpc-4915	128	3	literature	literature	NOUN
dpc-4915	128	4	,	,	PUNCT
dpc-4915	128	5	paradoxical	paradoxical	ADJ
dpc-4915	128	6	pyoderma	pyoderma	NOUN
dpc-4915	128	7	gangrenosum	gangrenosum	NOUN
dpc-4915	128	8	induced	induce	VERB
dpc-4915	128	9	by	by	ADP
dpc-4915	128	10	sec	sec	PROPN
dpc-4915	128	11	has	have	AUX
dpc-4915	128	12	been	be	AUX
dpc-4915	128	13	reported	report	VERB
dpc-4915	128	14	in	in	ADP
dpc-4915	128	15	only	only	ADV
dpc-4915	128	16	two	two	NUM
dpc-4915	128	17	cases	case	NOUN
dpc-4915	128	18	with	with	ADP
dpc-4915	128	19	hs	hs	PROPN
dpc-4915	128	20	[	[	X
dpc-4915	128	21	26	26	NUM
dpc-4915	128	22	,	,	PUNCT
dpc-4915	128	23	27	27	NUM
dpc-4915	128	24	]	]	PUNCT
dpc-4915	128	25	,	,	PUNCT
dpc-4915	128	26	and	and	CCONJ
dpc-4915	128	27	there	there	PRON
dpc-4915	128	28	are	be	VERB
dpc-4915	128	29	a	a	DET
dpc-4915	128	30	few	few	ADJ
dpc-4915	128	31	case	case	NOUN
dpc-4915	128	32	reports	report	NOUN
dpc-4915	128	33	reported	report	VERB
dpc-4915	128	34	in	in	ADP
dpc-4915	128	35	cases	case	NOUN
dpc-4915	128	36	where	where	SCONJ
dpc-4915	128	37	sec	sec	PROPN
dpc-4915	128	38	was	be	AUX
dpc-4915	128	39	used	use	VERB
dpc-4915	128	40	for	for	ADP
dpc-4915	128	41	psoriasis	psoriasis	NOUN
dpc-4915	128	42	[	[	X
dpc-4915	128	43	28	28	NUM
dpc-4915	128	44	-	-	SYM
dpc-4915	128	45	31	31	NUM
dpc-4915	128	46	]	]	PUNCT
dpc-4915	128	47	.	.	PUNCT
dpc-4915	129	1	the	the	DET
dpc-4915	129	2	clinical	clinical	ADJ
dpc-4915	129	3	condition	condition	NOUN
dpc-4915	129	4	of	of	ADP
dpc-4915	129	5	the	the	DET
dpc-4915	129	6	cases	case	NOUN
dpc-4915	129	7	generally	generally	ADV
dpc-4915	129	8	improved	improve	VERB
dpc-4915	129	9	with	with	ADP
dpc-4915	129	10	sec	sec	PROPN
dpc-4915	129	11	discontinuation	discontinuation	NOUN
dpc-4915	129	12	and	and	CCONJ
dpc-4915	129	13	anti	anti	ADJ
dpc-4915	129	14	-	-	ADJ
dpc-4915	129	15	inflammatory	inflammatory	ADJ
dpc-4915	129	16	drug	drug	NOUN
dpc-4915	129	17	changes	change	NOUN
dpc-4915	129	18	,	,	PUNCT
dpc-4915	129	19	as	as	ADP
dpc-4915	129	20	in	in	ADP
dpc-4915	129	21	our	our	PRON
dpc-4915	129	22	case	case	NOUN
dpc-4915	129	23	.	.	PUNCT
dpc-4915	130	1	upregulation	upregulation	NOUN
dpc-4915	130	2	of	of	ADP
dpc-4915	130	3	il-23	il-23	NOUN
dpc-4915	130	4	is	be	AUX
dpc-4915	130	5	observed	observe	VERB
dpc-4915	130	6	in	in	ADP
dpc-4915	130	7	pyoderma	pyoderma	NOUN
dpc-4915	130	8	gangrenosum	gangrenosum	NOUN
dpc-4915	130	9	lesions	lesion	NOUN
dpc-4915	130	10	,	,	PUNCT
dpc-4915	130	11	and	and	CCONJ
dpc-4915	130	12	targeted	target	VERB
dpc-4915	130	13	treatments	treatment	NOUN
dpc-4915	130	14	with	with	ADP
dpc-4915	130	15	ustekinumab	ustekinumab	NOUN
dpc-4915	130	16	,	,	PUNCT
dpc-4915	130	17	an	an	DET
dpc-4915	130	18	il-12/23	il-12/23	ADJ
dpc-4915	130	19	antibody	antibody	NOUN
dpc-4915	130	20	,	,	PUNCT
dpc-4915	130	21	have	have	AUX
dpc-4915	130	22	resulted	result	VERB
dpc-4915	130	23	in	in	ADP
dpc-4915	130	24	beneficial	beneficial	ADJ
dpc-4915	130	25	clinical	clinical	ADJ
dpc-4915	130	26	outcomes	outcome	NOUN
dpc-4915	131	1	[	[	X
dpc-4915	131	2	29	29	NUM
dpc-4915	131	3	,	,	PUNCT
dpc-4915	131	4	32	32	NUM
dpc-4915	131	5	,	,	PUNCT
dpc-4915	131	6	33	33	NUM
dpc-4915	131	7	]	]	PUNCT
dpc-4915	131	8	.	.	PUNCT
dpc-4915	132	1	il-23	il-23	NOUN
dpc-4915	132	2	-	-	PUNCT
dpc-4915	132	3	induced	induce	VERB
dpc-4915	132	4	activation	activation	NOUN
dpc-4915	132	5	of	of	ADP
dpc-4915	132	6	plasmacytoid	plasmacytoid	NOUN
dpc-4915	132	7	and	and	CCONJ
dpc-4915	132	8	dermal	dermal	VERB
dpc-4915	132	9	dendritic	dendritic	ADJ
dpc-4915	132	10	cells	cell	NOUN
dpc-4915	132	11	results	result	NOUN
dpc-4915	132	12	in	in	ADP
dpc-4915	132	13	t	t	PROPN
dpc-4915	132	14	helper	helper	NOUN
dpc-4915	132	15	17	17	NUM
dpc-4915	132	16	cells	cell	NOUN
dpc-4915	132	17	releasing	release	VERB
dpc-4915	132	18	il-17a	il-17a	PROPN
dpc-4915	132	19	,	,	PUNCT
dpc-4915	132	20	which	which	PRON
dpc-4915	132	21	then	then	ADV
dpc-4915	132	22	acts	act	VERB
dpc-4915	132	23	on	on	ADP
dpc-4915	132	24	epidermal	epidermal	ADJ
dpc-4915	132	25	keratinocytes	keratinocyte	NOUN
dpc-4915	132	26	,	,	PUNCT
dpc-4915	132	27	resulting	result	VERB
dpc-4915	132	28	in	in	ADP
dpc-4915	132	29	a	a	DET
dpc-4915	132	30	feedforward	feedforward	ADJ
dpc-4915	132	31	inflammatory	inflammatory	ADJ
dpc-4915	132	32	response	response	NOUN
dpc-4915	132	33	.	.	PUNCT
dpc-4915	133	1	however	however	ADV
dpc-4915	133	2	,	,	PUNCT
dpc-4915	133	3	inhibiting	inhibit	VERB
dpc-4915	133	4	il-17a	il-17a	PROPN
dpc-4915	133	5	may	may	AUX
dpc-4915	133	6	paradoxically	paradoxically	ADV
dpc-4915	133	7	increase	increase	VERB
dpc-4915	133	8	il-23	il-23	NOUN
dpc-4915	133	9	production	production	NOUN
dpc-4915	133	10	,	,	PUNCT
dpc-4915	133	11	triggering	trigger	VERB
dpc-4915	133	12	the	the	DET
dpc-4915	133	13	development	development	NOUN
dpc-4915	133	14	of	of	ADP
dpc-4915	133	15	pyoderma	pyoderma	NOUN
dpc-4915	133	16	gangrenosum	gangrenosum	NOUN
dpc-4915	134	1	[	[	X
dpc-4915	134	2	34	34	NUM
dpc-4915	134	3	]	]	PUNCT
dpc-4915	134	4	.	.	PUNCT
dpc-4915	135	1	limitations	limitation	NOUN
dpc-4915	135	2	of	of	ADP
dpc-4915	135	3	our	our	PRON
dpc-4915	135	4	study	study	NOUN
dpc-4915	135	5	include	include	VERB
dpc-4915	135	6	small	small	ADJ
dpc-4915	135	7	sample	sample	NOUN
dpc-4915	135	8	size	size	NOUN
dpc-4915	135	9	,	,	PUNCT
dpc-4915	135	10	lack	lack	NOUN
dpc-4915	135	11	of	of	ADP
dpc-4915	135	12	a	a	DET
dpc-4915	135	13	control	control	NOUN
dpc-4915	135	14	group	group	NOUN
dpc-4915	135	15	,	,	PUNCT
dpc-4915	135	16	and	and	CCONJ
dpc-4915	135	17	open	open	ADJ
dpc-4915	135	18	-	-	PUNCT
dpc-4915	135	19	label	label	NOUN
dpc-4915	135	20	design	design	NOUN
dpc-4915	135	21	.	.	PUNCT
dpc-4915	136	1	in	in	ADP
dpc-4915	136	2	addition	addition	NOUN
dpc-4915	136	3	,	,	PUNCT
dpc-4915	136	4	due	due	ADP
dpc-4915	136	5	to	to	ADP
dpc-4915	136	6	the	the	DET
dpc-4915	136	7	retrospective	retrospective	ADJ
dpc-4915	136	8	design	design	NOUN
dpc-4915	136	9	of	of	ADP
dpc-4915	136	10	our	our	PRON
dpc-4915	136	11	study	study	NOUN
dpc-4915	136	12	,	,	PUNCT
dpc-4915	136	13	we	we	PRON
dpc-4915	136	14	could	could	AUX
dpc-4915	136	15	not	not	PART
dpc-4915	136	16	use	use	VERB
dpc-4915	136	17	other	other	ADJ
dpc-4915	136	18	commonly	commonly	ADV
dpc-4915	136	19	used	use	VERB
dpc-4915	136	20	scoring	scoring	NOUN
dpc-4915	136	21	systems	system	NOUN
dpc-4915	136	22	such	such	ADJ
dpc-4915	136	23	as	as	ADP
dpc-4915	136	24	the	the	DET
dpc-4915	136	25	dermatological	dermatological	ADJ
dpc-4915	136	26	quality	quality	NOUN
dpc-4915	136	27	of	of	ADP
dpc-4915	136	28	life	life	NOUN
dpc-4915	136	29	index	index	NOUN
dpc-4915	136	30	,	,	PUNCT
dpc-4915	136	31	sartorius	sartorius	NOUN
dpc-4915	136	32	scoring	scoring	NOUN
dpc-4915	136	33	,	,	PUNCT
dpc-4915	136	34	and	and	CCONJ
dpc-4915	136	35	the	the	DET
dpc-4915	136	36	international	international	ADJ
dpc-4915	136	37	hidradenitis	hidradenitis	PROPN
dpc-4915	136	38	suppurativa	suppurativa	PROPN
dpc-4915	136	39	severity	severity	NOUN
dpc-4915	136	40	scoring	scoring	NOUN
dpc-4915	136	41	system	system	NOUN
dpc-4915	136	42	other	other	ADJ
dpc-4915	136	43	than	than	ADP
dpc-4915	136	44	hurley	hurley	NOUN
dpc-4915	136	45	staging	staging	NOUN
dpc-4915	136	46	and	and	CCONJ
dpc-4915	136	47	hiscr	hiscr	NOUN
dpc-4915	136	48	.	.	PUNCT
dpc-4915	137	1	however	however	ADV
dpc-4915	137	2	,	,	PUNCT
dpc-4915	137	3	despite	despite	SCONJ
dpc-4915	137	4	its	its	PRON
dpc-4915	137	5	limitations	limitation	NOUN
dpc-4915	137	6	,	,	PUNCT
dpc-4915	137	7	our	our	PRON
dpc-4915	137	8	study	study	NOUN
dpc-4915	137	9	is	be	AUX
dpc-4915	137	10	valuable	valuable	ADJ
dpc-4915	137	11	because	because	SCONJ
dpc-4915	137	12	it	it	PRON
dpc-4915	137	13	is	be	AUX
dpc-4915	137	14	one	one	NUM
dpc-4915	137	15	of	of	ADP
dpc-4915	137	16	the	the	DET
dpc-4915	137	17	most	most	ADV
dpc-4915	137	18	comprehensive	comprehensive	ADJ
dpc-4915	137	19	studies	study	NOUN
dpc-4915	137	20	on	on	ADP
dpc-4915	137	21	the	the	DET
dpc-4915	137	22	real	real	ADJ
dpc-4915	137	23	-	-	PUNCT
dpc-4915	137	24	world	world	NOUN
dpc-4915	137	25	experience	experience	NOUN
dpc-4915	137	26	of	of	ADP
dpc-4915	137	27	sec	sec	PROPN
dpc-4915	137	28	treatment	treatment	NOUN
dpc-4915	137	29	in	in	ADP
dpc-4915	137	30	patients	patient	NOUN
dpc-4915	137	31	with	with	ADP
dpc-4915	137	32	hs	hs	PROPN
dpc-4915	137	33	.	.	PROPN
dpc-4915	137	34	in	in	ADP
dpc-4915	137	35	line	line	NOUN
dpc-4915	137	36	with	with	ADP
dpc-4915	137	37	the	the	DET
dpc-4915	137	38	data	datum	NOUN
dpc-4915	137	39	of	of	ADP
dpc-4915	137	40	our	our	PRON
dpc-4915	137	41	study	study	NOUN
dpc-4915	137	42	and	and	CCONJ
dpc-4915	137	43	previous	previous	ADJ
dpc-4915	137	44	literature	literature	NOUN
dpc-4915	137	45	,	,	PUNCT
dpc-4915	137	46	sec	sec	PROPN
dpc-4915	137	47	appears	appear	VERB
dpc-4915	137	48	to	to	PART
dpc-4915	137	49	be	be	AUX
dpc-4915	137	50	an	an	DET
dpc-4915	137	51	effective	effective	ADJ
dpc-4915	137	52	and	and	CCONJ
dpc-4915	137	53	safe	safe	ADJ
dpc-4915	137	54	treatment	treatment	NOUN
dpc-4915	137	55	option	option	NOUN
dpc-4915	137	56	for	for	ADP
dpc-4915	137	57	hs	hs	PROPN
dpc-4915	137	58	,	,	PUNCT
dpc-4915	137	59	especially	especially	ADV
dpc-4915	137	60	when	when	SCONJ
dpc-4915	137	61	used	use	VERB
dpc-4915	137	62	in	in	ADP
dpc-4915	137	63	the	the	DET
dpc-4915	137	64	early	early	ADJ
dpc-4915	137	65	and	and	CCONJ
dpc-4915	137	66	mild	mild	ADJ
dpc-4915	137	67	stages	stage	NOUN
dpc-4915	137	68	of	of	ADP
dpc-4915	137	69	the	the	DET
dpc-4915	137	70	disease	disease	NOUN
dpc-4915	137	71	and	and	CCONJ
dpc-4915	137	72	in	in	ADP
dpc-4915	137	73	biologic	biologic	ADJ
dpc-4915	137	74	-	-	PUNCT
dpc-4915	137	75	naive	naive	ADJ
dpc-4915	137	76	patients	patient	NOUN
dpc-4915	137	77	.	.	PUNCT
dpc-4915	138	1	references	reference	NOUN
dpc-4915	138	2	1	1	NUM
dpc-4915	138	3	.	.	PUNCT
dpc-4915	138	4	goldburg	goldburg	PROPN
dpc-4915	138	5	sr	sr	PROPN
dpc-4915	138	6	,	,	PUNCT
dpc-4915	138	7	strober	strober	ADV
dpc-4915	138	8	be	be	AUX
dpc-4915	138	9	,	,	PUNCT
dpc-4915	138	10	payette	payette	PROPN
dpc-4915	138	11	mj	mj	PROPN
dpc-4915	138	12	.	.	PROPN
dpc-4915	138	13	hidradenitis	hidradenitis	PROPN
dpc-4915	138	14	suppurativa	suppurativa	PROPN
dpc-4915	138	15	:	:	PUNCT
dpc-4915	138	16	epidemiology	epidemiology	NOUN
dpc-4915	138	17	,	,	PUNCT
dpc-4915	138	18	clinical	clinical	ADJ
dpc-4915	138	19	presentation	presentation	NOUN
dpc-4915	138	20	,	,	PUNCT
dpc-4915	138	21	and	and	CCONJ
dpc-4915	138	22	pathogenesis	pathogenesis	NOUN
dpc-4915	138	23	.	.	PUNCT
dpc-4915	139	1	j	j	PROPN
dpc-4915	139	2	am	be	AUX
dpc-4915	139	3	acad	acad	ADJ
dpc-4915	139	4	dermatol	dermatol	NOUN
dpc-4915	139	5	.	.	PUNCT
dpc-4915	140	1	2020;82(5):1045	2020;82(5):1045	NUM
dpc-4915	140	2	-	-	SYM
dpc-4915	140	3	58	58	NUM
dpc-4915	140	4	.	.	PUNCT
dpc-4915	141	1	doi	doi	NOUN
dpc-4915	141	2	:	:	PUNCT
dpc-4915	141	3	10.1016	10.1016	NUM
dpc-4915	141	4	/	/	SYM
dpc-4915	141	5	j.jaad.2019	j.jaad.2019	PROPN
dpc-4915	141	6	.08.090	.08.090	PUNCT
dpc-4915	142	1	pmid:31604104	pmid:31604104	NOUN
dpc-4915	142	2	patients	patient	NOUN
dpc-4915	142	3	(	(	PUNCT
dpc-4915	142	4	adalimumab	adalimumab	NOUN
dpc-4915	142	5	was	be	AUX
dpc-4915	142	6	contraindicated	contraindicate	VERB
dpc-4915	142	7	)	)	PUNCT
dpc-4915	142	8	and	and	CCONJ
dpc-4915	142	9	17	17	NUM
dpc-4915	142	10	patients	patient	NOUN
dpc-4915	142	11	who	who	PRON
dpc-4915	142	12	were	be	AUX
dpc-4915	142	13	secondary	secondary	ADJ
dpc-4915	142	14	unresponsive	unresponsive	ADJ
dpc-4915	142	15	to	to	ADP
dpc-4915	142	16	adalimumab	adalimumab	VERB
dpc-4915	142	17	.	.	PUNCT
dpc-4915	143	1	seven	seven	NUM
dpc-4915	143	2	of	of	ADP
dpc-4915	143	3	21	21	NUM
dpc-4915	143	4	patients	patient	NOUN
dpc-4915	143	5	failed	fail	VERB
dpc-4915	143	6	to	to	PART
dpc-4915	143	7	complete	complete	VERB
dpc-4915	143	8	52	52	NUM
dpc-4915	143	9	weeks	week	NOUN
dpc-4915	143	10	of	of	ADP
dpc-4915	143	11	treatment	treatment	NOUN
dpc-4915	143	12	.	.	PUNCT
dpc-4915	144	1	of	of	ADP
dpc-4915	144	2	the	the	DET
dpc-4915	144	3	14	14	NUM
dpc-4915	144	4	patients	patient	NOUN
dpc-4915	144	5	who	who	PRON
dpc-4915	144	6	completed	complete	VERB
dpc-4915	144	7	52	52	NUM
dpc-4915	144	8	weeks	week	NOUN
dpc-4915	144	9	of	of	ADP
dpc-4915	144	10	treatment	treatment	NOUN
dpc-4915	144	11	,	,	PUNCT
dpc-4915	144	12	57.1	57.1	NUM
dpc-4915	144	13	%	%	NOUN
dpc-4915	144	14	(	(	PUNCT
dpc-4915	144	15	8/14	8/14	NUM
dpc-4915	144	16	)	)	PUNCT
dpc-4915	144	17	achieved	achieve	VERB
dpc-4915	144	18	hiscr	hiscr	NOUN
dpc-4915	144	19	at	at	ADP
dpc-4915	144	20	week	week	NOUN
dpc-4915	144	21	16	16	NUM
dpc-4915	144	22	and	and	CCONJ
dpc-4915	144	23	71.4	71.4	NUM
dpc-4915	144	24	%	%	NOUN
dpc-4915	144	25	(	(	PUNCT
dpc-4915	144	26	10/14	10/14	NUM
dpc-4915	144	27	)	)	PUNCT
dpc-4915	144	28	at	at	ADP
dpc-4915	144	29	week	week	NOUN
dpc-4915	144	30	52	52	NUM
dpc-4915	145	1	[	[	X
dpc-4915	145	2	14	14	NUM
dpc-4915	145	3	]	]	PUNCT
dpc-4915	145	4	.	.	PUNCT
dpc-4915	146	1	in	in	ADP
dpc-4915	146	2	the	the	DET
dpc-4915	146	3	retrospective	retrospective	ADJ
dpc-4915	146	4	multicenter	multicenter	NOUN
dpc-4915	146	5	study	study	NOUN
dpc-4915	146	6	reported	report	VERB
dpc-4915	146	7	by	by	ADP
dpc-4915	146	8	ribero	ribero	PROPN
dpc-4915	146	9	et	et	PROPN
dpc-4915	146	10	al	al	PROPN
dpc-4915	146	11	from	from	ADP
dpc-4915	146	12	italy	italy	PROPN
dpc-4915	146	13	,	,	PUNCT
dpc-4915	146	14	sec	sec	PROPN
dpc-4915	146	15	was	be	AUX
dpc-4915	146	16	used	use	VERB
dpc-4915	146	17	at	at	ADP
dpc-4915	146	18	a	a	DET
dpc-4915	146	19	dose	dose	NOUN
dpc-4915	146	20	of	of	ADP
dpc-4915	146	21	300	300	NUM
dpc-4915	146	22	mg/4	mg/4	NOUN
dpc-4915	146	23	weeks	week	NOUN
dpc-4915	146	24	following	follow	VERB
dpc-4915	146	25	the	the	DET
dpc-4915	146	26	loading	loading	NOUN
dpc-4915	146	27	dose	dose	VERB
dpc-4915	146	28	in	in	ADP
dpc-4915	146	29	31	31	NUM
dpc-4915	146	30	patients	patient	NOUN
dpc-4915	146	31	with	with	ADP
dpc-4915	146	32	hs	hs	PROPN
dpc-4915	146	33	(	(	PUNCT
dpc-4915	146	34	hurley	hurley	PROPN
dpc-4915	146	35	ii	ii	PROPN
dpc-4915	146	36	or	or	CCONJ
dpc-4915	146	37	iii	iii	X
dpc-4915	146	38	)	)	PUNCT
dpc-4915	146	39	who	who	PRON
dpc-4915	146	40	were	be	AUX
dpc-4915	146	41	contraindicated	contraindicate	VERB
dpc-4915	146	42	or	or	CCONJ
dpc-4915	146	43	unresponsive	unresponsive	ADJ
dpc-4915	146	44	to	to	ADP
dpc-4915	146	45	anti	anti	ADJ
dpc-4915	146	46	-	-	PROPN
dpc-4915	146	47	tnf	tnf	ADJ
dpc-4915	146	48	.	.	PUNCT
dpc-4915	147	1	17	17	NUM
dpc-4915	147	2	patients	patient	NOUN
dpc-4915	147	3	completed	complete	VERB
dpc-4915	147	4	28	28	NUM
dpc-4915	147	5	weeks	week	NOUN
dpc-4915	147	6	of	of	ADP
dpc-4915	147	7	target	target	NOUN
dpc-4915	147	8	therapy	therapy	NOUN
dpc-4915	147	9	.	.	PUNCT
dpc-4915	148	1	the	the	DET
dpc-4915	148	2	hiscr	hiscr	NOUN
dpc-4915	148	3	was	be	AUX
dpc-4915	148	4	achieved	achieve	VERB
dpc-4915	148	5	only	only	ADV
dpc-4915	148	6	by	by	ADP
dpc-4915	148	7	10	10	NUM
dpc-4915	148	8	%	%	NOUN
dpc-4915	148	9	of	of	ADP
dpc-4915	148	10	patients	patient	NOUN
dpc-4915	148	11	(	(	PUNCT
dpc-4915	148	12	3/31	3/31	NUM
dpc-4915	148	13	)	)	PUNCT
dpc-4915	148	14	at	at	ADP
dpc-4915	148	15	week	week	NOUN
dpc-4915	148	16	5	5	NUM
dpc-4915	148	17	,	,	PUNCT
dpc-4915	148	18	by	by	ADP
dpc-4915	148	19	26	26	NUM
dpc-4915	148	20	%	%	NOUN
dpc-4915	148	21	of	of	ADP
dpc-4915	148	22	patients	patient	NOUN
dpc-4915	148	23	(	(	PUNCT
dpc-4915	148	24	8/24	8/24	NUM
dpc-4915	148	25	)	)	PUNCT
dpc-4915	148	26	at	at	ADP
dpc-4915	148	27	week	week	NOUN
dpc-4915	148	28	16	16	NUM
dpc-4915	148	29	,	,	PUNCT
dpc-4915	148	30	and	and	CCONJ
dpc-4915	148	31	by	by	ADP
dpc-4915	148	32	41	41	NUM
dpc-4915	148	33	%	%	NOUN
dpc-4915	148	34	of	of	ADP
dpc-4915	148	35	patients	patient	NOUN
dpc-4915	148	36	(	(	PUNCT
dpc-4915	148	37	7/17	7/17	NUM
dpc-4915	148	38	)	)	PUNCT
dpc-4915	148	39	at	at	ADP
dpc-4915	148	40	week	week	NOUN
dpc-4915	148	41	28	28	NUM
dpc-4915	149	1	[	[	X
dpc-4915	149	2	15	15	NUM
dpc-4915	149	3	]	]	PUNCT
dpc-4915	149	4	.	.	PUNCT
dpc-4915	150	1	in	in	ADP
dpc-4915	150	2	the	the	DET
dpc-4915	150	3	study	study	NOUN
dpc-4915	150	4	of	of	ADP
dpc-4915	150	5	roccuzzo	roccuzzo	PROPN
dpc-4915	150	6	et	et	PROPN
dpc-4915	150	7	al	al	PROPN
dpc-4915	150	8	,	,	PUNCT
dpc-4915	150	9	24	24	NUM
dpc-4915	150	10	adult	adult	NOUN
dpc-4915	150	11	patients	patient	NOUN
dpc-4915	150	12	with	with	ADP
dpc-4915	150	13	hs	hs	PROPN
dpc-4915	150	14	(	(	PUNCT
dpc-4915	150	15	hurley	hurley	PROPN
dpc-4915	150	16	ii	ii	PROPN
dpc-4915	150	17	or	or	CCONJ
dpc-4915	150	18	iii	iii	X
dpc-4915	150	19	)	)	PUNCT
dpc-4915	150	20	who	who	PRON
dpc-4915	150	21	were	be	AUX
dpc-4915	150	22	switched	switch	VERB
dpc-4915	150	23	from	from	ADP
dpc-4915	150	24	adalimumab	adalimumab	NOUN
dpc-4915	150	25	to	to	ADP
dpc-4915	150	26	sec	sec	PROPN
dpc-4915	150	27	due	due	ADP
dpc-4915	150	28	to	to	ADP
dpc-4915	150	29	primary	primary	ADJ
dpc-4915	150	30	or	or	CCONJ
dpc-4915	150	31	secondary	secondary	ADJ
dpc-4915	150	32	failure	failure	NOUN
dpc-4915	150	33	and/or	and/or	CCONJ
dpc-4915	150	34	unacceptable	unacceptable	ADJ
dpc-4915	150	35	adverse	adverse	ADJ
dpc-4915	150	36	effects	effect	NOUN
dpc-4915	150	37	.	.	PUNCT
dpc-4915	151	1	six	six	NUM
dpc-4915	151	2	(	(	PUNCT
dpc-4915	151	3	25	25	NUM
dpc-4915	151	4	%	%	NOUN
dpc-4915	151	5	)	)	PUNCT
dpc-4915	152	1	patients	patient	NOUN
dpc-4915	152	2	achieved	achieve	VERB
dpc-4915	152	3	hiscr	hiscr	NOUN
dpc-4915	152	4	at	at	ADP
dpc-4915	152	5	3	3	NUM
dpc-4915	152	6	months	month	NOUN
dpc-4915	152	7	and	and	CCONJ
dpc-4915	152	8	13	13	NUM
dpc-4915	152	9	(	(	PUNCT
dpc-4915	152	10	56.5	56.5	NUM
dpc-4915	152	11	%	%	NOUN
dpc-4915	152	12	)	)	PUNCT
dpc-4915	152	13	at	at	ADP
dpc-4915	152	14	6	6	NUM
dpc-4915	152	15	months	month	NOUN
dpc-4915	152	16	of	of	ADP
dpc-4915	152	17	treatment	treatment	NOUN
dpc-4915	152	18	.	.	PUNCT
dpc-4915	153	1	patients	patient	NOUN
dpc-4915	153	2	with	with	ADP
dpc-4915	153	3	hurley	hurley	PROPN
dpc-4915	153	4	stage	stage	PROPN
dpc-4915	153	5	ii	ii	PROPN
dpc-4915	153	6	had	have	VERB
dpc-4915	153	7	a	a	DET
dpc-4915	153	8	better	well	ADJ
dpc-4915	153	9	response	response	NOUN
dpc-4915	153	10	to	to	ADP
dpc-4915	153	11	treatment	treatment	NOUN
dpc-4915	153	12	than	than	ADP
dpc-4915	153	13	those	those	PRON
dpc-4915	153	14	with	with	ADP
dpc-4915	153	15	hurley	hurley	PROPN
dpc-4915	153	16	iii	iii	PROPN
dpc-4915	154	1	[	[	X
dpc-4915	154	2	16	16	NUM
dpc-4915	154	3	]	]	PUNCT
dpc-4915	154	4	.	.	PUNCT
dpc-4915	155	1	these	these	DET
dpc-4915	155	2	results	result	NOUN
dpc-4915	155	3	supported	support	VERB
dpc-4915	155	4	the	the	DET
dpc-4915	155	5	effectiveness	effectiveness	NOUN
dpc-4915	155	6	of	of	ADP
dpc-4915	155	7	sec	sec	PROPN
dpc-4915	155	8	in	in	ADP
dpc-4915	155	9	cases	case	NOUN
dpc-4915	155	10	unresponsive	unresponsive	ADJ
dpc-4915	155	11	or	or	CCONJ
dpc-4915	155	12	contraindicated	contraindicate	VERB
dpc-4915	155	13	to	to	AUX
dpc-4915	155	14	adalimumab	adalimumab	NOUN
dpc-4915	155	15	.	.	PUNCT
dpc-4915	156	1	in	in	ADP
dpc-4915	156	2	the	the	DET
dpc-4915	156	3	multicenter	multicenter	ADJ
dpc-4915	156	4	real	real	ADJ
dpc-4915	156	5	-	-	PUNCT
dpc-4915	156	6	world	world	NOUN
dpc-4915	156	7	study	study	NOUN
dpc-4915	156	8	of	of	ADP
dpc-4915	156	9	haselgruber	haselgruber	PROPN
dpc-4915	156	10	et	et	PROPN
dpc-4915	156	11	al	al	PROPN
dpc-4915	156	12	,	,	PUNCT
dpc-4915	156	13	28	28	NUM
dpc-4915	156	14	of	of	ADP
dpc-4915	156	15	67	67	NUM
dpc-4915	156	16	patients	patient	NOUN
dpc-4915	156	17	with	with	ADP
dpc-4915	156	18	moderate	moderate	ADJ
dpc-4915	156	19	-	-	PUNCT
dpc-4915	156	20	severe	severe	ADJ
dpc-4915	156	21	hs	hs	PROPN
dpc-4915	156	22	(	(	PUNCT
dpc-4915	156	23	41.79	41.79	NUM
dpc-4915	156	24	%	%	NOUN
dpc-4915	156	25	)	)	PUNCT
dpc-4915	156	26	achieved	achieve	VERB
dpc-4915	156	27	hiscr	hiscr	NOUN
dpc-4915	156	28	at	at	ADP
dpc-4915	156	29	24	24	NUM
dpc-4915	156	30	weeks	week	NOUN
dpc-4915	156	31	with	with	ADP
dpc-4915	156	32	sec	sec	PROPN
dpc-4915	156	33	treatment	treatment	NOUN
dpc-4915	156	34	.	.	PUNCT
dpc-4915	157	1	sec	sec	PROPN
dpc-4915	157	2	was	be	AUX
dpc-4915	157	3	used	use	VERB
dpc-4915	157	4	at	at	ADP
dpc-4915	157	5	a	a	DET
dpc-4915	157	6	dose	dose	NOUN
dpc-4915	157	7	of	of	ADP
dpc-4915	157	8	300	300	NUM
dpc-4915	157	9	mg/4	mg/4	NOUN
dpc-4915	157	10	weeks	week	NOUN
dpc-4915	157	11	or	or	CCONJ
dpc-4915	157	12	300	300	NUM
dpc-4915	157	13	mg/2	mg/2	NOUN
dpc-4915	157	14	weeks	week	NOUN
dpc-4915	157	15	following	follow	VERB
dpc-4915	157	16	the	the	DET
dpc-4915	157	17	loading	loading	NOUN
dpc-4915	157	18	dose	dose	NOUN
dpc-4915	157	19	.	.	PUNCT
dpc-4915	158	1	they	they	PRON
dpc-4915	158	2	defined	define	VERB
dpc-4915	158	3	therapeutic	therapeutic	ADJ
dpc-4915	158	4	burden	burden	NOUN
dpc-4915	158	5	as	as	ADP
dpc-4915	158	6	the	the	DET
dpc-4915	158	7	cumulative	cumulative	ADJ
dpc-4915	158	8	sum	sum	NOUN
dpc-4915	158	9	of	of	ADP
dpc-4915	158	10	previous	previous	ADJ
dpc-4915	158	11	systemic	systemic	ADJ
dpc-4915	158	12	treatment	treatment	NOUN
dpc-4915	158	13	cycles	cycle	NOUN
dpc-4915	158	14	(	(	PUNCT
dpc-4915	158	15	whether	whether	SCONJ
dpc-4915	158	16	biological	biological	ADJ
dpc-4915	158	17	or	or	CCONJ
dpc-4915	158	18	not	not	PART
dpc-4915	158	19	)	)	PUNCT
dpc-4915	158	20	plus	plus	CCONJ
dpc-4915	158	21	the	the	DET
dpc-4915	158	22	total	total	ADJ
dpc-4915	158	23	number	number	NOUN
dpc-4915	158	24	of	of	ADP
dpc-4915	158	25	previous	previous	ADJ
dpc-4915	158	26	surgical	surgical	ADJ
dpc-4915	158	27	interventions	intervention	NOUN
dpc-4915	158	28	that	that	SCONJ
dpc-4915	158	29	the	the	DET
dpc-4915	158	30	patient	patient	NOUN
dpc-4915	158	31	had	have	AUX
dpc-4915	158	32	undergone	undergo	VERB
dpc-4915	158	33	for	for	ADP
dpc-4915	158	34	hs	hs	PROPN
dpc-4915	158	35	before	before	ADP
dpc-4915	158	36	initiating	initiate	VERB
dpc-4915	158	37	sec	sec	PROPN
dpc-4915	158	38	.	.	PUNCT
dpc-4915	159	1	they	they	PRON
dpc-4915	159	2	observed	observe	VERB
dpc-4915	159	3	a	a	DET
dpc-4915	159	4	negative	negative	ADJ
dpc-4915	159	5	correlation	correlation	NOUN
dpc-4915	159	6	between	between	ADP
dpc-4915	159	7	therapeutic	therapeutic	ADJ
dpc-4915	159	8	burden	burden	NOUN
dpc-4915	159	9	and	and	CCONJ
dpc-4915	159	10	achieving	achieve	VERB
dpc-4915	159	11	hiscr	hiscr	NOUN
dpc-4915	159	12	at	at	ADP
dpc-4915	159	13	week	week	NOUN
dpc-4915	159	14	24	24	NUM
dpc-4915	159	15	with	with	ADP
dpc-4915	159	16	sec	sec	PROPN
dpc-4915	160	1	[	[	X
dpc-4915	160	2	17	17	NUM
dpc-4915	160	3	]	]	PUNCT
dpc-4915	160	4	.	.	PUNCT
dpc-4915	161	1	this	this	DET
dpc-4915	161	2	correlation	correlation	NOUN
dpc-4915	161	3	,	,	PUNCT
dpc-4915	161	4	similar	similar	ADJ
dpc-4915	161	5	to	to	ADP
dpc-4915	161	6	the	the	DET
dpc-4915	161	7	results	result	NOUN
dpc-4915	161	8	of	of	ADP
dpc-4915	161	9	our	our	PRON
dpc-4915	161	10	study	study	NOUN
dpc-4915	161	11	,	,	PUNCT
dpc-4915	161	12	drew	draw	VERB
dpc-4915	161	13	attention	attention	NOUN
dpc-4915	161	14	to	to	ADP
dpc-4915	161	15	the	the	DET
dpc-4915	161	16	concept	concept	NOUN
dpc-4915	161	17	of	of	ADP
dpc-4915	161	18	a	a	DET
dpc-4915	161	19	window	window	NOUN
dpc-4915	161	20	of	of	ADP
dpc-4915	161	21	opportunity	opportunity	NOUN
dpc-4915	161	22	in	in	ADP
dpc-4915	161	23	the	the	DET
dpc-4915	161	24	management	management	NOUN
dpc-4915	161	25	of	of	ADP
dpc-4915	161	26	hs	hs	PROPN
dpc-4915	161	27	in	in	ADP
dpc-4915	161	28	the	the	DET
dpc-4915	161	29	early	early	ADJ
dpc-4915	161	30	stages	stage	NOUN
dpc-4915	161	31	of	of	ADP
dpc-4915	161	32	the	the	DET
dpc-4915	161	33	disease	disease	NOUN
dpc-4915	161	34	.	.	PUNCT
dpc-4915	162	1	in	in	ADP
dpc-4915	162	2	the	the	DET
dpc-4915	162	3	single	single	ADJ
dpc-4915	162	4	-	-	PUNCT
dpc-4915	162	5	center	center	NOUN
dpc-4915	162	6	study	study	NOUN
dpc-4915	162	7	reported	report	VERB
dpc-4915	162	8	by	by	ADP
dpc-4915	162	9	abu	abu	PROPN
dpc-4915	162	10	rached	rache	VERB
dpc-4915	162	11	et	et	PROPN
dpc-4915	162	12	al	al	PROPN
dpc-4915	162	13	from	from	ADP
dpc-4915	162	14	germany	germany	PROPN
dpc-4915	162	15	,	,	PUNCT
dpc-4915	162	16	13	13	NUM
dpc-4915	162	17	of	of	ADP
dpc-4915	162	18	42	42	NUM
dpc-4915	162	19	patients	patient	NOUN
dpc-4915	162	20	with	with	ADP
dpc-4915	162	21	moderate	moderate	ADJ
dpc-4915	162	22	-	-	PUNCT
dpc-4915	162	23	severe	severe	ADJ
dpc-4915	162	24	hs	hs	PROPN
dpc-4915	162	25	(	(	PUNCT
dpc-4915	162	26	41.9	41.9	NUM
dpc-4915	162	27	%	%	NOUN
dpc-4915	162	28	)	)	PUNCT
dpc-4915	162	29	achieved	achieve	VERB
dpc-4915	162	30	hiscr	hiscr	NOUN
dpc-4915	162	31	response	response	NOUN
dpc-4915	162	32	at	at	ADP
dpc-4915	162	33	16	16	NUM
dpc-4915	162	34	weeks	week	NOUN
dpc-4915	162	35	with	with	ADP
dpc-4915	162	36	sec	sec	PROPN
dpc-4915	162	37	treatment	treatment	NOUN
dpc-4915	162	38	.	.	PUNCT
dpc-4915	163	1	sec	sec	PROPN
dpc-4915	163	2	was	be	AUX
dpc-4915	163	3	used	use	VERB
dpc-4915	163	4	at	at	ADP
dpc-4915	163	5	a	a	DET
dpc-4915	163	6	dose	dose	NOUN
dpc-4915	163	7	of	of	ADP
dpc-4915	163	8	300	300	NUM
dpc-4915	163	9	mg/4	mg/4	NOUN
dpc-4915	163	10	weeks	week	NOUN
dpc-4915	163	11	,	,	PUNCT
dpc-4915	163	12	increased	increase	VERB
dpc-4915	163	13	to	to	ADP
dpc-4915	163	14	300	300	NUM
dpc-4915	163	15	mg/2	mg/2	NOUN
dpc-4915	163	16	weeks	week	NOUN
dpc-4915	163	17	if	if	SCONJ
dpc-4915	163	18	necessary	necessary	ADJ
dpc-4915	163	19	.	.	PUNCT
dpc-4915	164	1	adverse	adverse	ADJ
dpc-4915	164	2	events	event	NOUN
dpc-4915	164	3	were	be	AUX
dpc-4915	164	4	reported	report	VERB
dpc-4915	164	5	in	in	ADP
dpc-4915	164	6	6	6	NUM
dpc-4915	164	7	patients	patient	NOUN
dpc-4915	164	8	(	(	PUNCT
dpc-4915	164	9	14.3	14.3	NUM
dpc-4915	164	10	%	%	NOUN
dpc-4915	164	11	)	)	PUNCT
dpc-4915	164	12	,	,	PUNCT
dpc-4915	164	13	and	and	CCONJ
dpc-4915	164	14	treatment	treatment	NOUN
dpc-4915	164	15	discontinuation	discontinuation	NOUN
dpc-4915	164	16	occurred	occur	VERB
dpc-4915	164	17	in	in	ADP
dpc-4915	164	18	3	3	NUM
dpc-4915	164	19	patients	patient	NOUN
dpc-4915	164	20	(	(	PUNCT
dpc-4915	164	21	7.1	7.1	NUM
dpc-4915	164	22	%	%	NOUN
dpc-4915	164	23	)	)	PUNCT
dpc-4915	164	24	.	.	PUNCT
dpc-4915	165	1	median	median	ADJ
dpc-4915	165	2	tobacco	tobacco	NOUN
dpc-4915	165	3	pack	pack	NOUN
dpc-4915	165	4	years	year	NOUN
dpc-4915	165	5	and	and	CCONJ
dpc-4915	165	6	hs	hs	PROPN
dpc-4915	165	7	inguinal	inguinal	ADJ
dpc-4915	165	8	involvement	involvement	NOUN
dpc-4915	165	9	was	be	AUX
dpc-4915	165	10	significantly	significantly	ADV
dpc-4915	165	11	lower	low	ADJ
dpc-4915	165	12	in	in	ADP
dpc-4915	165	13	patients	patient	NOUN
dpc-4915	165	14	who	who	PRON
dpc-4915	165	15	achieved	achieve	VERB
dpc-4915	165	16	hiscr	hiscr	NOUN
dpc-4915	165	17	[	[	X
dpc-4915	165	18	18	18	NUM
dpc-4915	165	19	]	]	PUNCT
dpc-4915	165	20	.	.	PUNCT
dpc-4915	166	1	data	datum	NOUN
dpc-4915	166	2	on	on	ADP
dpc-4915	166	3	the	the	DET
dpc-4915	166	4	effectiveness	effectiveness	NOUN
dpc-4915	166	5	and	and	CCONJ
dpc-4915	166	6	safety	safety	NOUN
dpc-4915	166	7	of	of	ADP
dpc-4915	166	8	sec	sec	PROPN
dpc-4915	166	9	in	in	ADP
dpc-4915	166	10	patients	patient	NOUN
dpc-4915	166	11	with	with	ADP
dpc-4915	166	12	hs	hs	PRON
dpc-4915	166	13	have	have	AUX
dpc-4915	166	14	been	be	AUX
dpc-4915	166	15	reported	report	VERB
dpc-4915	166	16	in	in	ADP
dpc-4915	166	17	several	several	ADJ
dpc-4915	166	18	case	case	NOUN
dpc-4915	166	19	reports	report	VERB
dpc-4915	166	20	[	[	X
dpc-4915	166	21	19	19	NUM
dpc-4915	166	22	-	-	SYM
dpc-4915	166	23	23	23	NUM
dpc-4915	166	24	]	]	PUNCT
dpc-4915	166	25	.	.	PUNCT
dpc-4915	167	1	however	however	ADV
dpc-4915	167	2	,	,	PUNCT
dpc-4915	167	3	information	information	NOUN
dpc-4915	167	4	on	on	ADP
dpc-4915	167	5	real	real	ADJ
dpc-4915	167	6	-	-	PUNCT
dpc-4915	167	7	world	world	NOUN
dpc-4915	167	8	data	datum	NOUN
dpc-4915	167	9	is	be	AUX
dpc-4915	167	10	still	still	ADV
dpc-4915	167	11	limited	limited	ADJ
dpc-4915	167	12	.	.	PUNCT
dpc-4915	168	1	the	the	DET
dpc-4915	168	2	most	most	ADV
dpc-4915	168	3	common	common	ADJ
dpc-4915	168	4	comorbidity	comorbidity	NOUN
dpc-4915	168	5	in	in	ADP
dpc-4915	168	6	our	our	PRON
dpc-4915	168	7	study	study	NOUN
dpc-4915	168	8	population	population	NOUN
dpc-4915	168	9	was	be	AUX
dpc-4915	168	10	psoriasis	psoriasis	NOUN
dpc-4915	168	11	(	(	PUNCT
dpc-4915	168	12	35.5	35.5	NUM
dpc-4915	168	13	%	%	NOUN
dpc-4915	168	14	of	of	ADP
dpc-4915	168	15	cases	case	NOUN
dpc-4915	168	16	)	)	PUNCT
dpc-4915	168	17	.	.	PUNCT
dpc-4915	169	1	this	this	PRON
dpc-4915	169	2	is	be	AUX
dpc-4915	169	3	,	,	PUNCT
dpc-4915	169	4	of	of	ADP
dpc-4915	169	5	course	course	NOUN
dpc-4915	169	6	,	,	PUNCT
dpc-4915	169	7	due	due	ADP
dpc-4915	169	8	to	to	ADP
dpc-4915	169	9	the	the	DET
dpc-4915	169	10	fact	fact	NOUN
dpc-4915	169	11	that	that	SCONJ
dpc-4915	169	12	sec	sec	PROPN
dpc-4915	169	13	is	be	AUX
dpc-4915	169	14	given	give	VERB
dpc-4915	169	15	priority	priority	NOUN
dpc-4915	169	16	in	in	ADP
dpc-4915	169	17	treatment	treatment	NOUN
dpc-4915	169	18	selection	selection	NOUN
dpc-4915	169	19	in	in	ADP
dpc-4915	169	20	cases	case	NOUN
dpc-4915	169	21	where	where	SCONJ
dpc-4915	169	22	hs	hs	PRON
dpc-4915	169	23	and	and	CCONJ
dpc-4915	169	24	psoriasis	psoriasis	NOUN
dpc-4915	169	25	occur	occur	VERB
dpc-4915	169	26	together	together	ADV
dpc-4915	169	27	.	.	PUNCT
dpc-4915	170	1	large	large	ADJ
dpc-4915	170	2	population	population	NOUN
dpc-4915	170	3	studies	study	NOUN
dpc-4915	170	4	have	have	AUX
dpc-4915	170	5	shown	show	VERB
dpc-4915	170	6	that	that	SCONJ
dpc-4915	170	7	the	the	DET
dpc-4915	170	8	prevalence	prevalence	NOUN
dpc-4915	170	9	of	of	ADP
dpc-4915	170	10	hs	hs	PROPN
dpc-4915	170	11	in	in	ADP
dpc-4915	170	12	patients	patient	NOUN
dpc-4915	170	13	with	with	ADP
dpc-4915	170	14	psoriasis	psoriasis	NOUN
dpc-4915	170	15	is	be	AUX
dpc-4915	170	16	higher	high	ADJ
dpc-4915	170	17	than	than	ADP
dpc-4915	170	18	in	in	ADP
dpc-4915	170	19	controls	control	NOUN
dpc-4915	170	20	,	,	PUNCT
dpc-4915	170	21	and	and	CCONJ
dpc-4915	170	22	the	the	DET
dpc-4915	170	23	prevalence	prevalence	NOUN
dpc-4915	170	24	original	original	ADJ
dpc-4915	170	25	article	article	NOUN
dpc-4915	170	26	|	|	ADV
dpc-4915	170	27	dermatol	dermatol	ADJ
dpc-4915	170	28	pract	pract	NOUN
dpc-4915	170	29	concept	concept	NOUN
dpc-4915	170	30	.	.	PUNCT
dpc-4915	171	1	2025;15(1):4915	2025;15(1):4915	NUM
dpc-4915	171	2	7	7	NUM
dpc-4915	171	3	a	a	DET
dpc-4915	171	4	52	52	NUM
dpc-4915	171	5	-	-	PUNCT
dpc-4915	171	6	week	week	NOUN
dpc-4915	171	7	real	real	ADJ
dpc-4915	171	8	-	-	PUNCT
dpc-4915	171	9	life	life	NOUN
dpc-4915	171	10	study	study	NOUN
dpc-4915	171	11	.	.	PUNCT
dpc-4915	172	1	clin	clin	PROPN
dpc-4915	172	2	cosmet	cosmet	PROPN
dpc-4915	172	3	investig	investig	NOUN
dpc-4915	172	4	dermatol	dermatol	NOUN
dpc-4915	172	5	.	.	PUNCT
dpc-4915	173	1	2024;17:159	2024;17:159	NUM
dpc-4915	173	2	-	-	SYM
dpc-4915	173	3	66	66	NUM
dpc-4915	173	4	.	.	PUNCT
dpc-4915	174	1	doi	doi	NOUN
dpc-4915	174	2	:	:	PUNCT
dpc-4915	174	3	10.2147	10.2147	NUM
dpc-4915	174	4	/	/	SYM
dpc-4915	174	5	ccid.s449367	ccid.s449367	X
dpc-4915	174	6	pmid:38283798	pmid:38283798	ADJ
dpc-4915	174	7	pmcid	pmcid	NOUN
dpc-4915	174	8	:	:	PUNCT
dpc-4915	174	9	pmc10821645	pmc10821645	ADJ
dpc-4915	174	10	15	15	NUM
dpc-4915	174	11	.	.	PUNCT
dpc-4915	175	1	ribero	ribero	PROPN
dpc-4915	175	2	s	s	PROPN
dpc-4915	175	3	,	,	PUNCT
dpc-4915	175	4	ramondetta	ramondetta	VERB
dpc-4915	175	5	a	a	DET
dpc-4915	175	6	,	,	PUNCT
dpc-4915	175	7	fabbrocini	fabbrocini	NOUN
dpc-4915	175	8	g	g	NOUN
dpc-4915	175	9	,	,	PUNCT
dpc-4915	175	10	et	et	PROPN
dpc-4915	175	11	al	al	PROPN
dpc-4915	175	12	.	.	PROPN
dpc-4915	175	13	effectiveness	effectiveness	NOUN
dpc-4915	175	14	of	of	ADP
dpc-4915	175	15	secukinumab	secukinumab	NOUN
dpc-4915	175	16	in	in	ADP
dpc-4915	175	17	the	the	DET
dpc-4915	175	18	treatment	treatment	NOUN
dpc-4915	175	19	of	of	ADP
dpc-4915	175	20	moderate	moderate	ADJ
dpc-4915	175	21	-	-	PUNCT
dpc-4915	175	22	severe	severe	ADJ
dpc-4915	175	23	hidradenitis	hidradenitis	NOUN
dpc-4915	175	24	suppurativa	suppurativa	NOUN
dpc-4915	175	25	:	:	PUNCT
dpc-4915	175	26	results	result	VERB
dpc-4915	175	27	from	from	ADP
dpc-4915	175	28	an	an	DET
dpc-4915	175	29	italian	italian	ADJ
dpc-4915	175	30	multicentric	multicentric	ADJ
dpc-4915	175	31	retrospective	retrospective	ADJ
dpc-4915	175	32	study	study	NOUN
dpc-4915	175	33	in	in	ADP
dpc-4915	175	34	a	a	DET
dpc-4915	175	35	real	real	ADJ
dpc-4915	175	36	-	-	PUNCT
dpc-4915	175	37	life	life	NOUN
dpc-4915	175	38	setting	setting	NOUN
dpc-4915	175	39	.	.	PUNCT
dpc-4915	176	1	j	j	PROPN
dpc-4915	176	2	eur	eur	PROPN
dpc-4915	176	3	acad	acad	PROPN
dpc-4915	176	4	dermatol	dermatol	NOUN
dpc-4915	176	5	venereol	venereol	NOUN
dpc-4915	176	6	.	.	PUNCT
dpc-4915	177	1	2021;35(7):e441	2021;35(7):e441	NOUN
dpc-4915	177	2	-	-	PUNCT
dpc-4915	177	3	e2	e2	PROPN
dpc-4915	177	4	.	.	PUNCT
dpc-4915	178	1	doi:10.1111	doi:10.1111	PROPN
dpc-4915	178	2	/	/	SYM
dpc-4915	178	3	jdv.17178	jdv.17178	PRON
dpc-4915	178	4	pmid:33594790	pmid:33594790	NOUN
dpc-4915	178	5	16	16	NUM
dpc-4915	178	6	.	.	PUNCT
dpc-4915	179	1	roccuzzo	roccuzzo	VERB
dpc-4915	179	2	g	g	PROPN
dpc-4915	179	3	,	,	PUNCT
dpc-4915	179	4	repetto	repetto	PROPN
dpc-4915	179	5	f	f	PROPN
dpc-4915	179	6	,	,	PUNCT
dpc-4915	179	7	giordano	giordano	PROPN
dpc-4915	179	8	s	s	PROPN
dpc-4915	179	9	,	,	PUNCT
dpc-4915	179	10	et	et	PROPN
dpc-4915	179	11	al	al	PROPN
dpc-4915	179	12	.	.	PUNCT
dpc-4915	180	1	anti	anti	ADJ
dpc-4915	180	2	-	-	ADJ
dpc-4915	180	3	il17	il17	ADJ
dpc-4915	180	4	secukinumab	secukinumab	NOUN
dpc-4915	180	5	in	in	ADP
dpc-4915	180	6	hidradenitis	hidradenitis	PROPN
dpc-4915	180	7	suppurativa	suppurativa	PROPN
dpc-4915	180	8	:	:	PUNCT
dpc-4915	180	9	a	a	DET
dpc-4915	180	10	long	long	ADJ
dpc-4915	180	11	-	-	PUNCT
dpc-4915	180	12	term	term	NOUN
dpc-4915	180	13	drug	drug	NOUN
dpc-4915	180	14	survival	survival	NOUN
dpc-4915	180	15	analysis	analysis	NOUN
dpc-4915	180	16	.	.	PUNCT
dpc-4915	181	1	exp	exp	NOUN
dpc-4915	181	2	dermatol	dermatol	NOUN
dpc-4915	181	3	.	.	PUNCT
dpc-4915	182	1	2024;33(7):e15140	2024;33(7):e15140	NUM
dpc-4915	182	2	.	.	PUNCT
dpc-4915	182	3	doi	doi	NOUN
dpc-4915	182	4	:	:	PUNCT
dpc-4915	182	5	10.1111	10.1111	NUM
dpc-4915	182	6	/exd.15140	/exd.15140	NOUN
dpc-4915	182	7	pmid:39032087	pmid:39032087	NOUN
dpc-4915	182	8	17	17	NUM
dpc-4915	182	9	.	.	PUNCT
dpc-4915	183	1	haselgruber	haselgruber	PROPN
dpc-4915	183	2	s	s	PROPN
dpc-4915	183	3	,	,	PUNCT
dpc-4915	183	4	fernández	fernández	PROPN
dpc-4915	183	5	-	-	PUNCT
dpc-4915	183	6	crehuet	crehuet	NOUN
dpc-4915	183	7	-	-	PUNCT
dpc-4915	183	8	serrano	serrano	NOUN
dpc-4915	183	9	p	p	NOUN
dpc-4915	183	10	,	,	PUNCT
dpc-4915	183	11	fernández	fernández	PROPN
dpc-4915	183	12	ballesteros	ballesteros	PROPN
dpc-4915	183	13	md	md	PROPN
dpc-4915	183	14	,	,	PUNCT
dpc-4915	183	15	et	et	PROPN
dpc-4915	183	16	al	al	PROPN
dpc-4915	183	17	.	.	PUNCT
dpc-4915	183	18	insights	insight	NOUN
dpc-4915	183	19	into	into	ADP
dpc-4915	183	20	the	the	DET
dpc-4915	183	21	window	window	NOUN
dpc-4915	183	22	of	of	ADP
dpc-4915	183	23	opportunity	opportunity	NOUN
dpc-4915	183	24	and	and	CCONJ
dpc-4915	183	25	outcome	outcome	NOUN
dpc-4915	183	26	measures	measure	NOUN
dpc-4915	183	27	in	in	ADP
dpc-4915	183	28	patients	patient	NOUN
dpc-4915	183	29	with	with	ADP
dpc-4915	183	30	moderate	moderate	ADJ
dpc-4915	183	31	to	to	ADP
dpc-4915	183	32	severe	severe	ADJ
dpc-4915	183	33	hidradenitis	hidradenitis	PROPN
dpc-4915	183	34	suppurativa	suppurativa	NOUN
dpc-4915	183	35	treated	treat	VERB
dpc-4915	183	36	with	with	ADP
dpc-4915	183	37	secukinumab	secukinumab	NOUN
dpc-4915	183	38	:	:	PUNCT
dpc-4915	183	39	a	a	DET
dpc-4915	183	40	real	real	ADJ
dpc-4915	183	41	-	-	PUNCT
dpc-4915	183	42	world	world	NOUN
dpc-4915	183	43	study	study	NOUN
dpc-4915	183	44	.	.	PUNCT
dpc-4915	184	1	dermatol	dermatol	NOUN
dpc-4915	184	2	ther	ther	ADV
dpc-4915	184	3	(	(	PUNCT
dpc-4915	184	4	heidelb	heidelb	NOUN
dpc-4915	184	5	)	)	PUNCT
dpc-4915	184	6	.	.	PUNCT
dpc-4915	185	1	2024	2024	NUM
dpc-4915	185	2	.	.	PUNCT
dpc-4915	186	1	doi	doi	NOUN
dpc-4915	186	2	:	:	PUNCT
dpc-4915	186	3	10.1007	10.1007	NUM
dpc-4915	186	4	/	/	SYM
dpc-4915	186	5	s13555024	s13555024	NOUN
dpc-4915	186	6	-	-	PUNCT
dpc-4915	186	7	01209	01209	NUM
dpc-4915	186	8	-	-	PUNCT
dpc-4915	186	9	w	w	NOUN
dpc-4915	186	10	pmid:38896382	pmid:38896382	ADJ
dpc-4915	186	11	pmcid	pmcid	NOUN
dpc-4915	186	12	:	:	PUNCT
dpc-4915	186	13	pmc11264522	pmc11264522	NOUN
dpc-4915	186	14	18	18	NUM
dpc-4915	186	15	.	.	PUNCT
dpc-4915	187	1	abu	abu	PROPN
dpc-4915	187	2	rached	rache	VERB
dpc-4915	187	3	n	n	PROPN
dpc-4915	187	4	,	,	PUNCT
dpc-4915	187	5	haven	haven	PROPN
dpc-4915	187	6	y	y	PROPN
dpc-4915	187	7	,	,	PUNCT
dpc-4915	187	8	ocker	ocker	NOUN
dpc-4915	187	9	l	l	PROPN
dpc-4915	187	10	,	,	PUNCT
dpc-4915	187	11	stockfleth	stockfleth	PROPN
dpc-4915	187	12	e	e	NOUN
dpc-4915	187	13	,	,	PUNCT
dpc-4915	187	14	bechara	bechara	PROPN
dpc-4915	187	15	fg	fg	PROPN
dpc-4915	187	16	.	.	PUNCT
dpc-4915	187	17	real	real	ADJ
dpc-4915	187	18	-	-	PUNCT
dpc-4915	187	19	world	world	NOUN
dpc-4915	187	20	data	datum	NOUN
dpc-4915	187	21	about	about	ADP
dpc-4915	187	22	secukinumab	secukinumab	NOUN
dpc-4915	187	23	in	in	ADP
dpc-4915	187	24	hidradenitis	hidradenitis	PROPN
dpc-4915	187	25	suppurativa	suppurativa	PROPN
dpc-4915	187	26	:	:	PUNCT
dpc-4915	187	27	tobacco	tobacco	NOUN
dpc-4915	187	28	pack	pack	NOUN
dpc-4915	187	29	years	year	NOUN
dpc-4915	187	30	an	an	DET
dpc-4915	187	31	underestimated	underestimated	ADJ
dpc-4915	187	32	factor	factor	NOUN
dpc-4915	187	33	.	.	PUNCT
dpc-4915	188	1	clin	clin	PROPN
dpc-4915	188	2	exp	exp	NOUN
dpc-4915	188	3	dermatol	dermatol	NOUN
dpc-4915	188	4	.	.	PUNCT
dpc-4915	189	1	2024	2024	NUM
dpc-4915	189	2	.	.	PUNCT
dpc-4915	190	1	doi	doi	NOUN
dpc-4915	190	2	:	:	PUNCT
dpc-4915	190	3	10.1093	10.1093	NUM
dpc-4915	190	4	/	/	SYM
dpc-4915	190	5	ced	ced	PROPN
dpc-4915	190	6	/	/	SYM
dpc-4915	190	7	llae386	llae386	X
dpc-4915	190	8	pmid:39305502	pmid:39305502	PROPN
dpc-4915	190	9	19	19	NUM
dpc-4915	190	10	.	.	PUNCT
dpc-4915	191	1	marasca	marasca	PROPN
dpc-4915	191	2	c	c	PROPN
dpc-4915	191	3	,	,	PUNCT
dpc-4915	191	4	megna	megna	PROPN
dpc-4915	191	5	m	m	PROPN
dpc-4915	191	6	,	,	PUNCT
dpc-4915	191	7	balato	balato	VERB
dpc-4915	191	8	a	a	PRON
dpc-4915	191	9	,	,	PUNCT
dpc-4915	191	10	balato	balato	PROPN
dpc-4915	191	11	n	n	CCONJ
dpc-4915	191	12	,	,	PUNCT
dpc-4915	191	13	napolitano	napolitano	PROPN
dpc-4915	191	14	m	m	PROPN
dpc-4915	191	15	,	,	PUNCT
dpc-4915	191	16	fabbrocini	fabbrocini	PROPN
dpc-4915	191	17	g.	g.	PROPN
dpc-4915	191	18	secukinumab	secukinumab	PROPN
dpc-4915	191	19	and	and	CCONJ
dpc-4915	191	20	hidradenitis	hidradenitis	PROPN
dpc-4915	191	21	suppurativa	suppurativa	PROPN
dpc-4915	191	22	:	:	PUNCT
dpc-4915	191	23	friends	friend	NOUN
dpc-4915	191	24	or	or	CCONJ
dpc-4915	191	25	foes	foe	NOUN
dpc-4915	191	26	?	?	PUNCT
dpc-4915	192	1	jaad	jaad	NOUN
dpc-4915	192	2	case	case	NOUN
dpc-4915	192	3	rep	rep	PROPN
dpc-4915	192	4	.	.	PROPN
dpc-4915	192	5	2019;5(2):184	2019;5(2):184	NOUN
dpc-4915	192	6	-	-	SYM
dpc-4915	192	7	7	7	NUM
dpc-4915	192	8	.	.	PUNCT
dpc-4915	192	9	doi	doi	NOUN
dpc-4915	192	10	:	:	PUNCT
dpc-4915	192	11	10.1016	10.1016	NUM
dpc-4915	192	12	/j.jdcr.2018.12.002	/j.jdcr.2018.12.002	PUNCT
dpc-4915	193	1	pmid:30740502	pmid:30740502	INTJ
dpc-4915	193	2	pmcid	pmcid	ADJ
dpc-4915	193	3	:	:	PUNCT
dpc-4915	193	4	pmc6357542	pmc6357542	NOUN
dpc-4915	193	5	20	20	NUM
dpc-4915	193	6	.	.	PUNCT
dpc-4915	194	1	thorlacius	thorlacius	PROPN
dpc-4915	194	2	l	l	PROPN
dpc-4915	194	3	,	,	PUNCT
dpc-4915	194	4	theut	theut	NOUN
dpc-4915	194	5	riis	rii	VERB
dpc-4915	194	6	p	p	PROPN
dpc-4915	194	7	,	,	PUNCT
dpc-4915	194	8	jemec	jemec	PROPN
dpc-4915	194	9	gbe	gbe	PROPN
dpc-4915	194	10	.	.	PROPN
dpc-4915	195	1	severe	severe	ADJ
dpc-4915	195	2	hidradenitis	hidradenitis	PROPN
dpc-4915	195	3	suppurativa	suppurativa	PROPN
dpc-4915	195	4	responding	respond	VERB
dpc-4915	195	5	to	to	ADP
dpc-4915	195	6	treatment	treatment	NOUN
dpc-4915	195	7	with	with	ADP
dpc-4915	195	8	secukinumab	secukinumab	NOUN
dpc-4915	195	9	:	:	PUNCT
dpc-4915	195	10	a	a	DET
dpc-4915	195	11	case	case	NOUN
dpc-4915	195	12	report	report	NOUN
dpc-4915	195	13	.	.	PUNCT
dpc-4915	196	1	br	br	PROPN
dpc-4915	196	2	j	j	PROPN
dpc-4915	196	3	dermatol	dermatol	NOUN
dpc-4915	196	4	.	.	PUNCT
dpc-4915	197	1	2018;179(1):182	2018;179(1):182	NUM
dpc-4915	197	2	-	-	SYM
dpc-4915	197	3	5	5	NUM
dpc-4915	197	4	.	.	PUNCT
dpc-4915	197	5	doi	doi	NOUN
dpc-4915	197	6	:	:	PUNCT
dpc-4915	197	7	10.1111	10.1111	NUM
dpc-4915	197	8	/bjd.15769	/bjd.15769	NOUN
dpc-4915	197	9	pmid:28654150	pmid:28654150	NOUN
dpc-4915	197	10	21	21	NUM
dpc-4915	197	11	.	.	PUNCT
dpc-4915	198	1	schuch	schuch	ADJ
dpc-4915	198	2	a	a	PRON
dpc-4915	198	3	,	,	PUNCT
dpc-4915	198	4	fischer	fischer	PROPN
dpc-4915	198	5	t	t	PROPN
dpc-4915	198	6	,	,	PUNCT
dpc-4915	198	7	boehner	boehner	PROPN
dpc-4915	198	8	a	a	PROPN
dpc-4915	198	9	,	,	PUNCT
dpc-4915	198	10	biedermann	biedermann	PROPN
dpc-4915	198	11	t	t	PROPN
dpc-4915	198	12	,	,	PUNCT
dpc-4915	198	13	volz	volz	PROPN
dpc-4915	198	14	t.	t.	PROPN
dpc-4915	198	15	successful	successful	ADJ
dpc-4915	198	16	treatment	treatment	NOUN
dpc-4915	198	17	of	of	ADP
dpc-4915	198	18	severe	severe	ADJ
dpc-4915	198	19	recalcitrant	recalcitrant	ADJ
dpc-4915	198	20	hidradenitis	hidradenitis	NOUN
dpc-4915	198	21	suppurativa	suppurativa	NOUN
dpc-4915	198	22	with	with	ADP
dpc-4915	198	23	the	the	DET
dpc-4915	198	24	interleukin-17a	interleukin-17a	PROPN
dpc-4915	198	25	antibody	antibody	NOUN
dpc-4915	198	26	secukinumab	secukinumab	NOUN
dpc-4915	198	27	.	.	PUNCT
dpc-4915	199	1	acta	acta	PROPN
dpc-4915	199	2	derm	derm	PROPN
dpc-4915	199	3	venereol	venereol	NOUN
dpc-4915	199	4	.	.	PUNCT
dpc-4915	200	1	2018;98(1):151	2018;98(1):151	NUM
dpc-4915	200	2	-	-	PUNCT
dpc-4915	200	3	2	2	NUM
dpc-4915	200	4	.	.	PUNCT
dpc-4915	200	5	doi	doi	NOUN
dpc-4915	200	6	:	:	PUNCT
dpc-4915	200	7	10.2340/00015555	10.2340/00015555	NUM
dpc-4915	200	8	-	-	SYM
dpc-4915	200	9	2794	2794	NUM
dpc-4915	200	10	pmid:28902952	pmid:28902952	NOUN
dpc-4915	200	11	22	22	NUM
dpc-4915	200	12	.	.	PUNCT
dpc-4915	201	1	jørgensen	jørgensen	PROPN
dpc-4915	201	2	ar	ar	PROPN
dpc-4915	201	3	,	,	PUNCT
dpc-4915	201	4	yao	yao	PROPN
dpc-4915	201	5	y	y	PROPN
dpc-4915	201	6	,	,	PUNCT
dpc-4915	201	7	thomsen	thomsen	PROPN
dpc-4915	201	8	sf	sf	PROPN
dpc-4915	201	9	.	.	PUNCT
dpc-4915	202	1	therapeutic	therapeutic	ADJ
dpc-4915	202	2	response	response	NOUN
dpc-4915	202	3	to	to	PART
dpc-4915	202	4	secukinumab	secukinumab	VERB
dpc-4915	202	5	in	in	ADP
dpc-4915	202	6	a	a	DET
dpc-4915	202	7	36	36	NUM
dpc-4915	202	8	-	-	PUNCT
dpc-4915	202	9	year	year	NOUN
dpc-4915	202	10	-	-	PUNCT
dpc-4915	202	11	old	old	ADJ
dpc-4915	202	12	woman	woman	NOUN
dpc-4915	202	13	with	with	ADP
dpc-4915	202	14	hidradenitis	hidradenitis	PROPN
dpc-4915	202	15	suppurativa	suppurativa	PROPN
dpc-4915	202	16	.	.	PROPN
dpc-4915	202	17	case	case	NOUN
dpc-4915	202	18	rep	rep	PROPN
dpc-4915	202	19	dermatol	dermatol	NOUN
dpc-4915	202	20	med	me	VERB
dpc-4915	202	21	.	.	PUNCT
dpc-4915	203	1	2018;2018:8685136	2018;2018:8685136	NUM
dpc-4915	203	2	.	.	PUNCT
dpc-4915	204	1	doi	doi	NOUN
dpc-4915	204	2	:	:	PUNCT
dpc-4915	204	3	10.1155/2018/8685136	10.1155/2018/8685136	NUM
dpc-4915	204	4	pmid:29850284	pmid:29850284	NOUN
dpc-4915	204	5	pmcid	pmcid	NOUN
dpc-4915	204	6	:	:	PUNCT
dpc-4915	204	7	pmc592	pmc592	NOUN
dpc-4915	204	8	6496	6496	NUM
dpc-4915	204	9	23	23	NUM
dpc-4915	204	10	.	.	PUNCT
dpc-4915	205	1	villegas	villegas	PROPN
dpc-4915	205	2	-	-	PUNCT
dpc-4915	205	3	romero	romero	PROPN
dpc-4915	205	4	i	i	PROPN
dpc-4915	205	5	,	,	PUNCT
dpc-4915	205	6	collantes	collantes	NOUN
dpc-4915	205	7	-	-	PUNCT
dpc-4915	205	8	rodríguez	rodríguez	NOUN
dpc-4915	205	9	c	c	NOUN
dpc-4915	205	10	,	,	PUNCT
dpc-4915	205	11	valenzuela	valenzuela	PROPN
dpc-4915	205	12	-	-	PUNCT
dpc-4915	205	13	ubiña	ubiña	PROPN
dpc-4915	205	14	s	s	PROPN
dpc-4915	205	15	,	,	PUNCT
dpc-4915	205	16	jiménez	jiménez	PROPN
dpc-4915	205	17	-	-	PUNCT
dpc-4915	205	18	gallo	gallo	PROPN
dpc-4915	205	19	d.	d.	PROPN
dpc-4915	205	20	moderate	moderate	VERB
dpc-4915	205	21	to	to	ADP
dpc-4915	205	22	severe	severe	ADJ
dpc-4915	205	23	hidradenitis	hidradenitis	NOUN
dpc-4915	205	24	suppurativa	suppurativa	NOUN
dpc-4915	205	25	successfully	successfully	ADV
dpc-4915	205	26	treated	treat	VERB
dpc-4915	205	27	with	with	ADP
dpc-4915	205	28	secukinumab	secukinumab	NOUN
dpc-4915	205	29	.	.	PUNCT
dpc-4915	206	1	actas	actas	PROPN
dpc-4915	206	2	dermosifiliogr	dermosifiliogr	NOUN
dpc-4915	206	3	(	(	PUNCT
dpc-4915	206	4	engl	engl	PROPN
dpc-4915	206	5	ed	ed	NOUN
dpc-4915	206	6	)	)	PUNCT
dpc-4915	206	7	.	.	PUNCT
dpc-4915	207	1	2020;111(8):696	2020;111(8):696	NUM
dpc-4915	207	2	-	-	SYM
dpc-4915	207	3	8	8	NUM
dpc-4915	207	4	.	.	PUNCT
dpc-4915	207	5	doi	doi	NOUN
dpc-4915	207	6	:	:	PUNCT
dpc-4915	207	7	10.1016	10.1016	NUM
dpc-4915	207	8	/	/	SYM
dpc-4915	207	9	j.ad.2019.07.007	j.ad.2019.07.007	PROPN
dpc-4915	207	10	pmid:32553985	pmid:32553985	NOUN
dpc-4915	207	11	24	24	NUM
dpc-4915	207	12	.	.	PUNCT
dpc-4915	208	1	kridin	kridin	VERB
dpc-4915	208	2	k	k	PROPN
dpc-4915	208	3	,	,	PUNCT
dpc-4915	208	4	shani	shani	PROPN
dpc-4915	208	5	m	m	PROPN
dpc-4915	208	6	,	,	PUNCT
dpc-4915	208	7	schonmann	schonmann	PROPN
dpc-4915	208	8	y	y	PROPN
dpc-4915	208	9	,	,	PUNCT
dpc-4915	209	1	et	et	PROPN
dpc-4915	209	2	al	al	PROPN
dpc-4915	209	3	.	.	PUNCT
dpc-4915	209	4	psoriasis	psoriasis	NOUN
dpc-4915	209	5	and	and	CCONJ
dpc-4915	209	6	hidradenitis	hidradenitis	PROPN
dpc-4915	209	7	suppurativa	suppurativa	PROPN
dpc-4915	209	8	:	:	PUNCT
dpc-4915	209	9	a	a	DET
dpc-4915	209	10	large	large	ADJ
dpc-4915	209	11	-	-	PUNCT
dpc-4915	209	12	scale	scale	NOUN
dpc-4915	209	13	population	population	NOUN
dpc-4915	209	14	-	-	PUNCT
dpc-4915	209	15	based	base	VERB
dpc-4915	209	16	study	study	NOUN
dpc-4915	209	17	.	.	PUNCT
dpc-4915	210	1	j	j	PROPN
dpc-4915	210	2	am	be	AUX
dpc-4915	210	3	acad	acad	ADJ
dpc-4915	210	4	dermatol	dermatol	NOUN
dpc-4915	210	5	.	.	PUNCT
dpc-4915	211	1	2023;88(5):e231	2023;88(5):e231	NOUN
dpc-4915	211	2	-	-	PUNCT
dpc-4915	211	3	e6	e6	NOUN
dpc-4915	211	4	.	.	PUNCT
dpc-4915	212	1	doi	doi	NOUN
dpc-4915	212	2	:	:	PUNCT
dpc-4915	212	3	10.1016	10.1016	NUM
dpc-4915	212	4	/	/	SYM
dpc-4915	212	5	j.jaad.2018	j.jaad.2018	VERB
dpc-4915	212	6	.11.036	.11.036	PUNCT
dpc-4915	213	1	pmid:30502412	pmid:30502412	NOUN
dpc-4915	213	2	25	25	NUM
dpc-4915	213	3	.	.	PUNCT
dpc-4915	213	4	nguyen	nguyen	PROPN
dpc-4915	213	5	tv	tv	PROPN
dpc-4915	213	6	,	,	PUNCT
dpc-4915	213	7	damiani	damiani	PROPN
dpc-4915	213	8	g	g	PROPN
dpc-4915	213	9	,	,	PUNCT
dpc-4915	213	10	orenstein	orenstein	ADJ
dpc-4915	213	11	lav	lav	PROPN
dpc-4915	213	12	,	,	PUNCT
dpc-4915	213	13	hamzavi	hamzavi	PROPN
dpc-4915	213	14	i	i	PRON
dpc-4915	213	15	,	,	PUNCT
dpc-4915	213	16	jemec	jemec	VERB
dpc-4915	213	17	gb	gb	ADP
dpc-4915	213	18	.	.	PUNCT
dpc-4915	214	1	hidradenitis	hidradenitis	PROPN
dpc-4915	214	2	suppurativa	suppurativa	PROPN
dpc-4915	214	3	:	:	PUNCT
dpc-4915	214	4	an	an	DET
dpc-4915	214	5	update	update	NOUN
dpc-4915	214	6	on	on	ADP
dpc-4915	214	7	epidemiology	epidemiology	NOUN
dpc-4915	214	8	,	,	PUNCT
dpc-4915	214	9	phenotypes	phenotype	NOUN
dpc-4915	214	10	,	,	PUNCT
dpc-4915	214	11	diagnosis	diagnosis	NOUN
dpc-4915	214	12	,	,	PUNCT
dpc-4915	214	13	pathogenesis	pathogenesis	NOUN
dpc-4915	214	14	,	,	PUNCT
dpc-4915	214	15	comorbidities	comorbiditie	NOUN
dpc-4915	214	16	and	and	CCONJ
dpc-4915	214	17	quality	quality	NOUN
dpc-4915	214	18	of	of	ADP
dpc-4915	214	19	life	life	NOUN
dpc-4915	214	20	.	.	PUNCT
dpc-4915	215	1	j	j	PROPN
dpc-4915	215	2	eur	eur	PROPN
dpc-4915	215	3	acad	acad	PROPN
dpc-4915	215	4	dermatol	dermatol	NOUN
dpc-4915	215	5	venereol	venereol	NOUN
dpc-4915	215	6	.	.	PUNCT
dpc-4915	216	1	2021;35(1):50	2021;35(1):50	X
dpc-4915	216	2	-	-	SYM
dpc-4915	216	3	61	61	NUM
dpc-4915	216	4	.	.	PUNCT
dpc-4915	217	1	doi	doi	NOUN
dpc-4915	217	2	:	:	PUNCT
dpc-4915	217	3	10.1111	10.1111	NUM
dpc-4915	217	4	/jdv.16677	/jdv.16677	NOUN
dpc-4915	217	5	pmid:32460374	pmid:32460374	ADP
dpc-4915	217	6	26	26	NUM
dpc-4915	217	7	.	.	PUNCT
dpc-4915	218	1	avcı	avcı	PROPN
dpc-4915	218	2	c	c	PROPN
dpc-4915	218	3	,	,	PUNCT
dpc-4915	218	4	akın	akın	PROPN
dpc-4915	218	5	g	g	PROPN
dpc-4915	218	6	,	,	PUNCT
dpc-4915	218	7	akarsu	akarsu	PROPN
dpc-4915	218	8	s	s	PROPN
dpc-4915	218	9	,	,	PUNCT
dpc-4915	218	10	lebe	lebe	PROPN
dpc-4915	218	11	b.	b.	PROPN
dpc-4915	218	12	pyoderma	pyoderma	PROPN
dpc-4915	218	13	gangrenosum	gangrenosum	NOUN
dpc-4915	218	14	and	and	CCONJ
dpc-4915	218	15	behçet’s	behçet’s	NOUN
dpc-4915	218	16	-	-	PUNCT
dpc-4915	218	17	like	like	ADJ
dpc-4915	218	18	disease	disease	NOUN
dpc-4915	218	19	induced	induce	VERB
dpc-4915	218	20	by	by	ADP
dpc-4915	218	21	secukinumab	secukinumab	NOUN
dpc-4915	218	22	:	:	PUNCT
dpc-4915	218	23	a	a	DET
dpc-4915	218	24	paradoxical	paradoxical	ADJ
dpc-4915	218	25	drug	drug	NOUN
dpc-4915	218	26	reaction	reaction	NOUN
dpc-4915	218	27	.	.	PUNCT
dpc-4915	219	1	j	j	PROPN
dpc-4915	219	2	dermatolog	dermatolog	PROPN
dpc-4915	219	3	treat	treat	NOUN
dpc-4915	219	4	.	.	PUNCT
dpc-4915	220	1	2023;34(1):2235040	2023;34(1):2235040	NUM
dpc-4915	220	2	.	.	PUNCT
dpc-4915	220	3	doi	doi	NOUN
dpc-4915	220	4	:	:	PUNCT
dpc-4915	220	5	10.1080/09546634.2023.2235040	10.1080/09546634.2023.2235040	NUM
dpc-4915	220	6	pmid:37449310	pmid:37449310	NOUN
dpc-4915	220	7	27	27	NUM
dpc-4915	220	8	.	.	PUNCT
dpc-4915	221	1	clemente	clemente	PROPN
dpc-4915	221	2	-	-	PUNCT
dpc-4915	221	3	hernández	hernández	PROPN
dpc-4915	221	4	b	b	PROPN
dpc-4915	221	5	,	,	PUNCT
dpc-4915	221	6	álvarez	álvarez	NOUN
dpc-4915	221	7	-	-	PUNCT
dpc-4915	221	8	salafranca	salafranca	PROPN
dpc-4915	221	9	m	m	PROPN
dpc-4915	221	10	,	,	PUNCT
dpc-4915	221	11	muelas	muela	NOUN
dpc-4915	221	12	-	-	PUNCT
dpc-4915	221	13	rives	rive	NOUN
dpc-4915	221	14	i	i	PROPN
dpc-4915	221	15	,	,	PUNCT
dpc-4915	221	16	ollero	ollero	NOUN
dpc-4915	221	17	-	-	PUNCT
dpc-4915	221	18	domenche	domenche	NOUN
dpc-4915	221	19	l	l	NOUN
dpc-4915	221	20	,	,	PUNCT
dpc-4915	221	21	gracia	gracia	PROPN
dpc-4915	221	22	-	-	PUNCT
dpc-4915	221	23	cazaña	cazaña	PROPN
dpc-4915	221	24	t	t	PROPN
dpc-4915	221	25	,	,	PUNCT
dpc-4915	221	26	gilaberte	gilaberte	NOUN
dpc-4915	221	27	y.	y.	NOUN
dpc-4915	221	28	multifocal	multifocal	ADJ
dpc-4915	221	29	pyoderma	pyoderma	NOUN
dpc-4915	221	30	gangrenosum	gangrenosum	NOUN
dpc-4915	221	31	induced	induce	VERB
dpc-4915	221	32	by	by	ADP
dpc-4915	221	33	secukinumab	secukinumab	NOUN
dpc-4915	221	34	in	in	ADP
dpc-4915	221	35	a	a	DET
dpc-4915	221	36	2	2	NUM
dpc-4915	221	37	.	.	PUNCT
dpc-4915	221	38	vossen	vossen	PROPN
dpc-4915	221	39	a	a	PRON
dpc-4915	221	40	,	,	PUNCT
dpc-4915	221	41	van	van	PROPN
dpc-4915	221	42	der	der	NOUN
dpc-4915	221	43	zee	zee	PROPN
dpc-4915	221	44	hh	hh	PROPN
dpc-4915	221	45	,	,	PUNCT
dpc-4915	221	46	prens	pren	VERB
dpc-4915	221	47	ep	ep	PROPN
dpc-4915	221	48	.	.	PROPN
dpc-4915	221	49	hidradenitis	hidradenitis	PROPN
dpc-4915	221	50	suppurativa	suppurativa	PROPN
dpc-4915	221	51	:	:	PUNCT
dpc-4915	221	52	a	a	DET
dpc-4915	221	53	systematic	systematic	ADJ
dpc-4915	221	54	review	review	NOUN
dpc-4915	221	55	integrating	integrate	VERB
dpc-4915	221	56	inflammatory	inflammatory	ADJ
dpc-4915	221	57	pathways	pathway	NOUN
dpc-4915	221	58	into	into	ADP
dpc-4915	221	59	a	a	DET
dpc-4915	221	60	cohesive	cohesive	ADJ
dpc-4915	221	61	pathogenic	pathogenic	ADJ
dpc-4915	221	62	model	model	NOUN
dpc-4915	221	63	.	.	PUNCT
dpc-4915	222	1	front	front	ADJ
dpc-4915	222	2	immunol	immunol	NOUN
dpc-4915	222	3	.	.	PUNCT
dpc-4915	223	1	2018;9:2965	2018;9:2965	NOUN
dpc-4915	223	2	.	.	PUNCT
dpc-4915	224	1	doi	doi	NOUN
dpc-4915	224	2	:	:	PUNCT
dpc-4915	224	3	10.3389	10.3389	NUM
dpc-4915	224	4	/	/	SYM
dpc-4915	224	5	fimmu.2018.02965	fimmu.2018.02965	NOUN
dpc-4915	224	6	pmid:30619323	pmid:30619323	ADJ
dpc-4915	224	7	pmcid	pmcid	NOUN
dpc-4915	224	8	:	:	PUNCT
dpc-4915	224	9	pmc6302105	pmc6302105	NOUN
dpc-4915	224	10	3	3	X
dpc-4915	224	11	.	.	PUNCT
dpc-4915	224	12	melnik	melnik	PROPN
dpc-4915	224	13	bc	bc	PROPN
dpc-4915	224	14	,	,	PUNCT
dpc-4915	224	15	john	john	PROPN
dpc-4915	224	16	sm	sm	PROPN
dpc-4915	224	17	,	,	PUNCT
dpc-4915	224	18	chen	chen	PROPN
dpc-4915	224	19	w	w	PROPN
dpc-4915	224	20	,	,	PUNCT
dpc-4915	224	21	plewig	plewig	PROPN
dpc-4915	224	22	g.	g.	PROPN
dpc-4915	224	23	t	t	PROPN
dpc-4915	224	24	helper	helper	NOUN
dpc-4915	224	25	17	17	NUM
dpc-4915	224	26	cell	cell	NOUN
dpc-4915	224	27	/	/	SYM
dpc-4915	224	28	regulatory	regulatory	ADJ
dpc-4915	224	29	t	t	NOUN
dpc-4915	224	30	-	-	PUNCT
dpc-4915	224	31	cell	cell	NOUN
dpc-4915	224	32	imbalance	imbalance	NOUN
dpc-4915	224	33	in	in	ADP
dpc-4915	224	34	hidradenitis	hidradenitis	PROPN
dpc-4915	224	35	suppurativa	suppurativa	PROPN
dpc-4915	224	36	/	/	SYM
dpc-4915	224	37	acne	acne	NOUN
dpc-4915	224	38	inversa	inversa	NOUN
dpc-4915	224	39	:	:	PUNCT
dpc-4915	224	40	the	the	DET
dpc-4915	224	41	link	link	NOUN
dpc-4915	224	42	to	to	ADP
dpc-4915	224	43	hair	hair	NOUN
dpc-4915	224	44	follicle	follicle	NOUN
dpc-4915	224	45	dissection	dissection	NOUN
dpc-4915	224	46	,	,	PUNCT
dpc-4915	224	47	obesity	obesity	NOUN
dpc-4915	224	48	,	,	PUNCT
dpc-4915	224	49	smoking	smoking	NOUN
dpc-4915	224	50	and	and	CCONJ
dpc-4915	224	51	autoimmune	autoimmune	ADJ
dpc-4915	224	52	comorbidities	comorbiditie	NOUN
dpc-4915	224	53	.	.	PUNCT
dpc-4915	225	1	br	br	PROPN
dpc-4915	225	2	j	j	PROPN
dpc-4915	225	3	dermatol	dermatol	NOUN
dpc-4915	225	4	.	.	PUNCT
dpc-4915	226	1	2018;179(2):260	2018;179(2):260	NUM
dpc-4915	226	2	-	-	SYM
dpc-4915	226	3	72	72	NUM
dpc-4915	226	4	.	.	PUNCT
dpc-4915	227	1	doi	doi	NOUN
dpc-4915	227	2	:	:	PUNCT
dpc-4915	227	3	10.1111	10.1111	NUM
dpc-4915	227	4	/	/	SYM
dpc-4915	227	5	bjd.16561	bjd.16561	PROPN
dpc-4915	227	6	pmid:29573406	pmid:29573406	VERB
dpc-4915	227	7	4	4	NUM
dpc-4915	227	8	.	.	PUNCT
dpc-4915	227	9	matusiak	matusiak	PROPN
dpc-4915	227	10	ł	ł	PROPN
dpc-4915	227	11	,	,	PUNCT
dpc-4915	227	12	szczęch	szczęch	PROPN
dpc-4915	227	13	j	j	PROPN
dpc-4915	227	14	,	,	PUNCT
dpc-4915	227	15	bieniek	bieniek	VERB
dpc-4915	227	16	a	a	DET
dpc-4915	227	17	,	,	PUNCT
dpc-4915	227	18	nowicka	nowicka	NOUN
dpc-4915	227	19	-	-	PUNCT
dpc-4915	227	20	suszko	suszko	NOUN
dpc-4915	227	21	d	d	PROPN
dpc-4915	227	22	,	,	PUNCT
dpc-4915	227	23	szepietowski	szepietowski	PROPN
dpc-4915	227	24	jc	jc	PROPN
dpc-4915	227	25	.	.	PROPN
dpc-4915	227	26	increased	increase	VERB
dpc-4915	227	27	interleukin	interleukin	NOUN
dpc-4915	227	28	(	(	PUNCT
dpc-4915	228	1	il)-17	il)-17	PROPN
dpc-4915	228	2	serum	serum	NOUN
dpc-4915	228	3	levels	level	NOUN
dpc-4915	228	4	in	in	ADP
dpc-4915	228	5	patients	patient	NOUN
dpc-4915	228	6	with	with	ADP
dpc-4915	228	7	hidradenitis	hidradenitis	PROPN
dpc-4915	228	8	suppurativa	suppurativa	PROPN
dpc-4915	228	9	:	:	PUNCT
dpc-4915	228	10	implications	implication	NOUN
dpc-4915	228	11	for	for	ADP
dpc-4915	228	12	treatment	treatment	NOUN
dpc-4915	228	13	with	with	ADP
dpc-4915	228	14	anti	anti	ADJ
dpc-4915	228	15	-	-	ADJ
dpc-4915	228	16	il-17	il-17	ADJ
dpc-4915	228	17	agents	agent	NOUN
dpc-4915	228	18	.	.	PUNCT
dpc-4915	229	1	j	j	PROPN
dpc-4915	229	2	am	be	AUX
dpc-4915	229	3	acad	acad	ADJ
dpc-4915	229	4	dermatol	dermatol	NOUN
dpc-4915	229	5	.	.	PUNCT
dpc-4915	230	1	2017;76(4):670	2017;76(4):670	PROPN
dpc-4915	230	2	-	-	PUNCT
dpc-4915	230	3	5	5	NUM
dpc-4915	230	4	.	.	PUNCT
dpc-4915	230	5	doi	doi	NOUN
dpc-4915	230	6	:	:	PUNCT
dpc-4915	230	7	10.1016	10.1016	NUM
dpc-4915	230	8	/	/	SYM
dpc-4915	230	9	j.jaad.2016.10.042	j.jaad.2016.10.042	PROPN
dpc-4915	230	10	pmid:28041632	pmid:28041632	VERB
dpc-4915	230	11	5	5	NUM
dpc-4915	230	12	.	.	PUNCT
dpc-4915	231	1	kimball	kimball	PROPN
dpc-4915	231	2	ab	ab	PROPN
dpc-4915	231	3	,	,	PUNCT
dpc-4915	231	4	jemec	jemec	PROPN
dpc-4915	231	5	gbe	gbe	PROPN
dpc-4915	231	6	,	,	PUNCT
dpc-4915	231	7	alavi	alavi	VERB
dpc-4915	231	8	a	a	DET
dpc-4915	231	9	,	,	PUNCT
dpc-4915	231	10	et	et	PROPN
dpc-4915	231	11	al	al	PROPN
dpc-4915	231	12	.	.	PROPN
dpc-4915	231	13	secukinumab	secukinumab	PROPN
dpc-4915	231	14	in	in	ADP
dpc-4915	231	15	moderate	moderate	ADJ
dpc-4915	231	16	-	-	PUNCT
dpc-4915	231	17	to	to	ADP
dpc-4915	231	18	-	-	PUNCT
dpc-4915	231	19	severe	severe	ADJ
dpc-4915	231	20	hidradenitis	hidradenitis	NOUN
dpc-4915	231	21	suppurativa	suppurativa	NOUN
dpc-4915	231	22	(	(	PUNCT
dpc-4915	231	23	sunshine	sunshine	NOUN
dpc-4915	231	24	and	and	CCONJ
dpc-4915	231	25	sunrise	sunrise	VERB
dpc-4915	231	26	):	):	PUNCT
dpc-4915	231	27	week	week	NOUN
dpc-4915	231	28	16	16	NUM
dpc-4915	231	29	and	and	CCONJ
dpc-4915	231	30	week	week	NOUN
dpc-4915	231	31	52	52	NUM
dpc-4915	231	32	results	result	NOUN
dpc-4915	231	33	of	of	ADP
dpc-4915	231	34	two	two	NUM
dpc-4915	231	35	identical	identical	ADJ
dpc-4915	231	36	,	,	PUNCT
dpc-4915	231	37	multicentre	multicentre	NOUN
dpc-4915	231	38	,	,	PUNCT
dpc-4915	231	39	randomised	randomise	VERB
dpc-4915	231	40	,	,	PUNCT
dpc-4915	231	41	placebo	placebo	NOUN
dpc-4915	231	42	-	-	PUNCT
dpc-4915	231	43	controlled	control	VERB
dpc-4915	231	44	,	,	PUNCT
dpc-4915	231	45	double	double	ADJ
dpc-4915	231	46	-	-	PUNCT
dpc-4915	231	47	blind	blind	ADJ
dpc-4915	231	48	phase	phase	NOUN
dpc-4915	231	49	3	3	NUM
dpc-4915	231	50	trials	trial	NOUN
dpc-4915	231	51	.	.	PUNCT
dpc-4915	232	1	lancet	lancet	NOUN
dpc-4915	232	2	.	.	PUNCT
dpc-4915	233	1	2023;401(10378):747	2023;401(10378):747	NUM
dpc-4915	233	2	-	-	SYM
dpc-4915	233	3	61	61	NUM
dpc-4915	233	4	.	.	PUNCT
dpc-4915	234	1	doi	doi	NOUN
dpc-4915	234	2	:	:	PUNCT
dpc-4915	234	3	10.1016	10.1016	NUM
dpc-4915	234	4	/	/	SYM
dpc-4915	234	5	s01406736(23)00022	s01406736(23)00022	NOUN
dpc-4915	234	6	-	-	PUNCT
dpc-4915	234	7	3	3	NUM
dpc-4915	234	8	pmid:36746171	pmid:36746171	NOUN
dpc-4915	234	9	6	6	NUM
dpc-4915	234	10	.	.	PUNCT
dpc-4915	235	1	novartis	novartis	NOUN
dpc-4915	235	2	europharm	europharm	NOUN
dpc-4915	235	3	limited	limit	VERB
dpc-4915	235	4	.	.	PUNCT
dpc-4915	236	1	cosentyx	cosentyx	NOUN
dpc-4915	236	2	®	®	PROPN
dpc-4915	236	3	(	(	PUNCT
dpc-4915	236	4	secukinumab	secukinumab	NOUN
dpc-4915	236	5	):	):	PUNCT
dpc-4915	236	6	summary	summary	NOUN
dpc-4915	236	7	of	of	ADP
dpc-4915	236	8	product	product	NOUN
dpc-4915	236	9	characteristics	characteristic	NOUN
dpc-4915	236	10	[	[	X
dpc-4915	236	11	available	available	ADJ
dpc-4915	236	12	from	from	ADP
dpc-4915	236	13	:	:	PUNCT
dpc-4915	236	14	https://	https://	PROPN
dpc-4915	236	15	www.ema.europa.eu/en/documents/overview/cosentyx-epar	www.ema.europa.eu/en/documents/overview/cosentyx-epar	PROPN
dpc-4915	236	16	-medicine	-medicine	PROPN
dpc-4915	236	17	-	-	NOUN
dpc-4915	236	18	overview_en.pdf	overview_en.pdf	NOUN
dpc-4915	236	19	.	.	PUNCT
dpc-4915	237	1	7	7	X
dpc-4915	237	2	.	.	X
dpc-4915	237	3	novartis	novartis	NOUN
dpc-4915	237	4	europharm	europharm	NOUN
dpc-4915	237	5	limited	limit	VERB
dpc-4915	237	6	.	.	PUNCT
dpc-4915	238	1	cosentyx	cosentyx	PROPN
dpc-4915	238	2	®	®	PROPN
dpc-4915	238	3	(	(	PUNCT
dpc-4915	238	4	secukinumab	secukinumab	NOUN
dpc-4915	238	5	)	)	PUNCT
dpc-4915	238	6	biologic	biologic	NOUN
dpc-4915	238	7	license	license	NOUN
dpc-4915	238	8	application	application	NOUN
dpc-4915	238	9	(	(	PUNCT
dpc-4915	238	10	bla	bla	NOUN
dpc-4915	238	11	):	):	PUNCT
dpc-4915	238	12	761349	761349	NUM
dpc-4915	239	1	[	[	X
dpc-4915	239	2	available	available	ADJ
dpc-4915	239	3	from	from	ADP
dpc-4915	239	4	:	:	PUNCT
dpc-4915	239	5	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125	PROPN
dpc-4915	239	6	504s066,761349s004lbl.pdf	504s066,761349s004lbl.pdf	NUM
dpc-4915	239	7	.	.	NOUN
dpc-4915	239	8	8	8	NUM
dpc-4915	239	9	.	.	PUNCT
dpc-4915	239	10	kimball	kimball	PROPN
dpc-4915	239	11	ab	ab	PROPN
dpc-4915	239	12	,	,	PUNCT
dpc-4915	239	13	jemec	jemec	VERB
dpc-4915	239	14	gb	gb	PRON
dpc-4915	239	15	,	,	PUNCT
dpc-4915	239	16	yang	yang	PROPN
dpc-4915	239	17	m	m	PROPN
dpc-4915	239	18	,	,	PUNCT
dpc-4915	239	19	et	et	PROPN
dpc-4915	239	20	al	al	PROPN
dpc-4915	239	21	.	.	PUNCT
dpc-4915	240	1	assessing	assess	VERB
dpc-4915	240	2	the	the	DET
dpc-4915	240	3	validity	validity	NOUN
dpc-4915	240	4	,	,	PUNCT
dpc-4915	240	5	responsiveness	responsiveness	NOUN
dpc-4915	240	6	and	and	CCONJ
dpc-4915	240	7	meaningfulness	meaningfulness	NOUN
dpc-4915	240	8	of	of	ADP
dpc-4915	240	9	the	the	DET
dpc-4915	240	10	hidradenitis	hidradenitis	PROPN
dpc-4915	240	11	suppurativa	suppurativa	PROPN
dpc-4915	240	12	clinical	clinical	ADJ
dpc-4915	240	13	response	response	NOUN
dpc-4915	240	14	(	(	PUNCT
dpc-4915	240	15	hiscr	hiscr	PROPN
dpc-4915	240	16	)	)	PUNCT
dpc-4915	240	17	as	as	ADP
dpc-4915	240	18	the	the	DET
dpc-4915	240	19	clinical	clinical	ADJ
dpc-4915	240	20	endpoint	endpoint	NOUN
dpc-4915	240	21	for	for	ADP
dpc-4915	240	22	hidradenitis	hidradenitis	PROPN
dpc-4915	240	23	suppurativa	suppurativa	PROPN
dpc-4915	240	24	treatment	treatment	NOUN
dpc-4915	240	25	.	.	PUNCT
dpc-4915	241	1	br	br	PROPN
dpc-4915	241	2	j	j	PROPN
dpc-4915	241	3	dermatol	dermatol	NOUN
dpc-4915	241	4	.	.	PUNCT
dpc-4915	242	1	2014;171(6	2014;171(6	NUM
dpc-4915	242	2	):	):	PUNCT
dpc-4915	242	3	1434	1434	NUM
dpc-4915	242	4	-	-	SYM
dpc-4915	242	5	42	42	NUM
dpc-4915	242	6	.	.	PUNCT
dpc-4915	243	1	doi	doi	NOUN
dpc-4915	243	2	:	:	PUNCT
dpc-4915	243	3	10.1111	10.1111	NUM
dpc-4915	243	4	/	/	SYM
dpc-4915	243	5	bjd.13270	bjd.13270	PROPN
dpc-4915	243	6	pmid:25040429	pmid:25040429	ADP
dpc-4915	243	7	9	9	NUM
dpc-4915	243	8	.	.	PUNCT
dpc-4915	244	1	zouboulis	zouboulis	PROPN
dpc-4915	244	2	cc	cc	PROPN
dpc-4915	244	3	,	,	PUNCT
dpc-4915	244	4	passeron	passeron	PROPN
dpc-4915	244	5	t	t	PROPN
dpc-4915	244	6	,	,	PUNCT
dpc-4915	244	7	pariser	pariser	NOUN
dpc-4915	244	8	d	d	PROPN
dpc-4915	244	9	,	,	PUNCT
dpc-4915	244	10	et	et	PROPN
dpc-4915	244	11	al	al	PROPN
dpc-4915	244	12	.	.	PROPN
dpc-4915	244	13	secukinumab	secukinumab	PROPN
dpc-4915	244	14	in	in	ADP
dpc-4915	244	15	patients	patient	NOUN
dpc-4915	244	16	with	with	ADP
dpc-4915	244	17	moderate	moderate	ADJ
dpc-4915	244	18	-	-	PUNCT
dpc-4915	244	19	to	to	ADP
dpc-4915	244	20	-	-	PUNCT
dpc-4915	244	21	severe	severe	ADJ
dpc-4915	244	22	hidradenitis	hidradenitis	NOUN
dpc-4915	244	23	suppurativa	suppurativa	NOUN
dpc-4915	244	24	based	base	VERB
dpc-4915	244	25	on	on	ADP
dpc-4915	244	26	prior	prior	ADJ
dpc-4915	244	27	biologic	biologic	ADJ
dpc-4915	244	28	exposure	exposure	NOUN
dpc-4915	244	29	:	:	PUNCT
dpc-4915	244	30	an	an	DET
dpc-4915	244	31	efficacy	efficacy	NOUN
dpc-4915	244	32	and	and	CCONJ
dpc-4915	244	33	safety	safety	NOUN
dpc-4915	244	34	analysis	analysis	NOUN
dpc-4915	244	35	from	from	ADP
dpc-4915	244	36	the	the	DET
dpc-4915	244	37	sunshine	sunshine	NOUN
dpc-4915	244	38	and	and	CCONJ
dpc-4915	244	39	 	 	SPACE
dpc-4915	244	40	sunrise	sunrise	NOUN
dpc-4915	244	41	phase	phase	NOUN
dpc-4915	244	42	iii	iii	NUM
dpc-4915	244	43	trials	trial	NOUN
dpc-4915	244	44	.	.	PUNCT
dpc-4915	245	1	br	br	PROPN
dpc-4915	245	2	j	j	PROPN
dpc-4915	245	3	dermatol	dermatol	NOUN
dpc-4915	245	4	.	.	PUNCT
dpc-4915	246	1	2024;190(6):836	2024;190(6):836	NUM
dpc-4915	246	2	-	-	SYM
dpc-4915	246	3	45	45	NUM
dpc-4915	246	4	.	.	PUNCT
dpc-4915	246	5	doi	doi	NOUN
dpc-4915	246	6	:	:	PUNCT
dpc-4915	246	7	10.1093	10.1093	NUM
dpc-4915	246	8	/	/	SYM
dpc-4915	246	9	bjd	bjd	PROPN
dpc-4915	246	10	/	/	SYM
dpc-4915	246	11	ljae098	ljae098	PROPN
dpc-4915	246	12	pmid	pmid	PROPN
dpc-4915	246	13	:	:	PUNCT
dpc-4915	246	14	38470171	38470171	NUM
dpc-4915	246	15	10	10	NUM
dpc-4915	246	16	.	.	PUNCT
dpc-4915	247	1	prussick	prussick	PROPN
dpc-4915	247	2	l	l	PROPN
dpc-4915	247	3	,	,	PUNCT
dpc-4915	247	4	rothstein	rothstein	PROPN
dpc-4915	247	5	b	b	PROPN
dpc-4915	247	6	,	,	PUNCT
dpc-4915	247	7	joshipura	joshipura	X
dpc-4915	247	8	d	d	NOUN
dpc-4915	247	9	,	,	PUNCT
dpc-4915	247	10	et	et	PROPN
dpc-4915	247	11	al	al	PROPN
dpc-4915	247	12	.	.	PROPN
dpc-4915	247	13	open	open	ADJ
dpc-4915	247	14	-	-	PUNCT
dpc-4915	247	15	label	label	NOUN
dpc-4915	247	16	,	,	PUNCT
dpc-4915	247	17	investigator	investigator	NOUN
dpc-4915	247	18	initiated	initiate	VERB
dpc-4915	247	19	,	,	PUNCT
dpc-4915	247	20	single	single	ADJ
dpc-4915	247	21	-	-	PUNCT
dpc-4915	247	22	site	site	NOUN
dpc-4915	247	23	exploratory	exploratory	ADJ
dpc-4915	247	24	trial	trial	NOUN
dpc-4915	247	25	evaluating	evaluating	NOUN
dpc-4915	247	26	secukinumab	secukinumab	NOUN
dpc-4915	247	27	,	,	PUNCT
dpc-4915	247	28	an	an	DET
dpc-4915	247	29	anti	anti	ADJ
dpc-4915	247	30	-	-	ADJ
dpc-4915	247	31	interleukin-17a	interleukin-17a	ADJ
dpc-4915	247	32	monoclonal	monoclonal	NOUN
dpc-4915	247	33	antibody	antibody	NOUN
dpc-4915	247	34	,	,	PUNCT
dpc-4915	247	35	for	for	ADP
dpc-4915	247	36	patients	patient	NOUN
dpc-4915	247	37	with	with	ADP
dpc-4915	247	38	moderate	moderate	ADJ
dpc-4915	247	39	-	-	PUNCT
dpc-4915	247	40	to	to	ADP
dpc-4915	247	41	-	-	PUNCT
dpc-4915	247	42	severe	severe	ADJ
dpc-4915	247	43	hidradenitis	hidradenitis	PROPN
dpc-4915	247	44	suppurativa	suppurativa	PROPN
dpc-4915	247	45	.	.	PUNCT
dpc-4915	248	1	br	br	PROPN
dpc-4915	249	1	j	j	PROPN
dpc-4915	249	2	dermatol	dermatol	NOUN
dpc-4915	249	3	.	.	PUNCT
dpc-4915	250	1	2019;181(3):609	2019;181(3):609	NOUN
dpc-4915	250	2	-	-	SYM
dpc-4915	250	3	11	11	NUM
dpc-4915	250	4	.	.	PUNCT
dpc-4915	251	1	doi	doi	NOUN
dpc-4915	251	2	:	:	PUNCT
dpc-4915	251	3	10.1111	10.1111	NUM
dpc-4915	251	4	/	/	SYM
dpc-4915	251	5	bjd.17822	bjd.17822	NOUN
dpc-4915	251	6	pmid:30801662	pmid:30801662	NOUN
dpc-4915	251	7	11	11	NUM
dpc-4915	251	8	.	.	PUNCT
dpc-4915	252	1	casseres	cassere	NOUN
dpc-4915	252	2	rg	rg	PROPN
dpc-4915	252	3	,	,	PUNCT
dpc-4915	252	4	prussick	prussick	ADJ
dpc-4915	252	5	l	l	NOUN
dpc-4915	252	6	,	,	PUNCT
dpc-4915	252	7	zancanaro	zancanaro	NOUN
dpc-4915	252	8	p	p	X
dpc-4915	252	9	,	,	PUNCT
dpc-4915	252	10	et	et	PROPN
dpc-4915	252	11	al	al	PROPN
dpc-4915	252	12	.	.	PROPN
dpc-4915	252	13	secukinumab	secukinumab	PROPN
dpc-4915	252	14	in	in	ADP
dpc-4915	252	15	the	the	DET
dpc-4915	252	16	treatment	treatment	NOUN
dpc-4915	252	17	of	of	ADP
dpc-4915	252	18	moderate	moderate	ADJ
dpc-4915	252	19	to	to	ADP
dpc-4915	252	20	severe	severe	ADJ
dpc-4915	252	21	hidradenitis	hidradenitis	PROPN
dpc-4915	252	22	suppurativa	suppurativa	NOUN
dpc-4915	252	23	:	:	PUNCT
dpc-4915	252	24	results	result	NOUN
dpc-4915	252	25	of	of	ADP
dpc-4915	252	26	an	an	DET
dpc-4915	252	27	open	open	ADJ
dpc-4915	252	28	-	-	PUNCT
dpc-4915	252	29	label	label	NOUN
dpc-4915	252	30	trial	trial	NOUN
dpc-4915	252	31	.	.	PUNCT
dpc-4915	253	1	j	j	PROPN
dpc-4915	253	2	am	be	AUX
dpc-4915	253	3	acad	acad	ADJ
dpc-4915	253	4	dermatol	dermatol	NOUN
dpc-4915	253	5	.	.	PUNCT
dpc-4915	254	1	2020;82(6):1524	2020;82(6):1524	NUM
dpc-4915	254	2	-	-	SYM
dpc-4915	254	3	6	6	NUM
dpc-4915	254	4	.	.	PUNCT
dpc-4915	254	5	doi	doi	NOUN
dpc-4915	254	6	:	:	PUNCT
dpc-4915	254	7	10.1016	10.1016	NUM
dpc-4915	254	8	/	/	SYM
dpc-4915	254	9	j.jaad.2020.02.005	j.jaad.2020.02.005	X
dpc-4915	254	10	pmid:32044410	pmid:32044410	VERB
dpc-4915	254	11	12	12	NUM
dpc-4915	254	12	.	.	PUNCT
dpc-4915	255	1	reguiaï	reguiaï	PROPN
dpc-4915	255	2	z	z	NOUN
dpc-4915	255	3	,	,	PUNCT
dpc-4915	255	4	fougerousse	fougerousse	PROPN
dpc-4915	255	5	ac	ac	PROPN
dpc-4915	255	6	,	,	PUNCT
dpc-4915	255	7	maccari	maccari	PROPN
dpc-4915	255	8	f	f	PROPN
dpc-4915	255	9	,	,	PUNCT
dpc-4915	255	10	bécherel	bécherel	PROPN
dpc-4915	255	11	pa	pa	PROPN
dpc-4915	255	12	.	.	PROPN
dpc-4915	255	13	effectiveness	effectiveness	NOUN
dpc-4915	255	14	of	of	ADP
dpc-4915	255	15	secukinumab	secukinumab	NOUN
dpc-4915	255	16	in	in	ADP
dpc-4915	255	17	hidradenitis	hidradenitis	PROPN
dpc-4915	255	18	suppurativa	suppurativa	PROPN
dpc-4915	255	19	:	:	PUNCT
dpc-4915	255	20	an	an	DET
dpc-4915	255	21	open	open	ADJ
dpc-4915	255	22	study	study	NOUN
dpc-4915	255	23	(	(	PUNCT
dpc-4915	255	24	20	20	NUM
dpc-4915	255	25	cases	case	NOUN
dpc-4915	255	26	)	)	PUNCT
dpc-4915	255	27	.	.	PUNCT
dpc-4915	256	1	j	j	PROPN
dpc-4915	256	2	eur	eur	PROPN
dpc-4915	256	3	acad	acad	PROPN
dpc-4915	256	4	dermatol	dermatol	NOUN
dpc-4915	256	5	venereol	venereol	NOUN
dpc-4915	256	6	.	.	PUNCT
dpc-4915	257	1	2020;34(11):e750	2020;34(11):e750	X
dpc-4915	257	2	-	-	PUNCT
dpc-4915	257	3	e1	e1	NOUN
dpc-4915	257	4	.	.	PUNCT
dpc-4915	258	1	doi	doi	NOUN
dpc-4915	258	2	:	:	PUNCT
dpc-4915	258	3	10.1111	10.1111	NUM
dpc-4915	258	4	/	/	SYM
dpc-4915	258	5	jdv.16605	jdv.16605	NOUN
dpc-4915	258	6	pmid:32401354	pmid:32401354	NOUN
dpc-4915	258	7	13	13	NUM
dpc-4915	258	8	.	.	PUNCT
dpc-4915	259	1	melgosa	melgosa	PROPN
dpc-4915	259	2	ramos	ramos	PROPN
dpc-4915	259	3	fj	fj	PROPN
dpc-4915	259	4	,	,	PUNCT
dpc-4915	259	5	garcía	garcía	PROPN
dpc-4915	259	6	ruiz	ruiz	NOUN
dpc-4915	259	7	r	r	NOUN
dpc-4915	259	8	,	,	PUNCT
dpc-4915	259	9	estébanez	estébanez	PROPN
dpc-4915	259	10	corrales	corral	VERB
dpc-4915	259	11	a	a	PRON
dpc-4915	259	12	,	,	PUNCT
dpc-4915	259	13	mateu	mateu	PROPN
dpc-4915	259	14	puchades	puchade	VERB
dpc-4915	259	15	a.	a.	PROPN
dpc-4915	259	16	long	long	ADJ
dpc-4915	259	17	-	-	PUNCT
dpc-4915	259	18	term	term	NOUN
dpc-4915	259	19	secukinumab	secukinumab	NOUN
dpc-4915	259	20	efficacy	efficacy	NOUN
dpc-4915	259	21	in	in	ADP
dpc-4915	259	22	patients	patient	NOUN
dpc-4915	259	23	with	with	ADP
dpc-4915	259	24	moderate	moderate	ADJ
dpc-4915	259	25	to	to	ADP
dpc-4915	259	26	severe	severe	ADJ
dpc-4915	259	27	hidradenitis	hidradenitis	NOUN
dpc-4915	259	28	suppurativa	suppurativa	NOUN
dpc-4915	259	29	:	:	PUNCT
dpc-4915	259	30	a	a	DET
dpc-4915	259	31	retrospective	retrospective	ADJ
dpc-4915	259	32	single	single	ADJ
dpc-4915	259	33	-	-	PUNCT
dpc-4915	259	34	centre	centre	NOUN
dpc-4915	259	35	case	case	NOUN
dpc-4915	259	36	series	series	NOUN
dpc-4915	259	37	(	(	PUNCT
dpc-4915	259	38	23	23	NUM
dpc-4915	259	39	patients	patient	NOUN
dpc-4915	259	40	)	)	PUNCT
dpc-4915	259	41	.	.	PUNCT
dpc-4915	260	1	j	j	PROPN
dpc-4915	260	2	eur	eur	PROPN
dpc-4915	260	3	acad	acad	PROPN
dpc-4915	260	4	dermatol	dermatol	NOUN
dpc-4915	260	5	venereol	venereol	NOUN
dpc-4915	260	6	.	.	PUNCT
dpc-4915	261	1	2023;37(4):e517	2023;37(4):e517	NOUN
dpc-4915	261	2	-	-	PUNCT
dpc-4915	261	3	e9	e9	PROPN
dpc-4915	261	4	.	.	PUNCT
dpc-4915	261	5	doi	doi	NOUN
dpc-4915	261	6	:	:	PUNCT
dpc-4915	261	7	10.1111	10.1111	NUM
dpc-4915	261	8	/	/	SYM
dpc-4915	261	9	jdv.18685	jdv.18685	NUM
dpc-4915	261	10	pmid	pmid	PROPN
dpc-4915	261	11	:	:	PUNCT
dpc-4915	261	12	36268711	36268711	NUM
dpc-4915	261	13	14	14	NUM
dpc-4915	261	14	.	.	PUNCT
dpc-4915	262	1	martora	martora	PROPN
dpc-4915	262	2	f	f	PROPN
dpc-4915	262	3	,	,	PUNCT
dpc-4915	262	4	marasca	marasca	PROPN
dpc-4915	262	5	c	c	PROPN
dpc-4915	262	6	,	,	PUNCT
dpc-4915	262	7	cacciapuoti	cacciapuoti	PROPN
dpc-4915	262	8	s	s	PROPN
dpc-4915	262	9	,	,	PUNCT
dpc-4915	262	10	et	et	PROPN
dpc-4915	262	11	al	al	PROPN
dpc-4915	262	12	.	.	PROPN
dpc-4915	262	13	secukinumab	secukinumab	PROPN
dpc-4915	262	14	in	in	ADP
dpc-4915	262	15	hidradenitis	hidradenitis	PROPN
dpc-4915	262	16	suppurativa	suppurativa	NOUN
dpc-4915	262	17	patients	patient	NOUN
dpc-4915	262	18	who	who	PRON
dpc-4915	262	19	failed	fail	VERB
dpc-4915	262	20	adalimumab	adalimumab	NOUN
dpc-4915	262	21	:	:	PUNCT
dpc-4915	262	22	8	8	NUM
dpc-4915	262	23	original	original	ADJ
dpc-4915	262	24	article	article	NOUN
dpc-4915	262	25	|	|	ADV
dpc-4915	262	26	dermatol	dermatol	ADJ
dpc-4915	262	27	pract	pract	NOUN
dpc-4915	262	28	concept	concept	NOUN
dpc-4915	262	29	.	.	PUNCT
dpc-4915	263	1	2025;15(1):4915	2025;15(1):4915	NUM
dpc-4915	263	2	31	31	NUM
dpc-4915	263	3	.	.	PUNCT
dpc-4915	264	1	jin	jin	PROPN
dpc-4915	264	2	k	k	PROPN
dpc-4915	264	3	,	,	PUNCT
dpc-4915	264	4	matsuzaki	matsuzaki	PROPN
dpc-4915	264	5	y	y	PROPN
dpc-4915	264	6	,	,	PUNCT
dpc-4915	264	7	akasaka	akasaka	PROPN
dpc-4915	264	8	e	e	PROPN
dpc-4915	264	9	,	,	PUNCT
dpc-4915	264	10	nakano	nakano	PROPN
dpc-4915	264	11	h	h	PROPN
dpc-4915	264	12	,	,	PUNCT
dpc-4915	264	13	sawamura	sawamura	VERB
dpc-4915	264	14	d.	d.	PROPN
dpc-4915	264	15	pyoderma	pyoderma	PROPN
dpc-4915	264	16	gangrenosum	gangrenosum	NOUN
dpc-4915	264	17	triggered	trigger	VERB
dpc-4915	264	18	by	by	ADP
dpc-4915	264	19	switching	switch	VERB
dpc-4915	264	20	from	from	ADP
dpc-4915	264	21	adalimumab	adalimumab	NOUN
dpc-4915	264	22	to	to	ADP
dpc-4915	264	23	secukinumab	secukinumab	VERB
dpc-4915	264	24	.	.	PUNCT
dpc-4915	265	1	j	j	PROPN
dpc-4915	265	2	dermatol	dermatol	NOUN
dpc-4915	265	3	.	.	PUNCT
dpc-4915	266	1	2019;46(3):e108	2019;46(3):e108	NOUN
dpc-4915	266	2	-	-	PUNCT
dpc-4915	266	3	e9	e9	PROPN
dpc-4915	266	4	.	.	PUNCT
dpc-4915	266	5	doi:10.1111/1346	doi:10.1111/1346	NOUN
dpc-4915	266	6	-	-	PUNCT
dpc-4915	266	7	8138.14611	8138.14611	NUM
dpc-4915	266	8	pmid:30192400	pmid:30192400	NOUN
dpc-4915	266	9	32	32	NUM
dpc-4915	266	10	.	.	PUNCT
dpc-4915	267	1	benzaquen	benzaquen	PROPN
dpc-4915	267	2	m	m	PROPN
dpc-4915	267	3	,	,	PUNCT
dpc-4915	267	4	monnier	monnier	PROPN
dpc-4915	267	5	j	j	PROPN
dpc-4915	267	6	,	,	PUNCT
dpc-4915	267	7	beaussault	beaussault	VERB
dpc-4915	267	8	y	y	PROPN
dpc-4915	267	9	,	,	PUNCT
dpc-4915	267	10	rouby	rouby	VERB
dpc-4915	267	11	f	f	PROPN
dpc-4915	267	12	,	,	PUNCT
dpc-4915	268	1	berbis	berbis	PROPN
dpc-4915	268	2	p.	p.	NOUN
dpc-4915	268	3	pyoderma	pyoderma	NOUN
dpc-4915	268	4	gangrenosum	gangrenosum	NOUN
dpc-4915	268	5	arising	arise	VERB
dpc-4915	268	6	during	during	ADP
dpc-4915	268	7	treatment	treatment	NOUN
dpc-4915	268	8	of	of	ADP
dpc-4915	268	9	psoriasis	psoriasis	NOUN
dpc-4915	268	10	with	with	ADP
dpc-4915	268	11	adalimumab	adalimumab	NOUN
dpc-4915	268	12	:	:	PUNCT
dpc-4915	268	13	effectiveness	effectiveness	NOUN
dpc-4915	268	14	of	of	ADP
dpc-4915	268	15	ustekinumab	ustekinumab	NOUN
dpc-4915	268	16	.	.	PUNCT
dpc-4915	269	1	australas	australas	PROPN
dpc-4915	269	2	j	j	PROPN
dpc-4915	269	3	dermatol	dermatol	PROPN
dpc-4915	269	4	.	.	PUNCT
dpc-4915	270	1	2017;58(4):e270	2017;58(4):e270	NUM
dpc-4915	270	2	-	-	PUNCT
dpc-4915	270	3	e1	e1	NOUN
dpc-4915	270	4	.	.	PUNCT
dpc-4915	271	1	doi:10.1111	doi:10.1111	NOUN
dpc-4915	271	2	/	/	SYM
dpc-4915	271	3	ajd.12545	ajd.12545	PROPN
dpc-4915	271	4	pmid:28660635	pmid:28660635	PROPN
dpc-4915	271	5	33	33	NUM
dpc-4915	271	6	.	.	PUNCT
dpc-4915	272	1	guenova	guenova	PROPN
dpc-4915	272	2	e	e	NOUN
dpc-4915	272	3	,	,	PUNCT
dpc-4915	272	4	teske	teske	ADV
dpc-4915	272	5	a	a	DET
dpc-4915	272	6	,	,	PUNCT
dpc-4915	272	7	fehrenbacher	fehrenbacher	NOUN
dpc-4915	272	8	b	b	NOUN
dpc-4915	272	9	,	,	PUNCT
dpc-4915	272	10	et	et	PROPN
dpc-4915	272	11	al	al	PROPN
dpc-4915	272	12	.	.	PUNCT
dpc-4915	272	13	interleukin	interleukin	NOUN
dpc-4915	272	14	23	23	NUM
dpc-4915	272	15	expression	expression	NOUN
dpc-4915	272	16	in	in	ADP
dpc-4915	272	17	pyoderma	pyoderma	NOUN
dpc-4915	272	18	gangrenosum	gangrenosum	NOUN
dpc-4915	272	19	and	and	CCONJ
dpc-4915	272	20	targeted	target	VERB
dpc-4915	272	21	therapy	therapy	NOUN
dpc-4915	272	22	with	with	ADP
dpc-4915	272	23	ustekinumab	ustekinumab	NOUN
dpc-4915	272	24	.	.	PUNCT
dpc-4915	272	25	arch	arch	ADJ
dpc-4915	272	26	dermatol	dermatol	NOUN
dpc-4915	272	27	.	.	PUNCT
dpc-4915	273	1	2011;147(10):1203	2011;147(10):1203	NUM
dpc-4915	273	2	-	-	SYM
dpc-4915	273	3	5	5	NUM
dpc-4915	273	4	.	.	PUNCT
dpc-4915	274	1	doi:10.1001/	doi:10.1001/	PROPN
dpc-4915	274	2	archdermatol.2011.168	archdermatol.2011.168	NOUN
dpc-4915	274	3	.	.	PROPN
dpc-4915	274	4	pmid:21680759	pmid:21680759	NOUN
dpc-4915	274	5	34	34	NUM
dpc-4915	274	6	.	.	PUNCT
dpc-4915	274	7	alavi	alavi	PROPN
dpc-4915	274	8	a	a	PRON
dpc-4915	274	9	,	,	PUNCT
dpc-4915	274	10	french	french	ADJ
dpc-4915	274	11	le	le	PROPN
dpc-4915	274	12	,	,	PUNCT
dpc-4915	274	13	davis	davis	PROPN
dpc-4915	274	14	md	md	PROPN
dpc-4915	274	15	,	,	PUNCT
dpc-4915	274	16	brassard	brassard	PROPN
dpc-4915	274	17	a	a	PRON
dpc-4915	274	18	,	,	PUNCT
dpc-4915	274	19	kirsner	kirsner	ADJ
dpc-4915	274	20	rs	r	NOUN
dpc-4915	274	21	.	.	PUNCT
dpc-4915	275	1	pyoderma	pyoderma	NOUN
dpc-4915	275	2	gangrenosum	gangrenosum	NOUN
dpc-4915	275	3	:	:	PUNCT
dpc-4915	275	4	an	an	DET
dpc-4915	275	5	update	update	NOUN
dpc-4915	275	6	on	on	ADP
dpc-4915	275	7	pathophysiology	pathophysiology	NOUN
dpc-4915	275	8	,	,	PUNCT
dpc-4915	275	9	diagnosis	diagnosis	NOUN
dpc-4915	275	10	and	and	CCONJ
dpc-4915	275	11	treatment	treatment	NOUN
dpc-4915	275	12	.	.	PUNCT
dpc-4915	276	1	am	be	AUX
dpc-4915	276	2	j	j	PROPN
dpc-4915	276	3	clin	clin	PROPN
dpc-4915	276	4	dermatol	dermatol	NOUN
dpc-4915	276	5	.	.	PUNCT
dpc-4915	277	1	2017;18(3):355	2017;18(3):355	NUM
dpc-4915	277	2	-	-	SYM
dpc-4915	277	3	72	72	NUM
dpc-4915	277	4	.	.	PUNCT
dpc-4915	277	5	doi:10.1007	doi:10.1007	VERB
dpc-4915	277	6	/	/	SYM
dpc-4915	277	7	s40257	s40257	NOUN
dpc-4915	277	8	-	-	PUNCT
dpc-4915	277	9	017	017	NUM
dpc-4915	277	10	-	-	PUNCT
dpc-4915	277	11	0251	0251	NUM
dpc-4915	277	12	-	-	PUNCT
dpc-4915	277	13	7	7	NUM
dpc-4915	277	14	.	.	PUNCT
dpc-4915	277	15	pmid:28224502	pmid:28224502	VERB
dpc-4915	277	16	patient	patient	ADJ
dpc-4915	277	17	with	with	ADP
dpc-4915	277	18	hidradenitis	hidradenitis	PROPN
dpc-4915	277	19	suppurativa	suppurativa	PROPN
dpc-4915	277	20	.	.	PUNCT
dpc-4915	278	1	indian	indian	PROPN
dpc-4915	278	2	j	j	PROPN
dpc-4915	278	3	dermatol	dermatol	PROPN
dpc-4915	278	4	venereol	venereol	PROPN
dpc-4915	278	5	leprol	leprol	PROPN
dpc-4915	278	6	.	.	PUNCT
dpc-4915	279	1	2024:1	2024:1	NUM
dpc-4915	279	2	-	-	SYM
dpc-4915	279	3	3	3	NUM
dpc-4915	279	4	.	.	PUNCT
dpc-4915	279	5	doi	doi	NOUN
dpc-4915	279	6	:	:	PUNCT
dpc-4915	279	7	10.25259	10.25259	NUM
dpc-4915	279	8	/	/	SYM
dpc-4915	279	9	ijdvl_329_2024	ijdvl_329_2024	ADJ
dpc-4915	279	10	pmid	pmid	NOUN
dpc-4915	279	11	:	:	PUNCT
dpc-4915	279	12	39152828	39152828	NUM
dpc-4915	279	13	28	28	NUM
dpc-4915	279	14	.	.	PUNCT
dpc-4915	280	1	orita	orita	PROPN
dpc-4915	280	2	a	a	PRON
dpc-4915	280	3	,	,	PUNCT
dpc-4915	280	4	hoshina	hoshina	PROPN
dpc-4915	280	5	d	d	PROPN
dpc-4915	280	6	,	,	PUNCT
dpc-4915	280	7	hirosaki	hirosaki	PROPN
dpc-4915	280	8	k.	k.	PROPN
dpc-4915	280	9	pyoderma	pyoderma	PROPN
dpc-4915	280	10	gangrenosum	gangrenosum	NOUN
dpc-4915	280	11	caused	cause	VERB
dpc-4915	280	12	by	by	ADP
dpc-4915	280	13	secukinumab	secukinumab	NOUN
dpc-4915	280	14	successfully	successfully	ADV
dpc-4915	280	15	treated	treat	VERB
dpc-4915	280	16	with	with	ADP
dpc-4915	280	17	risankizumab	risankizumab	NOUN
dpc-4915	280	18	:	:	PUNCT
dpc-4915	280	19	a	a	DET
dpc-4915	280	20	case	case	NOUN
dpc-4915	280	21	report	report	NOUN
dpc-4915	280	22	and	and	CCONJ
dpc-4915	280	23	literature	literature	PROPN
dpc-4915	280	24	review	review	PROPN
dpc-4915	280	25	.	.	PUNCT
dpc-4915	281	1	clin	clin	PROPN
dpc-4915	281	2	exp	exp	NOUN
dpc-4915	281	3	dermatol	dermatol	NOUN
dpc-4915	281	4	.	.	PUNCT
dpc-4915	282	1	2022;47(7	2022;47(7	NUM
dpc-4915	282	2	):	):	PUNCT
dpc-4915	282	3	1372	1372	NUM
dpc-4915	282	4	-	-	SYM
dpc-4915	282	5	4	4	NUM
dpc-4915	282	6	.	.	PUNCT
dpc-4915	282	7	doi	doi	NOUN
dpc-4915	282	8	:	:	PUNCT
dpc-4915	282	9	10.1111	10.1111	NUM
dpc-4915	282	10	/	/	SYM
dpc-4915	282	11	ced.15183	ced.15183	X
dpc-4915	282	12	pmid:35298047	pmid:35298047	ADP
dpc-4915	282	13	29	29	NUM
dpc-4915	282	14	.	.	PUNCT
dpc-4915	283	1	petty	petty	PROPN
dpc-4915	283	2	aj	aj	PROPN
dpc-4915	283	3	,	,	PUNCT
dpc-4915	283	4	whitley	whitley	PROPN
dpc-4915	283	5	mj	mj	PROPN
dpc-4915	283	6	,	,	PUNCT
dpc-4915	283	7	balaban	balaban	PROPN
dpc-4915	283	8	a	a	PROPN
dpc-4915	283	9	,	,	PUNCT
dpc-4915	283	10	ellington	ellington	PROPN
dpc-4915	283	11	k	k	PROPN
dpc-4915	283	12	,	,	PUNCT
dpc-4915	283	13	marano	marano	PROPN
dpc-4915	283	14	al	al	PROPN
dpc-4915	283	15	.	.	PROPN
dpc-4915	283	16	pyoderma	pyoderma	NOUN
dpc-4915	283	17	gangrenosum	gangrenosum	NOUN
dpc-4915	283	18	induced	induce	VERB
dpc-4915	283	19	by	by	ADP
dpc-4915	283	20	secukinumab	secukinumab	NOUN
dpc-4915	283	21	in	in	ADP
dpc-4915	283	22	a	a	DET
dpc-4915	283	23	patient	patient	NOUN
dpc-4915	283	24	with	with	ADP
dpc-4915	283	25	psoriasis	psoriasis	NOUN
dpc-4915	283	26	successfully	successfully	ADV
dpc-4915	283	27	treated	treat	VERB
dpc-4915	283	28	with	with	ADP
dpc-4915	283	29	ustekinumab	ustekinumab	NOUN
dpc-4915	283	30	.	.	PUNCT
dpc-4915	284	1	jaad	jaad	PROPN
dpc-4915	284	2	case	case	PROPN
dpc-4915	284	3	rep	rep	PROPN
dpc-4915	284	4	.	.	PROPN
dpc-4915	284	5	2020;6(8):731	2020;6(8):731	NUM
dpc-4915	284	6	-	-	SYM
dpc-4915	284	7	3	3	NUM
dpc-4915	284	8	.	.	PUNCT
dpc-4915	284	9	doi	doi	NOUN
dpc-4915	284	10	:	:	PUNCT
dpc-4915	284	11	10.1016	10.1016	NUM
dpc-4915	284	12	/	/	SYM
dpc-4915	284	13	j.jdcr.2020.06.011	j.jdcr.2020.06.011	PROPN
dpc-4915	284	14	pmid:32715064	pmid:32715064	PROPN
dpc-4915	284	15	pmcid	pmcid	NOUN
dpc-4915	284	16	:	:	PUNCT
dpc-4915	284	17	pmc7369520	pmc7369520	NOUN
dpc-4915	284	18	30	30	NUM
dpc-4915	284	19	.	.	PUNCT
dpc-4915	284	20	wollina	wollina	PROPN
dpc-4915	284	21	u	u	PROPN
dpc-4915	284	22	,	,	PUNCT
dpc-4915	284	23	schönlebe	schönlebe	PROPN
dpc-4915	284	24	j	j	PROPN
dpc-4915	284	25	,	,	PUNCT
dpc-4915	284	26	fürll	fürll	PROPN
dpc-4915	284	27	c.	c.	PROPN
dpc-4915	284	28	pyoderma	pyoderma	PROPN
dpc-4915	284	29	gangrenosum	gangrenosum	NOUN
dpc-4915	284	30	induced	induce	VERB
dpc-4915	284	31	by	by	ADP
dpc-4915	284	32	secukinumab	secukinumab	NOUN
dpc-4915	284	33	-	-	PUNCT
dpc-4915	284	34	a	a	DET
dpc-4915	284	35	late	late	ADJ
dpc-4915	284	36	paradoxical	paradoxical	ADJ
dpc-4915	284	37	drug	drug	NOUN
dpc-4915	284	38	reaction	reaction	NOUN
dpc-4915	284	39	.	.	PUNCT
dpc-4915	285	1	dermatol	dermatol	NOUN
dpc-4915	285	2	ther	ther	ADV
dpc-4915	285	3	.	.	PUNCT
dpc-4915	286	1	2020;33(1):e13161	2020;33(1):e13161	NUM
dpc-4915	286	2	.	.	PUNCT
dpc-4915	286	3	doi	doi	NOUN
dpc-4915	286	4	:	:	PUNCT
dpc-4915	286	5	10.1111	10.1111	NUM
dpc-4915	286	6	/	/	SYM
dpc-4915	286	7	dth.13161	dth.13161	NUM
dpc-4915	286	8	pmid	pmid	NOUN
dpc-4915	286	9	:	:	PUNCT
dpc-4915	286	10	31705566	31705566	NUM